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ABSTRACT 
 
Perhexiline is an anti-anginal drug that is thought to shift myocardial metabolism from 
β-oxidation of fatty acids to glucose utilisation. An associated improvement in energy 
efficiency may be beneficial in ischaemia-reperfusion as an adjunct to established 
techniques for myocardial protection during cardiac surgery. In this thesis, I conduct a 
prospective double-blind randomised placebo-controlled trial of oral perhexiline in 
patients undergoing coronary artery surgery, obtaining samples of serum, right atrium 
and left ventricle. I measure the concentration of perhexiline using high performance 
liquid chromatography and find that although highly concentrated in the heart, it may 
not have reached steady-state in the ventricular myocardium. I perform enzymatic 
colourimetry and ultra-high resolution mass spectrometry to detect changes in 
carbohydrate and lipid metabolism; however, the myocardial metabolic profiles of 
patients on perhexiline are indistinguishable from controls. On analysing the results 
of the clinical trial, I find no improvement in the primary endpoint, the incidence of a 
low cardiac output episode, or any secondary outcomes. I conclude that preoperative 
oral perhexiline does not improve clinical markers of myocardial protection and 
despite significant accumulation in the myocardium, it has no significant effect on the 
measurable metabolic profile of the heart at the time of surgery. 
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1. INTRODUCTION 
 
1.1 Myocardial protection: the key to open heart surgery 
‘I became aware that surgeons obviously would never be able to correct or cure 
[many] heart conditions unless they were able to stop the circulation of the 
blood through the heart, open it and operate in a bloodless field under direct 
vision.’ 
(Bigelow, 1984) 
 
In his memoirs, Wilfred G. Bigelow reflects on his time with Alfred Blalock at the 
Johns Hopkins Hospital, Baltimore in 1946-47. In conjunction with Helen B. Taussig 
and Vivien T. Thomas, Blalock had developed a method for palliating complex 
intracardiac anomalies by forming a surgical shunt between the systemic and 
pulmonary circulations; this allowed deoxygenated blood to reach the lungs without 
passing through the right side of the heart (Blalock and Taussig, 1945). Prior to the 
introduction of this operation, life expectancy in such conditions was often limited to 
early childhood. Bigelow recognised both the importance of this pioneering ‘blue 
baby operation’ and the limitations of extra-cardiac palliation. To achieve anatomical 
correction, surgeons would need to venture inside the heart and this would require a 
totally new approach. Back in Toronto, he set to work on testing his hypothesis for 
making open heart surgery possible using hypothermia (Bigelow et al., 1950c). In his 
laboratory, anaesthetised dogs were cooled to 20 degrees Celsius by a blanket 
containing coils of circulating refrigerant. At this temperature, he found that total body 
oxygen consumption was reduced to 15% of baseline with a corresponding reduction 
in cardiac output (Bigelow et al., 1950b). The heart could be excluded from the 
circulation for up to 15 minutes by occluding the venae cavae and azygos vein, 
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enabling incision of the right auricle, intra-cardiac exploration and resuturing (Bigelow 
et al., 1950a). The animals were then revived to normal body temperature in a bath; 
in those that survived, apparently normal activity was resumed within a few days with 
no evidence of end-organ injury. These experiments demonstrated that by reducing 
metabolism, total body hypothermia had the potential to protect the heart, brain and 
other vital organs whilst allowing safe access to the cardiac chambers to repair 
defects. Bigelow presented his findings to the American Surgical Association meeting 
at Colorado Springs in April 1950 and his audience included two young surgeons 
from the University Hospital in Minneapolis, F. John Lewis and C. Walton Lillehei. 
Inspired by the potential application of hypothermia to cardiac surgery, they returned 
to Minnesota and began their own investigations (Miller, 2000). 
 
By 1952, satisfied with his laboratory experiments on dogs, Lewis was ready to use 
systemic hypothermia on a patient with congenital heart disease. On 2nd September, 
assisted by Richard L. Varco, Lillehei and others, a five year old girl was cooled down 
to 28 degrees Celsius over two hours using rubberised blankets (Lewis and Taufic, 
1953). Lewis opened the chest, isolated and snared the caval and azygous veins, 
then clamped the pulmonary artery and aorta, thereby isolating the heart and 
stopping the circulation. He opened the right atrium and identified the pathological 
lesion, an atrial septal defect measuring two centimetres; in a time when a diagnosis 
was often difficult to make pre-mortem, the surgeons were thankful that it had proven 
correct. The defect was repaired with direct suture, the atrial incision closed and the 
clamps released in 5½ minutes. The heart began to contract spontaneously and with 
some manual encouragement, rapidly regained its normal rhythm. By modulating 
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metabolism using hypothermia, Lewis and colleagues had introduced the application 
of myocardial protection to clinical practice. Eleven days later, the world’s first 
successful open heart surgery patient was discharged home and a new epoch in 
cardiac surgery had begun. 
 
Amidst the excitement, Lillehei was sceptical that total body hypothermia alone would 
permit more complex and time-consuming repairs (Miller, 2000). He was embarking 
on a new and altogether more controversial strategy of circulatory support – cross-
circulation. In earlier studies, by occluding the venae cavae, it had been shown that a 
dog could survive for up to two hours with a cardiac output as low as 10% of normal 
followed by a full recovery, termed ‘the azygous principle’ (Andreasen and Watson, 
1952). By connecting the great vessels of a patient to the femoral arteries of a much 
larger blood-matched donor, such as a parent, with intervening arterial and venous 
pumps, the recipient could be maintained on low-flow perfusion from the donor to 
enable opening of the heart and repair of structural defects (Warden et al., 1954). 
Between March 1954 and May 1955, Lillehei and colleagues used this technique of 
controlled cross-circulation to operate on 45 children including the first successful 
repairs of a ventricular septal defect, an atrioventricular septal defect and Tetralogy of 
Fallot (Lillehei et al., 1955a, Lillehei et al., 1955b). This seminal achievement was 
acknowledged by the Lasker Award for Clinical Medical Research in 1955 (Gott and 
Shumway, 2004). Remarkably, 28 (62%) children were discharged home and 20 
(44%) are alive today without significant limitations related to their original condition 
(Lillehei et al., 1986, Moller et al., 2009). Meanwhile, others were using alternative 
biological strategies for extracorporeal support; in Toronto, William T. Mustard 
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employed the freshly extricated lungs of rhesus monkeys as an artificial oxygenator, 
positioned inside bell jars and connected to a pump (Mustard and Thomson, 1957). 
Alas, the outcomes were almost universally poor and many surgeons were now 
working towards the holy grail of early cardiac surgery – a heart-lung machine. 
 
In order for such a device to be safe and effective, three factors would need to be 
overcome: predictable and reversible anticoagulation to prevent clot formation in the 
machine or excessive postoperative bleeding; a method for pumping blood without 
significant haemolysis; and a means of oxygenating the circulating blood whilst 
removing carbon dioxide (Stoney, 2009). By the middle of the last century, heparin 
and protamine were readily available, and several pumps used by the dairy sector 
could be adapted for the task; the major problem however was an artificial 
oxygenator. This challenge was taken up by numerous teams around the world 
through innovation, sharing of ideas and collaboration with industry, a feature that 
would become a driving force in the development of the speciality; by the time that 
the Space Race took off, the race to mechanise cardiac surgery was well underway. 
 
Its early leader was John H. Gibbon Jr. at the Jefferson Medical College in 
Philadelphia. Supported by engineers and funding from IBM during 1946-53, he 
developed a vertical screen oxygenator fed by roller pumps, culminating in the first 
successful heart operation using cardiopulmonary bypass (Gibbon, 1954). However, 
the machine was complicated, expensive, labour-intensive and at times 
temperamental; three of the first four patients died in the operating room and after 19 
years of laboratory development, Gibbon imposed a year-long moratorium on the 
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clinical use of his machine (Romaine-Davis, 1991). Inspired by Gibbon, Clarence 
Crafoord, Viking Olov Björk and Åke Senning at the Karolinska Institute, Stockholm 
had been working on a rotating disc oxygenator with engineers at the AGA Company 
and in July 1954, successfully removed a left atrial myxoma (Crafoord et al., 1957). 
Meanwhile at the Mayo Clinic in Rochester, John W. Kirklin and colleagues were 
modifying Gibbon’s complex vertical screen oxygenator (Kirklin et al., 1956) and just 
60 miles away in Minneapolis, Richard A. DeWall was developing a more simple 
bubble oxygenator system (DeWall et al., 1956). In May 1955, Lillehei switched from 
controlled cross-circulation to the DeWall bubble oxygenator and within a year, a 
sterile disposable version of the device was on the market (Lillehei et al., 1956). This 
inexpensive yet effective device enabled many medical centres to start a cardiac 
surgery programme and in the words of Denton A. Cooley (Lillehei et al., 1986): 
“Walt Lillehei brought the can opener to the cardiac surgery picnic.” 
 
Through the 1960s, the bubble oxygenator with an integrated defoaming chamber 
and heat exchanger, emerged as the dominant technology. By the mid-1980s, 
microporous hollow-fibre membrane oxygenators became commercially available and 
remain the most common in use around the world today. 
 
Whilst the advent of cardiopulmonary bypass (CPB) was a major milestone in the 
development of open heart surgery, other problems remained: opening the 
contracting heart had the potential for fatal massive air embolism; operating on the 
beating heart was technically difficult; and blood return through the coronary sinus 
and pulmonary veins often obscured the operative field (Cordell, 1995). Attention 
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now turned to developing methods for the elective and reversible arrest of the heart 
whilst the bypass machine maintained circulation to the brain and other vital organs. 
The key to open heart surgery would be allowing a safe period of cardiac arrest 
during cessation of coronary blood flow by minimising the effects of ischaemia, a 
concept known today as myocardial protection. 
 
In this thesis, I explore the metabolic pathways involved in generating energy for 
maintaining homeostasis and performing the contractile function of the myocardial 
cell, and the effect of ischaemia and subsequent reperfusion on these processes. I 
then focus on how the resulting injury can be minimised in the field of cardiac surgery 
through current and novel techniques, including the application of metabolic drug 
therapies. I present clinical and laboratory data obtained through a trial of the 
metabolic agent perhexiline in patients undergoing coronary artery bypass graft 
(CABG) surgery on CPB to evaluate its potential application to myocardial protection. 
I also use the opportunity to perform the first direct studies in humans on the 
myocardial pharmacokinetics of perhexiline and its effects on myocardial metabolism. 
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1.2 Metabolism and the myocardium 
‘And what is a man without energy? Nothing – nothing at all.’ 
(Twain, 1860) 
 
1.2.1 Adenosine triphosphate and the transfer of free energy 
All living things require a continual input of free energy for three major purposes: the 
performance of mechanical work in muscle contraction and cellular movement, the 
active transport of molecules and ions, and the synthesis of macromolecules from 
simple precursors. The metabolic pathways that drive these processes are highly 
efficient and have been remarkably conserved throughout evolution. 
 
Adenosine triphosphate (ATP) is the principal immediate donor of free energy in 
biological systems and is continuously formed and consumed. The triphosphate unit 
of ATP contains two phosphoanhydride bonds which release large amounts of free 
energy when hydrolysed to adenosine diphosphate (ADP) or adenosine 
monophosphate (AMP). The energy charge of a cell is the ratio of high-energy 
phosphoanhydride bonds to the mole fraction of ATP, ADP and AMP. If the energy 
charge falls, AMP levels rise and stimulate AMP-activated protein kinase (AMPK), a 
master regulator of intracellular metabolism. Allosteric activation of AMPK increases 
the cellular energy level by inhibiting synthetic, ATP-consuming pathways and 
stimulating catabolic, ATP-generating pathways including glycolysis and β-oxidation 
of fatty acids; AMPK thereby acts as a ‘fuel gauge’ for the cell (Hue and Rider, 2007). 
 
As the turnover of ATP is so high, it is not a useful mode of energy storage. In order 
to sustain contractile activity, muscle contains a reservoir of high-phosphoryl groups 
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in the form of phosphocreatine (PCr) which can readily transfer a ~P group to ATP 
catalysed by creatine kinase. PCr therefore acts as a short-term high-energy 
phosphate buffer enabling maintenance of a high ATP concentration during bursts of 
intense energy demand such as the initiation of exercise. Longer term energy storage 
is afforded by macromolecules such as glycogen and triglycerides that can be 
mobilised in response to energy needs. 
  
Hans Krebs (1957) described three stages in the generation of energy from the 
oxidation of foodstuffs: the digestion of complex macromolecules into smaller units; 
the conversion of these small molecules into a few simple units, principally the acetyl 
group of acetyl-CoA; and finally, the entry of these intermediates into the citric acid 
cycle and electron transport chain. The evolutionary endurance of these metabolic 
pathways is due to their efficiency in extracting the maximum yield of free energy 
through complete oxidation. The main substrates of metabolism are carbohydrates, 
fats and proteins although energy may also be derived from other molecules 
including ketones, lactate and alcohol. 
 
1.2.2 Glucose metabolism 
Complex carbohydrates from the diet are digested into monosaccharides and stored 
as glycogen mainly in the liver and skeletal muscle. The concentration of glucose in 
the blood is maintained at a relatively constant level by glycogenolysis and 
gluconeogenesis in the liver which exports glucose into the circulation for use in other 
tissues. Glucose is a polar molecule that moves into the cell by facilitated diffusion 
via passive glucose transporters in the plasma membrane. The GLUT1 isoform is 
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responsible for the low-level basal glucose uptake down a thermodynamic gradient 
required to sustain respiration in all cells. GLUT4 is the main glucose transporter 
expressed on myocardial cells and is stimulated by insulin, catecholamines and 
ischaemia, recruiting an increased number of transporters to the plasma membrane 
from intracellular vesicles (Depre et al., 1999). 
 
Once inside the cell, glucose is phosphorylated to glucose-6-phosphate (G6P) by 
hexokinase and directed into one of four alternative pathways in the cytosol: storage 
as glycogen, hexosamine biosynthesis, the pentose phosphate pathway or glycolysis 
(Bouche et al., 2004). Glycogen granules are a medium-term energy reserve that can 
be rapidly mobilised to meet a sudden demand for G6P; in muscle cells, a lack of 
glucose-6-phosphatase activity prevents glucose resynthesis or export, so G6P 
liberated from glycogen is obliged to enter one of the other metabolic pathways within 
the cell. The hexosamine biosynthetic pathway produces glucosamine and 
subsequently N-acetylglucosamine, a key regulator of post-translational nuclear and 
cytoplasmic protein activity in addition to being a precursor in the synthesis of 
glycosaminoglycans, proteoglycans and glycolipids (Hanover et al., 2010). The 
pentose phosphate pathway is primarily an anabolic process producing 5-carbon 
sugars but is also the major source of reduced nicotinamide adenine dinucleotide 
phosphate (NADPH), a reducing equivalent used in biosynthesis and oxidative-
reduction reactions including protection against oxidative stress. However, the 
majority of cytosolic G6P enters the glycolytic pathway to produce pyruvate. 
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1.2.3 Glycolysis 
The glycolytic (Embden-Meyerhof) pathway consists of two phases: a preparatory 
phase in which energy-absorbing steps facilitate the splitting of glucose into two 
molecules of glyceraldehyde-3-phosphate (G3P); and a pay-off phase where each 
G3P is oxidised to pyruvate and energy is harvested (figure 1). The end products of 
glycolysis are two pyruvate, two reduced nicotinamide adenine dinucleotide (NADH) 
and a net gain of two ATP, independent of the availability of oxygen. 
 
The pathway has two major roles: the oxidation of glucose to generate ATP and the 
provision of building blocks for synthetic reactions, and is regulated to meet these two 
major cellular needs. The reactions catalysed by hexokinase, phosphofructokinase 
(PFK) and pyruvate kinase are irreversible and thereby act as sites of control through 
reversible allosteric binding, phosphorylation and transcription. PFK is the key 
regulatory site for the rate of glycolysis. Allosteric control is elicited by a high 
concentration of ATP and reversed by AMP so that activity increases when the 
ATP/AMP ratio falls i.e. glycolysis is stimulated as the energy charge drops. Another 
key regulator of PFK activity is fructose 2,6-bisphosphate (F2,6-BP), the production 
and degradation of which are catalysed by phosphofructokinase 2 (PFK2) and 
fructose bisphosphate 2 (FBPase2) respectively, a bifunctional enzyme which 
responds to glucose availability via feedforward stimulation (Rider et al., 2004). 
Thereby, when glucose is abundant, the enzyme is dephosphorylated, activating 
PFK2 and inhibiting FBPase2, which leads to a rise in F2,6-BP, stimulation of PFK 
and the consequent acceleration of glycolysis. In addition, PFK is inhibited by a fall in 
pH thereby preventing excessive lactate formation and a further fall in pH. 
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As each glucose produces two G3P, glycolysis leads to 2 pyruvate, 2 NADH and a net gain of 2 ATP. 
 
Figure 1. The glycolytic pathway. 
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The fate of pyruvate is determined by the relative availability of oxygen. When 
oxygen is limited, pyruvate is reduced by lactate dehydrogenase (LDH) to produce 
lactate at the expense of consuming one NADH. Therefore, in the conversion of 
glucose to lactate, there is no net oxidation-reduction; the NADH formed in the 
oxidation of glyceraldehyde 3-phosphate is consumed in the reduction of pyruvate. 
This enables glycolysis to continue under anaerobic conditions, generating low levels 
of ATP which are crucial for cell viability prior to the return of an oxygen-rich 
environment. Lactate produced during anaerobic metabolism enters the bloodstream 
and is transported to the liver where it is reoxidised to pyruvate and then glucose via 
the gluconeogenic pathway. This process, known as the Cori cycle, enables a shift of 
the metabolic burden to the liver through the recycling of lactate. On the other hand, 
during aerobic conditions, the heart is a net importer of lactate which is converted to 
pyruvate, generating one NADH and thereby improving the redox status of the cell. 
Pyruvate is transported into the mitochondria by the monocarboxylase transporter 
where it is converted to acetyl-CoA or oxaloacetate and enters the citric acid cycle. 
 
1.2.4 Fatty acid metabolism 
Fatty acids are stored as triglycerides, uncharged esters of glycerol that are a highly 
concentrated source of energy; one gram of anhydrous fat stores more than six times 
as much energy as one gram of hydrated glycogen and is therefore the major 
reservoir of metabolic energy. Storage of triacylglycerol (TAG) occurs principally in 
the cytoplasm of adipose cells and is mobilised by hydrolysis to glycerol and fatty 
acids by lipases. Adrenaline, noradrenaline, glucagon and ACTH promote lipolysis 
through the activation of adenylate cyclase whilst insulin inhibits adipose cell lipases. 
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Free fatty acids (FFA) are released into the bloodstream and taken up into cells by 
transporters. The myocardium also has a small endogenous store of triglycerides 
with a high rate of turnover, providing an important source of fatty acids for oxidative 
metabolism when the exogenous supply is reduced (Saddik and Lopaschuk, 1991).  
 
On the outer mitochondrial membrane, fatty acids are activated by esterification to 
acyl-CoA, a reaction catalysed by fatty acyl-CoA synthetase that consumes one ATP. 
Activated long chain fatty acids are shuttled across the mitochondrial membranes by 
the carnitine-palmitoyltransferase (CPT) enzyme system (figure 2). Acyl-CoA is 
conjugated to carnitine by CPT-1 located on the outer mitochondrial membrane and 
then shuttled into the matrix by a translocase. On the inner mitochondrial membrane, 
CPT-2 liberates acyl-CoA allowing carnitine to be returned to the cytosol by the 
translocase in exchange for another acyl-carnitine (Lopaschuk et al., 2010). 
 
 
 
Figure 2. The carnitine-palmitoyltransferase system. 
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Energy is derived from fatty acids through β-oxidation in the mitochondrial matrix. A 
saturated molecule of acyl-CoA is degraded by a recurring series of four reactions: 
oxidation by acyl-CoA dehydrogenase and flavin adenine dinucleotide (FAD), 
hydration, oxidation by nicotinamide adenine dinucleotide (NAD+) and thiolysis by 
another molecule of coenzyme A (figure 3). Each sequence shortens the fatty acyl 
chain by two carbon atoms and produces one FADH2, one NADH and an acetyl-CoA. 
Therefore, one molecule of palmitate, a C16-chain fatty acid, yields eight molecules of 
acetyl-CoA (C2), seven FADH2 and seven NADH to enter the citric acid cycle and 
electron transport chain. Odd-chain fatty acids are a minority and generate propionyl-
CoA (C3) and acetyl-CoA in the final round of degradation; propionyl-CoA is 
converted into succinyl-CoA and enters the cycle (Lopaschuk et al., 2010). 
 
 
 
Figure 3. The β-oxidation of fatty acids. 
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Fatty acid metabolism in the heart is closely regulated and responsive to energy 
demand. CPT-1 is the key determinant of long-chain fatty acid uptake into the 
mitochondria for β-oxidation and is potently inhibited by allosteric binding of malonyl-
CoA. The concentration of malonyl-CoA is dependent on the balance between its 
synthesis by acetyl-CoA carboxylase (ACC) and its degradation by malonyl-CoA 
decarboxylase (MCD). ACC activity in the heart is regulated by AMPK, the cellular 
fuel sensor, which increases β-oxidation during times of energy need and applies the 
malonyl-CoA brake when demand is reduced. ACC is also under indirect hormonal 
control, activated by insulin but inhibited by adrenaline (Lopaschuk et al., 2010). 
 
1.2.5 Citric acid cycle 
Also known as the tricarboxylic acid or Krebs cycle, the citric acid cycle is the central 
metabolic pathway in all living beings that use oxygen in cellular respiration and is the 
final common pathway for the oxidation of fuel molecules – carbohydrates, fatty acids 
and amino acids. This series of reactions takes place in mitochondria, organelles that 
are believed to have originated as phagocytosed respiring bacteria but became 
domesticated within eukaryotic cells in a symbiotic energy-producing relationship. 
Unlike glycolysis, the citric acid cycle can only operate under aerobic conditions; 
whilst molecular oxygen does not directly participate in the cycle, it is essential for the 
regeneration of NAD+ and FAD by accepting electrons in the electron transport chain. 
 
The oxidative decarboxylation of pyruvate (C3) to form acetyl-CoA (C2) in the 
mitochondrial matrix is the link between glycolysis and the citric acid cycle. Catalysed 
by the pyruvate dehydrogenase (PDH) complex, it is the key irreversible rate-limiting 
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step for glucose oxidation, regulating the flow of carbohydrate-derived acetyl-CoA 
into the cycle. The activity of PDH is stringently controlled through phosphorylation 
and dephosphorylation by the enzymes pyruvate dehydrogenase kinase (PDK) and 
PDH-phosphatase respectively. PDK deactivates PDH, reducing glucose oxidation in 
response to increases in NADH/NAD+, acetyl-CoA/CoA or ATP/ADP ratios i.e. it is 
turned off when the energy charge in the cell is high and biosynthetic intermediates 
are abundant (Goodwin et al., 1998). 
 
 
 
Figure 4. The citric acid cycle. 
 
 
Pyruvate
Pyruvate dehydrogenase
CoA-SH + NAD+
CO2 + H
+ + NADH
Citrate
Isocitrate
α-ketoglutarate
Succinyl-CoASuccinate
Fumarate
Malate
Oxaloacetate
Citrate synthase
Aconitase
Isocitrate 
dehydrogenase
α-ketoglutarate 
dehydrogenase
Succinyl-CoA 
synthetase
Succinate 
dehydrogenase
Fumarase
Malate 
dehydrogenase
GDP + Pi
H2O
NAD+ + CoA-SH
NADH + H+ + CO2
CoA-SH + GTP
NAD+
NADH + H+ CO2
FADH2
FAD
H+ + NADH
NAD+
H2O
CoA-SH
Pyruvate carboxylase
HCO3- + ATP
ADP + Pi
Acetyl-CoA
Pyruvate
17 
 
Acetyl-CoA (C2) enters the citric acid cycle by condensing with oxaloacetate (C4) to 
form citrate (C6). Through a series of reactions (figure 4), oxaloacetate is regenerated 
with the liberation of energy in the form of intermediates; in effect, oxaloacetate is a 
catalyst for the cycle as it participates in the overall reaction but is not consumed by 
it. The net product of one molecule of acetyl-CoA entering the cycle is two molecules 
of CO2, one GTP, three reduced NADH and one FADH2. Of note, the two carbon 
atoms that enter the cycle as acetyl-CoA are not the same two that are released as 
CO2 in that round. 
 
The citric acid cycle is precisely regulated to meet the energy needs of the cell. 
Pyruvate carboxylase is activated by acetyl-CoA to covert pyruvate into oxaloacetate 
which increases the rate of the cycle. Whilst most of the acetyl-CoA that enters the 
cycle is derived from fatty acids, it is the production of oxaloacetate from glycolysis-
derived pyruvate that determines flux through the cycle and therefore the rate of 
energy production (Jitrapakdee et al., 2008). The activities of citrate synthase, 
isocitrate dehydrogenase and the α-ketoglutarate dehydrogenase complex are also 
diminished by a high energy charge and several steps in the cycle require NAD+ or 
FAD carriers which are only abundant when energy charge is low. 
 
In the fasted state, when the effects of insulin are absent and plasma glucose is low, 
oxaloacetate in the liver is consumed to form glucose via the gluconeogenic pathway 
and is unavailable for condensation with acetyl-CoA derived from fatty acid oxidation 
to enter the citric acid cycle. In these conditions, acetyl-CoA is diverted into formation 
of ketone bodies – acetoacetate and β-hydroxybutyrate. Initially regarded as waste 
18 
 
products released into the blood, it is now known that ketone bodies are normal fuels 
of respiration and quantitatively important sources of energy; indeed the heart uses 
acetoacetate in preference to glucose (Kodde et al., 2007). Acetoacetate is activated 
by the transfer of coenzyme A from succinyl-CoA and then cleaved by thiolase to 
produce two molecules of acetyl-CoA which can enter the cycle. Ketone bodies may 
be regarded as a transportable form of acetyl units that are exported from the liver 
during fasting for oxidation elsewhere. 
 
Anaplerosis is the replenishment of the pool of biosynthetic intermediates in the citric 
acid cycle. Whilst α-ketoglutarate and oxaloacetate are amino acid precursors, 
surplus amino acids may also be used as a metabolic fuel by conversion to pyruvate, 
acetoacetate, acetyl-CoA or other cycle intermediates. Overall, intermediates must 
be replenished by anaplerosis else the cycle will rapidly halt due to a lack of 
oxaloacetate (Owen et al., 2002). 
 
1.2.6 Electron transport chain 
The NADH and FADH2 formed during glycolysis, fatty acid oxidation and the citric 
acid cycle are energy-rich molecules that have a high electron transfer potential. The 
inner mitochondrial membrane is impermeable to NADH and so electrons from 
glycolytic NADH enter the mitochondria via the malate-aspartate shuttle (figure 5). 
The net effect of the shuttle is purely redox, regenerating NAD+ and enabling 
electrons from cytosolic NADH to participate in the electron transport chain. Oxidative 
phosphorylation is the complex process through which ATP is formed as a result of 
the transfer of electrons to oxygen by a series of electron carriers (Rich, 2003). 
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Figure 5. The malate-aspartate shuttle. 
 
According to Mitchell’s (1961) Nobel prize-winning chemiosmotic hypothesis, it 
occurs across the inner mitochondrial membrane and is the major source of ATP 
production in aerobic organisms. In the first phase of oxidative phosphorylation, 
electron-motive force is converted into proton-motive force. Electrons are transferred 
from NADH to O2 through a chain of three large protein complexes: NADH 
dehydrogenase (Complex I), cytochrome bc1 complex (III) and cytochrome c oxidase 
(IV) (figure 6). FADH2 enters the pathway via succinate dehydrogenase (II) and 
ubiquinone (Q) after the first proton pumping site and therefore produces less ATP 
than NADH. The flow of electrons within these transmembrane complexes leads to 
the pumping of protons across the inner mitochondrial membrane from the matrix to 
the intermembrane space. In the second phase, the potential of the transmembrane 
proton concentration gradient is converted into phosphoryl potential in the form of 
high-energy bonds. The flow of protons back into the mitochondrial matrix through 
the proton channel core of F0F1-ATP-synthase is coupled to the formation of ATP 
from ADP and inorganic phosphate. 
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Figure 6. The electron transport chain. 
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In recent years, the yield of ATP synthesis from the electron transport chain has been 
re-evaluated (Rich, 2003). It is now apparent that one complete revolution of the 
motor element of ATP synthase requires ten H+ and generates 3 ATP whilst an 
additional proton is consumed in transporting each ATP to the cytosol via ATP-ADP 
translocase; hence the net synthesis of cytoplasmic ATP from ADP should operate 
on a ratio of 13:3 H+/ATP. It has been estimated that ten protons are pumped out of 
the matrix for each NADH and six protons for each FADH2 donating a pair of 
electrons to the transport chain. Consequently, it is predicted that NADH generates 3 
x 10/13 ≈ 2.3 cytosolic ATP and oxidation of succinate via FADH2 produces 3 x 6/13 
≈ 1.4 ATP per electron pair donated. The complete oxidation of one molecule of 
glucose to CO2 through glycolysis, the citric acid cycle and oxidative phosphorylation 
therefore generates a net yield of approximately 30 ATP, of which 26 are harvested 
via the electron transport chain. On the other hand, one molecule of the fatty acid 
palmitate (C16) produces a net yield of around 106 ATP through β-oxidation, the citric 
acid cycle and oxidative phosphorylation, demonstrating the greater caloric value of 
fats than carbohydrates. However, it is important to note that the energy derived from 
substrates is not equal. The oxidation of fatty acids requires approximately 12% more 
oxygen by stoichiometry than that of glucose to generate an equivalent amount of 
ATP due to an increased FADH2 to NADH ratio; in terms of oxygen consumption, 
glucose is a more efficient fuel (Liedtke, 1981). Whilst almost all ATP is generated 
through the same final common pathways, the yields and costs of oxidation have 
significant implications on substrate selection especially when oxygen is limited. 
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1.2.7 Myocardial substrate utilisation 
The human heart consumes up to 5kg of ATP per day, more than any other organ of 
the body per gram of tissue. Myocardial energy reserves are limited, so ATP must be 
continually produced by the catabolism of carbon compounds. Metabolism is tightly 
controlled at many levels to produce sufficient ATP to meet the immediate contractile 
and homeostatic demands of the heart. A complex and integrated signalling pathway 
has evolved to regulate supply precisely and respond to changes in demand for 
energy. The heart is a true omnivore, metabolising a variety of competing substrates 
from the bloodstream (figure 7). Under normal aerobic conditions, it generates 70% 
of its ATP from the β-oxidation of fatty acids, 10-30% from the uptake and oxidation 
of glucose and the remainder from lactate, pyruvate, ketones and amino acids 
(Taegtmeyer, 2007). The relative utilisation of substrates is determined by availability, 
blood supply, cardiac workload, hormonal control and the regulation of metabolic 
genes at a transcriptional level resulting in the altered expression of receptors, 
transporters, enzymes and regulators as an adaptive response (Taegtmeyer, 2002). 
 
The glucose-fatty acid cycle, or Randle (1963) cycle, is the primary local regulatory 
mechanism for determining substrate oxidation. An abundance of FFA undergoing β-
oxidation increases the ratios of acetyl-CoA/CoA and NADH/NAD+ which stimulate 
PDK to inhibit the PDH complex and decrease the entry of pyruvate into the citric 
acid cycle. Hence, FFA are preferentially oxidised over glucose and are the dominant 
substrate for myocardial metabolism. A counter balance is achieved through the 
potent inhibition of CPT-1 by malonyl-CoA, thereby decreasing the uptake of FFA into 
the mitochondria and reducing β-oxidation (Ussher and Lopaschuk, 2008). 
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Figure 7. An overview of myocardial substrate metabolism. 
 
Mitochondrial ATP synthesis is dependent upon the electrochemical proton gradient 
across the inner membrane. Uncoupling proteins (UCP) 1-5 are membrane transport 
proteins that enable re-entry of protons into the matrix without the generation of ATP. 
UCP3 is a transporter that exports excess fatty acid anions out of the matrix; once in 
the intermembrane space, the anion can associate with a proton, re-esterify with CoA 
and be transported back into the matrix. This has the benefit of recycling CoA but at a 
cost of ATP and a net leak of protons from the matrix (Lopaschuk et al., 2010). Futile 
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cycling of fatty acid intermediates also contributes to non-contractile consumption of 
ATP, reducing the net energy yield from fatty acids and decreasing cardiac efficiency. 
 
An acute increase in cardiac workload, during exercise or inotropic stimulation, 
requires a substantial rise in ATP generation. This need is initially met through stores 
of PCr and then by the preferential oxidation of intracellular glycogen, lactate and 
glucose (Goodwin et al., 1998). If the high energy requirement remains, triglycerides 
mobilised from adipose tissue in response to catecholamine stimulation provide an 
additional substrate. This metabolic reserve forms a link between coronary flow 
reserve (supply) and contraction (demand) (Kassiotis et al., 2008). 
 
Substrate utilisation is influenced by circulating hormones, most notably insulin and 
the catecholamines, through α- and β-receptor stimulation. Adrenergic hormones 
stimulate cellular ATP production through the oxidation of all available substrates. 
Local glycogenolysis and recruitment of glucose transporters is enhanced whilst 
stimulation of lipolysis in adipose cells and gluconeogenesis in the liver increase the 
availability of circulating fatty acids and glucose. Insulin, on the other hand, has a 
glucose-selective effect by stimulating glucose uptake, glucose oxidation and 
glycogen synthesis but inhibiting fatty acid oxidation. The activated insulin receptor 
initiates phosphorylation cascades including the insulin receptor substrates (IRS), 
phosphatidyl-inositol-3-kinase (PI3K), glycogen synthase kinase 3 (GSK-3) and Akt 
which mediates many of its metabolic effects. There is emerging evidence that 
circulating adipokines, such as leptin, may be important modulators of myocardial 
metabolism particularly via promotion of fatty acid oxidation (Karmazyn et al., 2008). 
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Mitochondrial oxidative energy metabolism is also regulated at a gene transcription 
level. Peroxisome proliferator-activated receptor γ co-activator-1 (PGC-1α) is a 
master regulator of myocardial metabolism that functions to increase β-oxidation of 
fatty acids, inhibit pyruvate oxidation via the citric acid cycle and promote 
mitochondrial biogenesis (Finck and Kelly, 2007). 
 
Therefore, in addition to substrate and oxygen availability, myocardial metabolism is 
subject to multiple levels of control including workload (seconds → minutes), 
hormones (minutes → hours) and gene transcription (hours → days). Whilst these 
regulators have independent mechanisms of action, their effects are interlinked. 
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1.3 Ischaemia and reperfusion 
‘Myocardial reperfusion: a double-edged sword?’ 
(Braunwald and Kloner, 1985) 
 
In the healthy heart, over 95% of the energy generated is derived from mitochondrial 
oxidative phosphorylation, with the remainder from glycolysis. The optimal metabolic 
and contractile function of the myocardium therefore requires a continuous supply of 
oxygen and substrates; if this is reduced or interrupted, the efficient production of 
ATP is inhibited. The consequences that result depend upon the degree and 
persistence of the metabolic insult. In chronic heart failure, impairment of substrate 
metabolism contributes to contractile dysfunction and ventricular remodelling; this 
maladaptive response is characterised by downregulation of fatty acid oxidation, 
increased glycolysis and an impaired reserve for mitochondrial oxidative flux (Stanley 
et al., 2005). On the other hand, ischaemia and subsequent reperfusion precipitate 
an acute metabolic challenge that threatens cell survival. 
 
1.3.1 Ischaemia 
In low-flow ischaemia, PCr stores are rapidly exhausted and the falling energy charge 
of the cell activates AMPK to promote anaerobic energy production and suppress 
energy-requiring biosynthetic processes. AMPK promotes the utilisation of glucose by 
promoting glucose uptake and activating PFK to accelerate the rate of glycolysis in 
an attempt to make up for the reduction in oxidative ATP production. However, it also 
inhibits acetyl-CoA carboxylase leading to a fall in malonyl-CoA levels and a 
subsequent increase in the uptake and β-oxidation of FFA (Hopkins et al., 2003). In 
ischaemia, catecholamine-induced lipolysis causes a dramatic rise in circulating FFA 
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levels which dominate competition for residual oxidative capacity but have a 
detrimental effect on the ischaemic myocardium (Liedtke, 1981); this is exacerbated 
during cardiac surgery as the administration of heparin also increases plasma FFA. A 
relative increase in the β-oxidation of FFA inhibits the pyruvate dehydrogenase 
complex, uncoupling glycolysis from the citric acid cycle; the fate of pyruvate is 
shifted from oxidation to lactate production, enabling ATP production to continue 
through anaerobic metabolism at the expense of contributing to cellular acidosis and 
further reducing myocardial contractile function (Depre et al., 1999). High levels of 
FFA are associated with a fall in myocardial metabolic efficiency of around 30% 
(Myrmel et al., 1992), significantly more than the 12% predicted by stoichiometry 
alone (Liedtke, 1981). This oxygen-wasting effect is proposed to occur via the 
activation of PPARα, upregulation of the expression of mitochondrial uncoupling 
proteins and dissipation of the electrochemical gradient (Murray et al., 2004). In 
addition, accumulation of β-oxidation intermediates has been shown to induce 
diastolic dysfunction during ischaemia (Kennedy et al., 2000). 
 
During total ischaemia, glucose uptake cannot be increased although mobilisation of 
glycogen stores enables a temporary increase in glycolytic lactate production. 
Despite stimulation of AMPK, oxidation of fatty acids and glucose stops due to lack of 
oxygen. The accumulation of long-chain acyl-carnitines contributes to the initiation of 
cell-to-cell electrical uncoupling and predisposes to arrhythmias (Yamada et al., 
1994). The low level of cytosolic ATP produced during ischaemia is primarily used to 
maintain cellular ion homeostasis in the face of worsening acidosis. Progressive loss 
of ATP is accompanied by degradation of adenine nucleotides and a massive rise in 
28 
 
the concentration of inorganic phosphate. If total ischaemia persists, glycolysis halts 
due to the accumulation of lactate and protons and the inability to regenerate NAD+. 
As cytosolic phosphorylation potential falls further, there is failure of ATP-dependent 
Ca2+ pumps in the plasma membrane and sarcoplasmic reticulum (Crompton, 1999). 
Intracellular acidosis activates plasma membrane Na+-H+ exchange, leading to 
increased intracellular sodium; this subsequently drives the Na+-Ca2+ membrane 
pump with a marked rise in cytosolic calcium (figure 8). A lack of ATP, intracellular 
acidosis and calcium overload results in cessation of contractile function and without 
restoration of myocardial perfusion, cell death is inevitable within 40-60 minutes. 
 
 
 
Figure 8. An overview of ischaemia-reperfusion injury. 
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1.3.2 Reperfusion 
Clearly reperfusion of the ischaemic myocardium is the prerequisite for limiting cell 
death and the potential return of contractile function. However reperfusion may have 
unwanted effects of its own and cause additional cellular damage, known as 
reperfusion injury. The extent of myocardial injury is therefore a composite of that 
caused by ischaemia and reperfusion; this has clinical importance since interventions 
targeting the reperfusion phase may be implemented when there has already been a 
significant period of ischaemia, such as in a patient presenting with a myocardial 
infarction (Kharbanda, 2010). 
 
During reperfusion of the ischaemic heart, the rate of glycolysis remains elevated but 
FFA dominate oxidative energy production at the expense of pyruvate (Liu et al., 
1996). Activation of AMPK persists into reperfusion, inhibiting ACC and leading to low 
levels of malonyl-CoA. CPT-1-mediated uptake and β-oxidation of FFA is accelerated 
to meet the energy demand of the cell but at the expense of continued PDH complex 
inhibition. Despite the restoration of glucose availability, glycolysis remains 
uncoupled from the citric acid cycle and increased production of lactate and protons 
worsens the cellular acidosis and decreases cardiac efficiency. Washout of the acidic 
extracellular environment during reperfusion further increases the pH gradient across 
the plasma membrane, promoting a second wave of rising intracellular sodium and 
further calcium overload in the cytosol and mitochondria (Crompton, 1999). The 
increased requirement for ATP to restore ischemia-induced alterations in ion 
homeostasis also contributes to the impairment in contractile function during 
reperfusion. 
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The return of molecular oxygen to ischaemic tissue leads to oxidative stress with the 
formation of ROS including superoxide anions (•O2
-), hydroxyl radicals (•OH-) and 
hydrogen peroxide (H2O2). Reperfusion causes an immediate burst of •O2
- production 
due to the build up of one-electron donors in the respiratory chain during the 
preceding ischaemia; mitochondria are therefore especially vulnerable to oxidative 
stress on reperfusion (Lenaz, 1998). The release of ROS rapidly exceeds the 
capacity of endogenous antioxidant scavenging systems resulting in damage to 
mitochondrial and cellular components through lipid peroxidation, protein oxidation 
and DNA mutations. ROS also stimulate an acute inflammatory response with 
activation, adherence and chemotaxis of leukocytes, activation of complement and 
direct endothelial damage. 
 
Over the last two decades, opening of the mitochondrial permeability transition pore 
(mPTP) has emerged as the central hypothesis for the triggering of cell death during 
ischaemia-reperfusion injury (Crompton, 1999). The mPTP is a non-selective, high 
conductance channel that forms at sites where the inner and outer mitochondrial 
membranes converge although its exact structure is yet to be defined. Assembly and 
opening of the mPTP during reperfusion is triggered by mitochondrial calcium 
overload and promoted by the rise in inorganic phosphate, loss of ATP and protective 
adenine nucleotides, and increased oxidative stress (figure 8). By rendering the inner 
mitochondrial membrane freely permeable to protons, widespread opening of the 
mPTP dissipates the transmembrane proton concentration gradient, uncoupling 
oxidative phosphorylation such that mitochondria hydrolyse rather than synthesise 
ATP (figure 9). The ATP-generating capacity of the cell is overwhelmed and a vicious 
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cycle of impaired energy metabolism, further loss of calcium homeostasis and 
progressive pore opening leads to necrotic cell death. If the ischaemic insult is less 
severe and mPTP opening is more limited, enabling the cell to maintain sufficient 
ATP for viability, rupture of the outer mitochondrial membrane may trigger a caspase 
cascade, leading to apoptotic cell death (Crompton, 1999). 
 
 
 
Figure 9. The mitochondrial permeability transition pore and ATP hydrolysis. 
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reperfusion injury (Gomez et al., 2008). An alternative intrinsic mechanism, the 
Survivor Activating Factor Enhancement (SAFE) pathway, has also been described 
in which the pro-inflammatory cytokine TNFα paradoxically activates the JAK/STAT3 
signalling pathway to promote cell survival (Lecour, 2009). These pathways represent 
potential therapeutic targets for attenuating the cellular effects of ischaemia-
reperfusion in the heart and other organs. 
 
1.3.3 Ischaemia-reperfusion injury in cardiac surgery 
Most cardiac surgery involves a period of elective myocardial ischaemia; as such, 
this represents both a clinical challenge and a practical opportunity to examine the 
effects of ischaemia-reperfusion on the human myocardium. A prolonged period of 
ischaemia results in myocardial necrosis with permanent loss of contractile function 
and release of large quantities of intracellular markers, such as creatine kinase and 
troponins, into the circulation. A short period of total or low-flow ischaemia invariably 
causes temporary contractile dysfunction which persists after blood flow and ATP 
production are restored. This post-ischaemic hangover is termed myocardial stunning 
as it ultimately leads to biochemical, physiological and clinical recovery (Braunwald 
and Kloner, 1982). The degree of clinical dysfunction due to myocardial stunning can 
be assessed by measuring cardiac contractility in the early postoperative period, 
either as absolute cardiac output or the frequency of a low cardiac output episode. As 
impairment of the stunned myocardium is reversible upon adrenergic stimulation 
(Ellis et al., 1984), the quantity of inotropic support required is also a marker of the 
effects of ischaemia-reperfusion injury. The clinical application of these markers of 
ischaemia-reperfusion injury will be discussed further in Chapter 3, section 2.7. 
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1.4 Myocardial protection: principles and practice 
‘Be still my heart; thou hast known worse than this’ 
(Homer, c.850 BC) 
 
The term myocardial protection refers to the strategies used to prevent or attenuate 
the myocardial dysfunction that occurs during or after cardiac surgery due to an 
ischaemic insult (Mentzer et al., 2008). It provides a window of opportunity for 
permissive ischaemia during which interventions can be performed without significant 
irreversible damage to the myocardium on reperfusion. Whilst this principle was 
recognised by Bigelow and exploited by Lewis almost 60 years ago, it soon became 
clear that systemic hypothermia alone would be insufficient for more challenging 
intra-cardiac procedures and focused solutions would be required to prolong the 
tolerable ischaemic period. 
 
1.4.1 Cardioplegia: the solution to myocardial protection? 
In July 1955, Denis G. Melrose and colleagues at the Postgraduate Medical School in 
London published an experimental report in The Lancet on elective cardiac arrest 
using potassium citrate. Adult dogs were maintained with either a heart-lung machine 
or systemic hypothermia whilst the venae cavae, pulmonary artery and aorta were 
ligated. A solution of concentrated potassium citrate was injected into the aortic root, 
entering the coronary arteries and rapidly arresting the heart in diastole. A simulated 
intracardiac procedure was performed during which the heart remained pink and 
serial coronary sinus samples indicated that little oxygen was being extracted. 
However, reperfusion almost inevitably resulted in ventricular fibrillation and 
resumption of normal contraction was unreliable. Using lower concentrations of 
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potassium citrate diluted in blood, Melrose found improved consistency of recovery in 
his experimental model, concluding: 
‘The oxygen consumption of the quiescent heart is very low, and at normal 
body-temperature, cessation of the coronary circulation for over fifteen minutes 
does not endanger such a heart. Although a great deal of further work remains 
to be done, this method may offer an opportunity for useful surgery on the 
motionless heart, without the danger of air embolism.’ 
 
In a further study, Bentall and Melrose (1957) demonstrated that lactate 
concentrations in coronary effluent following potassium arrest were about one-third of 
those after arrest without potassium citrate; although not performing contractile work, 
the arrested heart remained metabolically active. Three years after the initial report, 
Gerbode and Melrose (1958) published their collaborative work, successfully using 
potassium citrate arrest in 34 patients undergoing open heart surgery in Stanford, 
California. The technique gained in popularity and several groups reported similar 
results including Sealy and co-workers (1959) who coined the term ‘cardioplegia’. 
However, others experienced frequent dysrrhythmias and severe ventricular 
dysfunction following its use and the technique was widely abandoned following a 
report from the US National Heart Institute (McFarland et al., 1960) in which 79% of 
patients who had died after open heart procedures using potassium citrate arrest 
were found to have histological evidence of focal myocardial necrosis. 
 
Over the next 15 years, several alternatives to chemical arrest were utilised for 
myocardial protection: intermittent aortic occlusion with direct coronary perfusion, 
cross-clamping with induced fibrillation, topical hypothermia, and normothermic 
ischaemia. However, these techniques were limited by subendocardial ischaemia, a 
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short period of ‘safe’ ischaemic arrest, flooding of the operative field and non-uniform 
cooling of the heart (Shiroishi, 1999). Most significantly, Cooley and associates 
(1972) coined the term ‘stone heart’ for an ischaemic contracture of the left ventricle 
due to severe depletion of myocardial ATP which led to the death of a number of 
patients following normothermic arrest (Hearse et al., 1977). 
 
Although the use of potassium citrate in clinical practice had ceased in the early 
1960s, a few researchers continued to investigate the potential of chemical 
cardioplegia. Bernhard Hoelscher (1967) in Berlin concluded that the damaging 
effects of Melrose solution were not due to the potassium ion rather the calcium- and 
magnesium-chelating action of the citrate ion leading to intracellular and extracellular 
oedema. Another German pioneer, Hans J. Bretschneider (1975) from the University 
of Göttingen, developed an alternative cardioplegia that used a low sodium, calcium-
free solution to prevent excitation and therefore contraction. In Aarhus, Denmark, 
Tyge Søndergaard and colleagues (1975) used a modified form of Bretschneider 
solution in 100 patients and reported superior myocardial protection to the coronary 
perfusion technique. However, much of Bretschneider’s original work was published 
in the German language literature and went largely unnoticed elsewhere. 
 
Across the Atlantic in New York, William A. Gay Jr. and Paul A. Ebert (1973) were re-
exploring the use of potassium-induced arrest. Using an isolated, supported dog 
heart model, they achieved arrest by continuous coronary perfusion with a 
normothermic mixture of blood and an isotonic high-potassium chloride solution also 
containing sodium chloride, glucose and bicarbonate. They demonstrated a 75-85% 
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reduction in oxygen consumption in the arrested hearts compared with those that 
were spontaneously beating but nonworking, paced or in ventricular fibrillation. 
Following one hour of potassium-induced arrest, resuscitated hearts demonstrated 
only a mild reduction in contractile function whilst those exposed to normothermic 
ischaemia could not be resuscitated. Their improvement over the Melrose method 
was attributed to the balanced osmolality of their solution and the replacement of 
citrate ions with chloride. 
 
Meanwhile at St. Thomas’ Hospital, London, a buffered potassium-based 
cardioplegia solution was also being refined and in 1976, David J. Hearse and 
colleagues published their landmark study on the isolated rat heart in Circulation. 
Their Solution No.1 comprised 4°C Ringer’s solution with the addition of 16mM 
potassium chloride, 16mM magnesium chloride and 1mM procaine hydrochloride. In 
fact, the components of this solution form the basis of crystalloid cardioplegia still in 
use today; co-author Mark V. Braimbridge later wrote (1992): 
‘Many surgeons have said to me since that it was this article which first 
persuaded them that cardioplegia was the way to go.’ 
 
By the end of the 1970s, cold crystalloid potassium-based cardioplegia was 
established as the dominant method for myocardial protection in cardiac surgery 
(Shiroishi, 1999). Later studies used detailed dose-response curves to determine the 
composition of the optimal cardioplegic solution, leading to the introduction of St. 
Thomas’ Hospital Solution No.2 which was demonstrated to be superior to the 
original (Ledingham et al., 1987). The technique enabled surgeons to induce a rapid 
depolarised arrest of the heart that was readily reversible and preserved contractile 
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function in the post-ischaemic period. Reliable myocardial protection using 
cardioplegia was a catalyst for the industrial age of cardiac surgery. Coronary artery 
bypass grafting and valve replacement surgery were being performed with increasing 
frequency at a rapidly growing number of centres and improved organ protection 
enabled the practical application of thoracic transplantation, maintaining a viable 
extracorporeal organ en route between donor and recipient. 
 
1.4.2 The metabolic basis of cardioplegia and hypothermia 
Like every organ, the heart is able to withstand a certain period of time of interrupted 
substrate and oxygen supply without suffering irreversible injury, termed ischaemic 
tolerance. The central principle of myocardial protection is to safely extend this period 
by reducing the metabolic demand of the myocardium to facilitate surgical 
intervention. Other than the inevitable loss of energy as heat, the vast majority of 
ATP generated in the myocardium is utilised for mechanical work with the remainder 
for the maintenance of cellular homeostasis (Taegtmeyer, 2007). Resting the heart in 
diastole whilst maintaining the systemic circulation with cardiopulmonary bypass 
therefore provides a rationale for lowering myocardial energy demand; in addition, 
hypothermia reduces the rate of chemical reactions and hence energy consumption 
in biological systems according to the Arrhenius equation (Levine, 2005). 
 
The landmark studies of Gerald D. Buckberg and associates at the University of 
California, Los Angeles demonstrated that myocardial oxygen consumption was 
reduced by almost 90% in the normothermic arrested heart (1.10ml/100g/min) 
compared with perfused full beating (8.7), empty beating (5.59) or fibrillating (6.50) 
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hearts (Hottenrott et al., 1974, Buckberg et al., 1977). In addition, hypothermia led to 
a further stepwise reduction in oxygen consumption of the arrested hearts to 
0.83ml/100g/min at 32°C, 0.59 at 28°C and 0.31 at 22°C (figure 10). The oxygen 
consumption of the cooled, empty, arrested heart may therefore be reduced to less 
than 3.5% of baseline requirements. 
 
 
 
 
 
 
 
 
Figure 10. Left ventricular myocardial oxygen uptake.1 
 
Buckberg (1987) defined a number of key principles for optimising elective cardiac 
arrest with cardioplegia in order to reduce ischaemia-reperfusion injury. Firstly, arrest 
should occur promptly after the onset of ischaemia to avoid rapid energy depletion by 
ischaemic electromechanical work. Secondly, lowering the temperature of the 
solution further reduces the metabolic rate and may be supplemented by direct 
topical cooling. Thirdly, the enrichment of cardioplegia with substrates for aerobic and 
                                            
1
 Reprinted from The Journal of Thoracic and Cardiovascular Surgery, 73(1), Buckberg GD, Brazier 
JR, Nelson RL, Goldstein SM, McConnell DH, Cooper N. Studies of the effects of hypothermia on 
regional myocardial blood flow and metabolism during cardiopulmonary bypass. I. The adequately 
perfused beating, fibrillating and arrested heart, 87-94, Copyright 1977, with permission from Elsevier. 
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anaerobic metabolism including oxygen, glucose and citric acid cycle intermediates, 
particularly glutamate and aspartate, promotes anaplerosis and enhances substrate 
utilisation. Fourthly, the use of a buffer, such as bicarbonate or tromethamine, to 
maintain optimal extracellular pH despite increased anaerobic generation of protons, 
promotes metabolic recovery. Fifthly, the addition of membrane stabilisers (e.g. 
procaine) and oxygen radical scavengers (e.g. co-enzyme Q10) decreases the 
harmful effects of reperfusion. Finally, controlling extracellular osmolality and oncotic 
pressure reduces the extent of myocardial oedema and maintain cellular integrity. 
 
According to these principles, further refinements have since been made to enhance 
the efficacy of potassium cardioplegia. Buckberg’s group found that replacing the 
crystalloid solution with whole blood as the vehicle for delivery improved experimental 
and clinical myocardial protection (Follette et al., 1978). Blood offers a number of 
theoretical advantages including augmented oxygen delivery, ideal oncotic pressure, 
effective buffering capacity with carbonic anhydrase, endogenous free-radical 
scavengers and less haemodilution when a large volume of cardioplegia is used 
(Barner, 1991). However, the largest randomised controlled trial of cold blood versus 
cold crystalloid cardioplegia (Ovrum et al., 2004) reported no significant difference in 
myocardial protection for patients undergoing CABG. On the other hand, a recent 
meta-analysis (Guru et al., 2006) found that: 
‘Blood cardioplegia provides superior myocardial protection as compared with 
crystalloid cardioplegia, including lower rates of low output syndrome and early 
CK-MB increase, whereas the incidence of myocardial infarction and death are 
similar. On balance, and despite the limitations of this investigation, the 
evidence supports the use of blood rather than crystalloid cardioplegia for 
coronary surgery.’ 
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Nelson and colleagues (1976) demonstrated the importance of intermittent reinfusion 
of cardioplegia to compensate for washout from non-coronary collateral flow. 
Solorzano and associates (1978) promoted the use of retrograde cardioplegia 
perfusion via the coronary sinus as an alternative to antegrade administration via the 
aortic root. Teoh et al. (1986) demonstrated that a ‘hot shot’ terminal dose of warm 
blood cardioplegia improves metabolic and functional recovery following protection 
with cold blood cardioplegia. Another recent meta-analysis (Fan et al., 2010), 
comparing the effects of warm versus cold cardioplegia, concluded: 
‘Using warm cardioplegia for myocardial protection during heart surgery 
resulted in similar incidences of clinical events, significant improvement in 
postoperative cardiac index and reduction in postoperative enzyme release as 
compared with cold cardioplegia.’ 
 
However, definitive evidence in the form of contemporary, prospective, multi-centre, 
randomised controlled trials demonstrating survival advantage for different 
compositions, temperatures or routes of delivery is lacking. Hyperkalaemic arrest 
remains the mainstay of myocardial protection in the modern era; a survey of practice 
in the UK found that of surgeons performing CABG on CPB, 56% use cold blood 
cardioplegia, 14% use warm blood, 14% use crystalloid and just 16% do not use 
cardioplegia at all, preferring cross-clamp fibrillation (Karthik et al., 2004). It has been 
estimated that more than four tonnes of depolarising potassium are passed through 
the coronary arteries of 800,000 patients undergoing cardiac surgery in 2500 centres 
worldwide each year (Dobson, 2010). 
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1.4.3 Myocardial protection into the 21st century 
Outcomes following cardiac surgery continue to improve in the British Isles and 
across the developed world. Between 2001 and 2008 the mortality rate for isolated 
CABG in the UK & Ireland fell from 2.3% to 1.5%, despite an increase in patients’ risk 
profiles due to age and co-morbidities (Bridgewater et al., 2009); medium term 
survival following CABG also increased to over 90% at 5 years after surgery. 
Currently, 17% of surgical revascularisation in the UK & Ireland is performed on the 
beating heart, without the use of cardiopulmonary bypass or cardioplegic arrest, so 
called ‘off-pump’ surgery with apparently similar outcomes. There has also been a 
recent take-off in transcatheter aortic valve implantation (TAVI) as a beating-heart 
alternative to open aortic valve replacement in symptomatic patients who are deemed 
too high risk for conventional surgery (Vahanian et al., 2008). So if the outcomes of 
cardiac surgery are now so good and there is a move towards performing some 
common procedures without stopping the heart at all, why is there a need to further 
improve strategies for myocardial protection? 
 
Following cardiac surgery using standard techniques for myocardial protection, 
around one-in-three patients have a period of clinical dysfunction due to myocardial 
stunning, most of whom require inotropes to support the heart during its recovery 
(Arnold et al., 1985, Quinn et al., 2006). An episode of non-fatal low cardiac output 
syndrome in the early postoperative period has been shown to be associated with a 
significant reduction in late survival following CABG (Fremes et al., 2000). The need 
for inotropic support is also associated with prolonged length of stay, morbidity and 
mortality, in addition to added cost and resource utilisation, and has been identified 
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as a risk factor for reduced quality of life ten years after surgery (Herlitz et al., 2005). 
Inadequate myocardial protection may lead to permanent injury, diffuse necrosis 
resulting in fibrosis, remodelling and long-term impairment of ventricular function. 
 
The population undergoing cardiac surgery is becoming older, with more complex 
patterns of heart disease and more frequent co-morbidities, such as diabetes 
mellitus, hypertension and renal impairment (Bridgewater et al., 2009). The 
myocardium is often poorly functioning with a low ejection fraction and is more 
vulnerable to a low cardiac output episode in the early postoperative period. These 
patients increasingly require more urgent and complicated surgery, involving multiple 
valve procedures frequently in combination with revascularisation. There is also a 
move towards complex valve repair rather than replacement for mitral pathology and 
concomitant procedures such as radiofrequency ablation for atrial fibrillation. Such 
factors contribute towards increasing the length of ischaemic arrest and the risk of 
inadequate myocardial protection. At the other end of the spectrum, there has been a 
move in congenital cardiac surgery towards earlier intervention to repair complex 
lesions in neonates and infants. Metabolism in the immature heart exhibits marked 
differences in substrate utilisation, insulin sensitivity, calcium handling and 
antioxidant defences (Doenst et al., 2003b); therefore adult-derived solutions to 
myocardial protection may not be optimal for the paediatric heart (Allen, 2004). In 
cardiac transplantation, improved protection of organs may also extend the 
acceptable cold ischaemic time, increasing geographical flexibility and enabling 
better harmonisation of organ supply and demand (Banner et al., 2008). 
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In summary, current techniques for myocardial protection using cardioplegia and 
hypothermia are not a panacea for prolonged, recoverable ischaemia but extend the 
metabolic window of opportunity. Recent data demonstrate that length of cardioplegic 
arrest remains an independent predictor of mortality in contemporary practice 
(Doenst et al., 2008). The need for longer periods of ischaemia in more metabolically 
vulnerable patients necessitates further research to improve protective strategies. 
 
1.4.4 Novel techniques to improve myocardial protection 
Current research strategies to attenuate ischaemia-reperfusion injury in cardiac 
surgery fall into two categories: innovative mechanisms to achieve arrest through 
cardioplegia and adjuvant therapies to improve myocardial protection. The search for 
an alternative to hyperkalaemic cardioplegia has resurfaced due to concerns over the 
effect of depolarised arrest on ionic imbalances, endothelial injury, coronary spasm 
and myocardial stunning; apart from lowering oxygen demands through 
electromechanical arrest, there is accumulating evidence that hyperkalaemia per se 
offers little or no direct cardioprotection (Dobson, 2010). Several agents that arrest 
the heart in a polarised state, maintaining resting myocyte membrane potential, have 
been studied in experimental models. Dobson and Jones (2004) proposed using 
adenosine and lidocaine in a normokalaemic cardioplegic solution, whilst in the UK, 
Chambers and colleagues have investigated the use of tetrodotoxin, a selective 
sodium channel blocker (Snabaitis et al., 1997), and esmolol, an inhibitor of calcium 
and sodium channels (Bessho and Chambers, 2002), demonstrating improved 
myocardial protection in isolated rat hearts. However, none of these agents have yet 
been adequately tested in randomised controlled clinical trials. 
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Over the last two decades, the focus of most translational research groups has been 
on identifying adjuncts to be used alongside the established clinical methods of 
hyperkalaemic arrest and hypothermia. Three main areas have been investigated: 
induction of endogenous protective mechanisms through local or remote ischaemic 
conditioning; pharmacological mimicking of endogenous protection; and targeting 
other components of the ischaemia-reperfusion cascade (Kharbanda, 2010). 
 
The concept of ischaemic conditioning proposes that brief periods of ischaemia lead 
to the induction of endogenous protective mechanisms that diminish the 
consequences of a subsequent more prolonged ischaemic insult. It was first 
described in a canine model (Murry et al., 1986) and later demonstrated to be 
preserved in humans undergoing cardiac surgery (Yellon et al., 1993). A recent meta-
analysis of 933 patients from 22 trials found that ischaemic preconditioning was 
associated with significant reductions in ventricular arrhythmias, inotrope 
requirements and critical care stay (Walsh et al., 2008). The authors concluded that 
ischaemic preconditioning may provide additional myocardial protection over 
cardioplegia alone. Lately, there has been growing interest in remote ischaemic 
preconditioning in which the initial ischaemic stimulus is applied to a distant organ, 
such as a limb, to improve protection of the target organ (Przyklenk et al., 1993). This 
technique has additional advantages in being non-invasive, simple to apply and 
otherwise benign, and early clinical studies suggested a significant reduction in 
myocardial injury and inotrope requirements in children (Cheung et al., 2006) and 
adults (Hausenloy et al., 2007) undergoing cardiac surgery. However, the largest trial 
published to date on 162 patients from our group in Birmingham found no 
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improvement in early postoperative haemodynamics or troponin release (Rahman et 
al., 2010) raising questions as to how much additional benefit is provided by 
preconditioning over adequate cardioplegic arrest. 
 
The exact pathway that mediates cardioprotection through ischaemic preconditioning 
remains unclear. It is thought that the ischaemic stimulus generates autocoids such 
as adenosine, bradykinin and opioids which recruit pro-survival kinase signalling 
pathways though activation of their receptors in the target tissue (Hausenloy and 
Yellon, 2008). These cascades converge through the inactivation of GSK-3β to inhibit 
opening of the mPTP and improve cell survival. A number of pharmacological agents 
have been investigated for their ability to trigger these cellular cardioprotective 
pathways including adenosine, bradykinin, opioids, atrial natriuretic peptide, 
cyclosporine A, high-dose HMG-CoA reductase inhibitors and volatile anaesthetic 
agents, such as isoflurane (Venugopal et al., 2009, Kharbanda, 2010). Many agents 
targeting other cellular processes have also been investigated, either via systemic 
therapy or supplementation of cardioplegia, with some experimental but limited 
clinical success. These include antioxidants (N-acetylcysteine, aprotinin, allopurinol, 
vitamin E), substrate supplements (L-glutamate, phosphocreatine), modulators of 
ionic flux (cariporide, levosimendan) and nitric oxide donors (nitrite infusion). 
 
The failure to translate novel cardioprotective strategies from bench to bedside is 
hugely disappointing and has been attributed to the inadequacy of animal models 
and inappropriate design of clinical trials, amongst others (Hausenloy et al., 2010). 
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2. MODULATING MYOCARDIAL METABOLISM 
 
2.1 Metabolic therapy for myocardial protection 
‘Metabolism – the lost child of Cardiology.’ 
(Taegtmeyer, 2000) 
 
The first principle for the manipulation of myocardial metabolism is that inducing a 
shift in substrate utilisation from fatty acids to glucose will increase the efficiency of 
energy production and decrease the potentially harmful effects of fatty acid oxidation 
during ischaemia-reperfusion (Taegtmeyer, 2002). Physiological or pharmacological 
suppression of FFA uptake and/or β-oxidation stimulates myocardial glucose 
utilisation, in part by reducing the suppression of PDH complex and maintaining the 
entry of glycolytic pyruvate into the citric acid cycle. Coupling of glycolysis to glucose 
oxidation is increased, the production of lactate and protons is reduced and the 
efficiency of ATP production per mole of oxygen is improved. The enhanced 
energetic status of the cell leads to downregulation of AMPK and PPARα, with 
reduced expression of mitochondrial uncoupling proteins and diminished proton 
leakage across the inner mitochondrial membrane (Lopaschuk et al., 2010). The 
impact of ischaemia on the cell is thereby reduced translating into enhanced recovery 
of cardiac function on reperfusion. 
 
In recent years, a second principle of metabolic protection has emerged through the 
activation of anti-apoptotic pro-survival pathways (Opie and Sack, 2002). It is thought 
that key glycolytic enzymes may induce protection against ischaemia-reperfusion by 
activation of the RISK pathway via the PI3K-Akt cascade, leading to inactivation of 
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GSK-3β and inhibition of mPTP formation (Hausenloy and Yellon, 2004). This 
common cardioprotective mechanism has been implicated in other therapeutic 
strategies although its relative importance in metabolic therapy, compared with direct 
improvements in oxidative efficiency, is yet to be established. 
 
A number of pharmacological agents have been developed that act at various points 
in the metabolic pathways to alter the supply of substrates to the heart, decrease the 
mitochondrial uptake or β-oxidation of fatty acids, or promote the preferential 
oxidation of glucose (figure 11). These metabolic therapies have mainly been studied 
in patients with acute or chronic myocardial ischaemia and heart failure (Lee et al., 
2004, Abozguia et al., 2006). However, their established and proposed mechanisms 
of action suggest that they may have a role in myocardial protection against 
ischaemia-reperfusion injury as adjuncts to cardioplegia and hypothermia. Rather 
than further reducing metabolic demand per se, inducing a shift in myocardial 
metabolism may enable these requirements to be met more efficiently from available 
energy sources whilst upregulating innate cardioprotective pro-survival pathways. An 
increase in ischaemic tolerance would reduce cellular injury on reperfusion, enhance 
recovery of contractile function and improve clinical outcomes. 
 
In this chapter, I review the evidence for the potential role of glucose-insulin-
potassium (GIK) and other metabolic agents in myocardial protection, including a 
systematic review, provide a detailed discussion on the clinical and experimental use 
of perhexiline, and propose a series of hypotheses on perhexiline, its uptake into the 
heart, its effect on myocardial metabolism and its application to myocardial protection 
during cardiac surgery to be tested in the remainder of this thesis. 
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Figure 11. Cellular sites of action of metabolic therapies. 
 
2.1.1 Glucose-Insulin-Potassium 
The most extensively studied therapeutic strategy in myocardial metabolism is 
altering the availability and use of substrates using insulin, usually in the form of GIK 
solution. This was first used in the treatment of acute myocardial infarction (Sodi-
Pallares et al., 1962) and in low cardiac output syndrome after cardiac surgery not 
responding to other therapies (Braimbridge et al., 1969). 
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The mechanism of action of insulin on the myocardium has not been fully elucidated; 
it seems that multiple metabolic and non-metabolic mechanisms have complimentary 
effects but their relative importance is yet to be established (Doenst et al., 2003a). 
 
 Increased glycogen content: GIK has been shown to increase myocardial 
glycogen content which may then be used for anaerobic ATP production during 
ischaemia; however, the rate of glycogen turnover rather than content may be 
more important in ischaemic tolerance (Goodwin et al., 1995). 
 Decreased free fatty acid metabolism: Insulin suppresses lipolysis in adipose 
tissue, reducing circulating levels of FFA, acyl-carnitine accumulation in the 
cytosol and peroxide formation due to incomplete oxidation. It also inhibits FFA 
oxidation through activation of acetyl-CoA-carboxylase, increasing malonyl-CoA 
and thereby inhibiting mitochondrial uptake of acyl-CoA for β-oxidation (Gamble 
and Lopaschuk, 1997). Reduced uncoupling of glycolysis and glucose oxidation 
enhances ATP production per mole of oxygen consumed and decreases 
anaerobic lactate formation. 
 Increased glycolytic ATP production: Insulin promotes glucose uptake via GLUT4 
and cytosolic ATP production through glycolysis which may be used to maintain 
basal cell function. However, during low-flow ischaemia, this also increases lactate 
production and intracellular acidosis which may negatively impact on contractile 
function (Neely and Morgan, 1974); low-flow may be sufficient to remove the 
waste products but remains a conceptual obstacle to the use of GIK in ischaemia. 
 Anaplerosis: Citric acid cycle intermediates are depleted in ischaemia, impairing 
the turnover rate of the cycle and reducing energy production. During reperfusion, 
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GIK enables more effective replenishment of cycle intermediates via anaplerosis, 
a process which is particularly active in the myocardium (Taegtmeyer et al., 1997). 
 Pro-survival pathways: Insulin activates MAP kinases and the pro-survival RISK 
pathway, via PI3K-Akt and the suppression of GSK-3β, thereby modulating the 
acute inflammatory response and reducing apoptosis in ischaemia-reperfusion 
(Sack and Yellon, 2003). It has also been shown to activate the Nrf2-antioxidant 
response element pathway and reduce oxidative stress (Wang et al., 2012). 
 Other non-metabolic mechanisms: Insulin is a known systemic vasodilator, 
lowering peripheral vascular resistance and improving cardiac output, but has also 
been shown to have a direct inotropic effect on the heart (Doenst et al., 1999). 
 
Early randomised trials in the pre-thrombolysis/primary PCI era suggested that GIK 
may have been beneficial in reducing in-hospital mortality following myocardial 
infarction (Fath-Ordoubadi and Beatt, 1997). However, the CREATE-ECLA trial, the 
largest randomised controlled trial of high-dose GIK in patients with ST-elevation 
myocardial infarction, recruited over 20,000 patients from 470 centres worldwide and 
showed no clinical benefit, including subgroups with diabetes or heart failure (Mehta 
et al., 2005). A subsequent meta-analysis declared that GIK therapy is not beneficial 
in the modern management of acute myocardial infarction (Mamas et al., 2010). 
However, it has been suggested that the neutral outcome may reflect the competing 
benefits of GIK and harm of systemic hyperglycaemia (Kloner and Nesto, 2008). 
 
Patients undergoing cardiac surgery are in a state of starvation, generate a stress 
response with endogenous catecholamine release and are administered a large 
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bolus of heparin which liberates FFA during CPB (Wittnich et al., 1984); insulin 
resistance during the early postoperative period is also common. As myocardial 
ischemia due to aortic cross-clamping is an elective event, the potential benefits of a 
metabolic shift, suppression of lipolysis and increased glucose availability with GIK 
may be instituted prior to the ischaemic insult and continued to meet the increased 
requirements of reperfusion. Therefore GIK may be particularly useful in the setting of 
improving myocardial protection during cardiac surgery. 
 
Two meta-analyses have been performed to examine the use of GIK in cardiac 
surgery. Bothe and colleagues (2004) found 11 randomised trials comprising 468 
patients that investigated the recovery of contractile function as a primary endpoint. 
Six studies found a significant improvement in cardiac index with GIK, one was 
neutral and four did not have comparable statistical analyses. The authors estimated 
a weighted-mean of relative improvement in postoperative recovery of cardiac 
function of 11.4% with GIK versus controls; sub-group analysis found that continuing 
GIK following surgery increased the relative improvement from 6.1% to 19.5%. 
Similarly, Fan and associates (2011) identified 33 randomised controlled trials with 
2113 patients undergoing cardiac surgery. GIK was associated with significantly 
fewer myocardial infarctions (RR 0.63, 95% CI 0.42-0.95, p 0.03), lower inotrope 
requirements (RR 0.66, 95% CI 0.45-0.96, p 0.03), higher postoperative cardiac 
index (WMD 0.43L/min/m2, 95% CI 0.31-0.55, p<0.001) and reduced length of stay 
on ICU (WMD -7.96 hours, 95% CI -13.36--2.55, p 0.004). They concluded that: 
‘GIK significantly reduced myocardial injury and improved haemodynamic 
performance in patients undergoing cardiac surgery.’ 
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However, both meta-analyses were limited by the weaknesses of the published trials 
included: low number of patients, historical nature of some trials, potential publication 
bias, and marked heterogeneity of GIK regimes, including dose, timing, duration of 
therapy and patient groups. In addition, as a load-sensitive parameter, cardiac index 
is affected by other cardiac physiological variables which were not often reported. 
 
Our group in Birmingham has reported two of the largest randomised controlled trials 
of systemic GIK as an adjunct to myocardial protection in cardiac surgery. The 
MESSAGE trial (Quinn et al., 2006) examined the use of perioperative GIK infusion 
versus placebo in 280 non-diabetic patients undergoing CABG. The infusion of GIK 
contained 70 IU/L of insulin, commenced at 0.75ml/kg/hr at induction of anaesthesia 
and continued until six hours after ischaemia. GIK significantly improved early cardiac 
indices (p<0.01) and reduced the incidence of low cardiac output episodes (p=0.02) 
and inotrope requirements (p<0.01) versus controls. In addition, there was a 
decrease in peak troponin-I release with GIK (p=0.03) but no difference in area-
under-the-curve up to 72 hours after ischaemia (p 0.27). The authors concluded that: 
‘Systemic GIK has beneficial cardiovascular and myocardial protective effects... 
even in the presence of hyperglycaemia. It can thus be considered an effective, 
inexpensive and safe adjunctive myocardial protective technique.’ 
 
More recently, the HINGE trial (Howell et al., 2011) reported the use of a similar 
regime in a randomised controlled trial of 217 non-diabetic patients with left 
ventricular hypertrophy undergoing aortic valve replacement +/- CABG. We found 
that perioperative GIK was associated with a significant reduction in the incidence of 
low cardiac output episodes (p<0.01) and inotrope usage (p<0.01) but there was no 
difference in the release of troponin-T (DiM at 6 hours -0.01, 95% CI -0.09-0.07, p 
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0.81). Left ventricular biopsies obtained after the administration of GIK but before 
ischaemia demonstrated a substantial increase in the phosphorylation of AMPK and 
Akt and a significant rise in protein O-linked β-N-acetylglucosamination, confirming 
that insulin directly modulates myocardial metabolism and upregulates pro-survival 
pathways in these patients. Further unpublished data (Howell, 2010) showed that 
GIK significantly increased pre-ischaemia atrial glycogen content and markedly 
suppressed plasma FFA concentrations during reperfusion compared with controls. 
 
An alternative approach to the use of insulin in myocardial protection involves the use 
of insulin-enhanced cardioplegia solution. However, despite encouraging results from 
smaller, non-randomised studies, the Insulin Cardioplegia trial randomised 1127 
patients but found no benefit in high-risk patients undergoing isolated CABG (Rao et 
al., 2002). The cellular effects of insulin at the onset of ischaemia are limited 
compared with the administration of systemic GIK which also augments pre-
ischaemic myocardial glycogen stores, suppresses plasma FFA and increases 
substrate availability during reperfusion to meet the heightened energy demands and 
the replenishment of citric acid cycle intermediates via anaplerosis. 
 
To date, GIK has not been widely adopted for routine clinical use in cardiac surgery; 
this is likely to be due not only to the perceived lack of evidence but also the 
burdensome nature of its administration and monitoring against a backdrop of 
improving outcomes. There have been no large multicentre randomised controlled 
trials and most studies that have been reported were weakened by low numbers of 
patients, heterogeneous inclusion criteria and trial protocols, and inadequate study 
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design, often with a lack of randomisation. There remains no standardised protocol 
for the administration of GIK in myocardial protection with variation in total insulin 
dose up to one hundred-fold in reported trials (Bothe et al., 2004). The mechanisms 
of action of insulin are not fully established and remain controversial. Furthermore, 
there is concern over the potential negative effects of hyperglycaemia with systemic 
GIK, which has been shown to be an independent risk factor for worse outcomes 
after cardiac surgery (Doenst et al., 2005), and the reported lack of benefit in the 
modern management of acute myocardial infarction (Kloner and Nesto, 2008).  
 
Our experience in Birmingham reflects potential practical issues with the routine use 
of GIK. In addition to the reported benefits, intensive management of blood glucose 
was obligatory and vasoconstrictor requirements were markedly increased; the trial 
setting also enabled a greater level of medical input in the early postoperative period. 
High-dose insulin regimes are used routinely in a few centres with expertise (Doenst 
et al., 2003a) but their widespread application is not practical. There is a need for 
another metabolic agent with a similar efficacy to insulin but without its limitations. 
 
2.1.2 Other metabolic therapies 
Numerous drugs have been found to modulate myocardial metabolism by acting at 
different potential sites within the metabolic pathways, as previously shown in figure 
11. The common product is a shift from β-oxidation of fatty acids to the preferential 
oxidation of glucose and is achieved principally via several mechanisms of action: 
reduced uptake of fatty acids into the mitochondria, direct inhibition of β-oxidation or 
facilitated entry of pyruvate into the citric acid cycle. 
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Carnitine palmitoyltransferase-1 (CPT-1) inhibitors: perhexiline, etomoxir, oxfenicine, 
amiodarone. Located on the outer membrane, CPT-1 is the first component and rate-
limiting step for the uptake of long-chain fatty acids into mitochondria (figure 2). 
Pharmacological inhibition of CPT-1 reproduces the physiological action of malonyl-
CoA by reducing access of fatty acids to the mitochondrial matrix for β-oxidation and 
represents a powerful point of control for determining myocardial substrate utilisation. 
Etoxomir, an irreversible CPT-1 inhibitor, was shown to protect isolated working rat 
hearts from fatty acid-induced ischaemic injury with improved functional recovery 
(Lopaschuk et al., 1988). However, long-term inhibition of CPT-1 leads to the cellular 
accumulation of phospholipids; etomoxir showed early promise in a study of patients 
with heart failure but was withdrawn from the market after the premature cessation of 
a larger trial due to liver dysfunction (Holubarsch et al., 2007). There is currently no 
clinical data for the use of oxfenicine whilst amiodarone is only a weak CPT-1 
inhibitor, principally used for its Class III anti-arrhythmic properties. On the other 
hand, perhexiline is the most potent CPT-1 inhibitor available for clinical use and will 
be discussed in greater detail in section 2.2. 
 
Malonyl-CoA decarboxylase (MCD) inhibitors: Malonyl-CoA is the intrinsic inhibitor of 
fatty acid uptake through potent inhibition of mitochondrial CPT-1. Activation of 
AMPK during ischaemia and persisting into reperfusion leads to a marked decline in 
malonyl-CoA and the excessive oxidation of fatty acids. Therefore, the malonyl-CoA 
axis represents a novel therapeutic target for reducing β-oxidation (Ussher and 
Lopaschuk, 2008), although at present, no agents are available for clinical use. 
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Carnitine biosynthesis inhibitors: Mildronate is a reversible inhibitor of γ-butyrobetaine 
hydroxylase, a key enzyme in the biosynthesis of carnitine. The lower availability of 
free carnitine leads to a fall in CPT activity, mitochondrial uptake and β-oxidation of 
long-chain fatty acids. It is not currently licensed for therapeutic use in the UK. 
 
Fatty acid oxidation inhibitors: trimetazidine, ranolazine. Widely used across Europe 
as an anti-anginal agent, trimetazidine has been shown to inhibit long-chain 3-
ketoacyl-CoA thiolase, a key enzyme in the β-oxidation pathway (Kantor et al., 2000) 
although its mechanism of action remains controversial (MacInnes et al., 2003). 
Whilst its downstream site of action is theoretically much less potent than CPT-1 
inhibition, it is not associated with tissue phospholipidosis in chronic use. Several 
studies have shown that pre-treatment with trimetazidine reduces injury and improves 
recovery of cardiac function after ischaemia-reperfusion in animal models; a potential 
role in myocardial protection has been strengthened by evidence for its enhancement 
of pro-survival pathways (Khan et al., 2010), prevention of apoptosis (Ruixing et al., 
2007) and inhibition of mPTP opening (Argaud et al., 2005). However, the 
administration of trimetazidine-enriched cardioplegia without pre-treatment offered no 
haemodynamic or metabolic improvement in a swine model of myocardial protection 
(Silveira Filho et al., 2008). 
 
Ranolazine may also be a partial fatty acid inhibitor but its primary effect is now 
established as inhibition of late sodium channels (Hale et al., 2008). However, in the 
isolated rat heart model, it has been shown to have therapeutic potential as an 
additive to cardioplegia (Hwang et al., 2009). 
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Pyruvate dehydrogenase kinase (PDK) inhibitors: Dichloroacetate (DCA) facilitates 
entry of pyruvate into the citric acid cycle for oxidation by indirect activation of PDH 
complex. In an isolated rat heart model, DCA has been shown to be protective in the 
recovery of post-ischaemic ventricular function (Taniguchi et al., 2001). However, 
optimal protection was afforded by the combination of DCA, insulin and N6-
cyclohexyladenosine, an adenosine A1 receptor antagonist and partial inhibitor of 
glycolysis (Gandhi et al., 2008); recovery of function was inversely proportional to H+ 
production during reperfusion. DCA is currently only used in the treatment of inherited 
mitochondrial disorders to prevent lactic acidosis by improved glycolytic coupling. 
 
Several metabolic intermediates have also shown promise either as additives to 
cardioplegia e.g. pyruvate (Knott et al., 2006), fructose-1,6-biphosphate (Riedel et al., 
2004) or with intravenous loading e.g. L-glutamate (Bitzikas et al., 2005). However, 
this approach has intrinsic weaknesses: non-selective supplementation requires huge 
quantities of substrate to significantly affect target tissue concentration and may have 
metabolic side-effects; cardioplegia additives are delivered to the myocardium but still 
depend upon either uptake along a concentration gradient or an efficient membrane 
transport system; increased anaerobic metabolism during ischaemia may worsen 
cellular acidosis; and neither strategy increases substrate supply on reperfusion. 
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2.1.3 Metabolic therapy in cardiac surgery: a systematic review 
Numerous drugs directly modulate cellular metabolic pathways and have been shown 
to ameliorate ischaemia-reperfusion in animal models. Either alone or in combination, 
they may have a role as adjuncts to myocardial protection during cardiac surgery. In 
order to establish the current evidence supporting metabolic agents other than insulin 
and metabolite supplements, I performed a systematic review of the literature. 
 
Methods 
Data sources: A systematic literature search of Medline (1950-July 2011), Embase 
(1982-July 2011) and Cochrane Library 2011 was performed. To achieve maximum 
sensitivity of the search and identify all relevant studies, a combination of terms were 
used including metabolism, myocardial protection, heart surgery, ischaemia, 
perhexiline, etomoxir, oxfenicine, trimetazidine, mildronate, dichloroacetate and 
malonyl CoA decarboxylase. No language restrictions were placed. The search also 
included online trial registries and reference lists of relevant review articles. 
Study selection: All studies assessing the use of a pharmacological agent, other than 
insulin/GIK, with a confirmed or proposed metabolic action in myocardial ischaemia-
reperfusion were included. Studies were excluded if the subjects were non-human, 
there was no comparative group, the drug was not given before or during ischaemia, 
the intervention was not cardiac surgery, or the outcome measures did not include 
clinical, physiological or biochemical markers of myocardial function or injury. 
Data extraction and assessment: Eligibility was assessed in a standardised manner 
by a single reviewer. Included studies were assessed for their characteristics and 
quality indicators using the Jadad score (Jadad et al., 1996). 
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Results 
The identification, screening, eligibility and inclusion of studies is documented in a 
flow diagram (figure 12) according to the PRISMA statement (Moher et al., 2009). 
Sixty three records were screened of which 55 were excluded: 41 involved non-
human subjects, 13 did not involve cardiac surgery and one reference was an 
unpublished abstract. Eight full-text articles were assessed for eligibility and all were 
included in the review (table 1), seven used trimetazidine and one evaluated 
mildronate and trimetazidine; no comparable studies on perhexiline, etomoxir, 
oxfenicine, dichloroacetate or malonyl CoA decarboxylase inhibitors were identified. 
 
 
 
Figure 12. PRISMA flow diagram of study selection. 
 
Records identified through 
database searching
62
Records screened 63
Additional records identified 
through other sources
1
Records remaining after
duplicates removed
63
Records excluded 55
Full-text articles assessed 8 Full-text articles excluded 0
Studies included in review 8
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Study Drug Language Random Patients Jadad 
Fabiani et al. (1992) Trimetazidine English Yes 19 1 
Vedrinne et al. (1996) Trimetazidine English Yes 30 4 
Tünerir et al. (1999) Trimetazidine English Yes 40 2 
Iskesen et al. (2006) Trimetazidine English Yes 24 1 
Gordeev et al. (2007) Mildronate & 
Trimetazidine 
Russian Yes 119 1 
Iskesen et al. (2009) Trimetazidine English Yes  30 1 
Lopatin et al. (2009) Trimetazidine Russian Yes 306 2 
Martins et al. (2011) Trimetazidine English Yes 60 5 
  
Table 1. Characteristics of studies included in the systematic review. 
 
Studies were mostly published in the English language but contained few patients 
(median 35, range 19-306) and were of low quality (mean Jadad score 2.1). In seven 
studies, the trial drug was given orally for at least two weeks preoperatively; in the 
other, intravenous loading was given at the time of surgery with supplemental 
trimetazidine in the cardioplegia, which was also given in one of the oral studies 
(table 2). None of the studies detected any significant improvement in perioperative 
haemodynamics with metabolic therapy. Two studies reported an improvement in left 
ventricular systolic function following surgery; one also found a reduction in areas of 
hypokinesia with trimetazidine (p<0.01) and mildronate (p<0.01) compared with 
controls but no difference between the active treatments (Gordeev et al., 2007). 
However, the other study continued trimetazidine for three years after surgery and 
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only detected an improvement in ejection fraction after one year and exercise testing 
after three years which may reflect the long-term efficacy of the drug in heart failure 
rather than any improvement in myocardial protection during surgery (Lopatin and 
Dronova, 2009). Likewise, another study found that pre-treatment with trimetazidine 
improved cardiac function before but not after surgery (Martins et al., 2011). Four 
studies reported a reduction in troponin and/or CK-MB release with trimetazidine, 
suggesting less myocardial ischaemia-reperfusion injury. Two studies observed a 
significant decline in plasma malondialdehyde, a product of lipid peroxidation and 
marker of oxidative stress, with trimetazidine although another found no difference. 
One study found that it also preserved systemic endogenous antioxidant capacity. 
 
Study Drug Route Timing Outcomes 
Fabiani et al. (1992) Trimetazidine oral & CP 3 weeks ↔ CI, ↓ MDA 
Vedrinne et al. (1996) Trimetazidine iv & CP Intra-op ↔ CI, ↔ MDA 
Tünerir et al. (1999) Trimetazidine oral 3 weeks ↓ troponin-T, ↔ CI 
Iskesen et al. (2006) Trimetazidine oral 2 weeks ↓ MDA, ↑ SOD, ↑ GP 
Gordeev et al. (2007) Mildronate 
Trimetazidine 
oral 
oral 
2 weeks 
2 weeks 
Both ↑ LVEF, ↑ local 
contractility, ↓ RWMA 
Iskesen et al. (2009) Trimetazidine oral 2 weeks ↓ troponin-T,↓ CK-MB  
Lopatin et al. (2009) Trimetazidine oral 2 weeks ↑ LVEF, ↓ CK-MB 
Martins et al. (2011) Trimetazidine oral 2 weeks ↓ troponin-T, ↔ LVEF 
CI, cardiac index; CK-MB, creatine kinase isoenzyme; CP, cardioplegia; GP, glutathione peroxidise; 
LVEF, left ventricular ejection fraction; LVSWI, left ventricular stroke work index; MDA, 
malondialdehyde; RWMA, regional wall motion abnormalities; SOD, superoxide dismutase. 
 
Table 2. Interventions and results of studies included in the systematic review. 
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Conclusions 
In a systematic review of the literature to identify the current evidence supporting the 
use of metabolic therapies other than insulin as adjuncts to myocardial protection in 
cardiac surgery, I found little proof of benefit to support their use. Only eight studies 
applicable to cardiac surgery were identified; these were often small, poorly designed 
and reported, reflected in low Jadad scores, with heterogeneity of trial patients, 
protocols and endpoints and invariably underpowered to detect clinically important 
outcomes. Only one study demonstrated a significant improvement in any measure of 
cardiac function in the early postoperative period (Gordeev et al., 2007) whilst four 
found a reduction in clinical markers of myocardial injury. Two studies identified a 
reduction in markers of oxidative stress but none examined the effect of metabolic 
therapies on the pro-survival pathways implicated in the mechanism of action of 
insulin. Indeed, in the entire literature on metabolic therapies other than GIK, only two 
studies recruited more than one hundred patients undergoing surgery. 
 
All studies used trimetazidine (Vastarel), a widely available anti-anginal agent 
developed and marketed by Les Laboratoires Servier, France. One study also 
investigated mildronate, a drug produced by Grindex in Latvia but currently used little 
outside Russia and the Baltic States. Trimetazidine showed potential in reducing 
troponin release following surgery but given the size of the studies and the lack of 
haemodynamic and other outcome data, there is insufficient evidence to support its 
routine use. Furthermore, there is currently no clinical evidence for the application of 
other metabolic therapies, including perhexiline, to improve myocardial protection 
against ischaemia-reperfusion injury during cardiac surgery. 
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2.2 Perhexiline 
‘New tricks for an old drug.’ 
(Frenneaux, 2002) 
 
2.2.1 The rise and fall of carnitine-palmitoyltransferase inhibition 
Developed by Richardson-Merrell Pharmaceuticals Limited in the late 1960s, 
perhexiline was first marketed during the 1970s as an anti-anginal agent (Ashrafian 
et al., 2007). It proved to be highly effective for the symptomatic relief of exertional 
angina pectoris and was particularly useful as mono-therapy in patients who were 
either unsuitable or failed to respond to beta-blockers (Burns-Cox et al., 1971). Early 
experimental and clinical studies suggested that whilst perhexiline led to coronary 
vasodilatation and increased coronary blood flow, it was not associated with 
intolerable reductions in blood pressure or heart rate. Perhexiline was introduced to 
the United Kingdom in 1975 and by the end of that decade, had become widely used 
across Europe with particular popularity in France. 
 
Alas, reports of serious adverse events soon began to emerge describing severe 
peripheral neuropathy (Lhermitte et al., 1976) and potentially fatal hepatotoxicity 
(Pessayre et al., 1979). By August 1983, 80 cases of liver failure and 131 cases of 
neuropathy associated with perhexiline had been reported to the UK authorities 
(Shah, 2006). Similarly in France, it accounted for 8.9% of all hepatic adverse drug 
reactions between 1976 and 1980 (Albin et al., 1981) but no correlation was 
established between perhexiline use and increased mortality in a large observational 
study, although length of follow-up was limited (Killalea and Krum, 2001). Toxicity 
appeared in a small number of patients on long-term therapy; in a report of two 
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patients who died from cirrhosis after receiving perhexiline, Pessayre and colleagues 
(1979) concluded that: 
‘Prolonged administration of perhexiline maleate may induce... ultrastructural 
and histochemical lesions resembling those of phospholipidosis.’  
 
It later emerged that the severe prolonged inhibition of mitochondrial β-oxidation 
leads to microvesicular steatosis and liver failure (Fromenty and Pessayre, 1995). 
Patients with neuropathy were found to have higher plasma levels of perhexiline with 
a prolonged half-life (Singlas et al., 1978) whilst impaired drug metabolism in those 
with side-effects suggested a genetic susceptibility to toxicity (Shah et al., 1982). 
 
Perhexiline was withdrawn in the United Kingdom in 1985 and then worldwide in 
1988 (Shah, 2006) with the exception of Australia and New Zealand, where it 
remains licensed for the treatment of patients with refractory angina conditional upon 
therapeutic monitoring (Inglis and Stewart, 2006). Clinical use and research interest 
in perhexiline has persisted, most notably at The Queen Elizabeth Hospital, Adelaide 
through defining the safe therapeutic range, developing dosing regimens, 
establishing methods for therapeutic drug monitoring, and improving the 
understanding of its pharmacokinetic and pharmacogenomic properties (Horowitz et 
al., 1986, Stewart et al., 1996, Davies et al., 2006a). Today, perhexiline maleate 
(PEXSIG) is manufactured by Sigma Pharmaceuticals Ltd. in Baulkham Hills, New 
South Wales, Australia and is marketed internationally by Swedish Orphan Biovitrium 
AB, a Swedish based pharmaceutical company specialising in emerging late stage 
development of orphan and speciality drugs for rare diseases. 
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Over the last 40 years, research interest in perhexiline has waxed and waned. On 
searching Medline for the period 1969-2010, there were 575 publications in peer-
reviewed journals featuring the term perhexiline in the title, abstract or text. Plotted 
against year of publication, there has been a bimodal frequency distribution (figure 
13). The greatest interest occurred during the late 1970s and early 1980s with a peak 
of 48 publications in 1978 but declined such that following its withdrawal in 1988, the 
number of reports per annum did not reach double figures again until 2006. A second 
wave of publications has been driven by Professor John D. Horowitz (21 papers 
since 2000) and Associate Professor Benedetta C. Sallustio (9 papers) in Adelaide, 
South Australia and Professor Michael P. Frenneaux now in Aberdeen (8 papers), all 
of whom have been instrumental in facilitating the work contained in this thesis. 
 
 
* international withdrawal of perhexiline 
 
Figure 13. Frequency of publications on perhexiline in peer-reviewed journals. 
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2.2.2 Chemistry 
Perhexiline, or 2-(2,2-dicyclohexylethyl) piperidine, is prepared for pharmaceutical 
use as the maleate salt (C19H36N
+.C4H3O4
-), containing a racemic mixture of the (+) 
and (–) enantiomers. 
 
* chiral carbon 
Figure 14. The chemical structure of perhexiline. 
 
It consists of a CH-CH2 backbone with two saturated cyclohexane rings 
(hydrophobic) and a pyridine group (hydrophilic), making the whole molecule 
amphipathic. Each of the rings assumes a chair formation but it is chiral due to 
asymmetry of the second carbon of the piperidine ring (figure 14). Attempts to predict 
the biological actions of perhexiline based on its chemical structure have not been 
fruitful (Dawson et al., 1986). 
 
2.2.3 Mechanisms of action 
Early work with a canine right heart perfusion model using intravenous perhexiline 
found that whilst left ventricular work (blood pressure x cardiac output) decreased 
due to a fall in both blood pressure and heart rate, left ventricular efficiency (Δ work / 
Δ myocardial oxygen consumption) was increased suggesting that perhexiline 
H 
N 
* 
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improves metabolic efficiency (Cho et al., 1970). In human studies, Pepine and 
colleagues (1974) assessed haemodynamic and metabolic changes with atrial pacing 
after two weeks of treatment with oral perhexiline. They showed that perhexiline 
increased cardiac output, improved lactate utilisation and enhanced myocardial 
oxygen extraction without altering coronary flow, suggesting a shift in cardiac 
metabolism from predominately fatty acids towards the more efficient utilisation of 
carbohydrates (Vaughan Williams, 1980). Consistent with this hypothesis, ex vivo rat 
liver preparations treated with perhexiline showed inhibition of mitochondrial β-
oxidation of fatty acids (Deschamps et al., 1994). 
 
In a landmark paper, Kennedy and colleagues (1996) from the University of Adelaide 
performed classical pharmacological inhibition studies in which rat heart and liver 
homogenates were isolated and treated with perhexiline. The kinetics of 
mitochondrial fatty acid transport were examined in the presence of varying 
concentrations of perhexiline and confirmed it to be a potent inhibitor of CPT-1. 
Indeed, perhexiline was more potent at inhibiting cardiac than hepatic CPT-1 with a 
half-maximal inhibitory concentration (IC50) of 77µmol/L and 148µmol/L in heart and 
liver mitochondria, respectively. They also found that unlike malonyl-CoA, the 
principle endogenous inhibitor of CPT-1, which acts at a cytoplasmic regulatory site, 
perhexiline also appeared to act via a protected site facing the intermembrane space. 
However, unlike etomoxir, perhexiline is a partial inhibitor of fatty acid oxidation with 
competitive inhibition of CPT-1, implying that it may be overcome by high cellular 
levels of fatty acids. They concluded that the anti-anginal properties of perhexiline 
were due to improved metabolic efficiency through CPT-1 inhibition. It was also 
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proposed that this may be protective in myocardial ischaemia, since other CPT-1 
inhibitors had been shown to markedly delay the uncoupling effects of ischaemia by 
reducing the accumulation of long-chain acyl-carnitines (Yamada et al., 1994). 
 
Perhexiline was found to be concentrated at least 20-fold in rat heart homogenate 
compared with plasma due to its amphipathic nature (Kennedy et al., 1996). 
Similarly, Deschamps et al. (1994) had previously reported the progressive uptake of 
perhexiline into isolated mouse liver mitochondria, reaching a concentration 20-fold 
higher than in the incubation medium; it was proposed that similar to other cationic 
amines with lipophilic moieties, protonated perhexiline enters the matrix by diffusion 
along the mitochondrial membrane potential. These studies suggest a cumulative rise 
in the relative concentrations of perhexiline across the compartments from plasma to 
cytoplasm to mitochondrial matrix. Therefore, the concentration required for the 
inhibition of CPT-1 in a broken cell preparation may be achieved in vivo at its 
mitochondrial active site at therapeutic plasma concentrations. 
 
Kennedy and colleagues (2000) also provided evidence from a perfused rat heart 
model that perhexiline inhibits CPT-2. Unlike oxfenicine, perhexiline had no effect on 
ischaemia-induced long-chain acyl-carnitine accumulation by simultaneous inhibition 
of the enzymes responsible for its formation (CPT-1) and degradation (CPT-2). 
Perhexiline inhibited lactate release and increased acetyl-CoA concentrations in the 
myocardium under normal flow conditions, which may improve oxidative coupling of 
glucose during ischaemia by increasing substrate availability for the citric acid cycle. 
Whilst it was found to enhance diastolic function during ischaemia, perhexiline failed 
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to improve contractility during reperfusion compared with controls. The authors were 
surprised by this lack of benefit in reperfusion and speculated that it may be related 
to the incomplete nature of the ischaemia and the short length of exposure to 
perhexiline in their model. 
 
In a further study, Unger et al. (2005) found that acute exposure to perhexiline did not 
inhibit palmitate oxidation in either isolated cardiomyocytes or working rat hearts. 
Following 24 hours of pre-treatment with perhexiline, cardiac work and efficiency 
improved by approximately 30% but without any effect on fatty acids oxidation; only 
by 48 hours was palmitate oxidation reduced. The dissociation between metabolic 
and efficiency effects led the authors to conclude that: 
‘...perhexiline increases myocardial efficiency by a mechanism that is largely or 
entirely independent of its effects on CPT.’ 
 
The delayed metabolic effect was attributed to gradual myocardial accumulation of 
perhexiline in order to reach inhibitory levels in the cytosol and mitochondrial matrix 
and supports the concept of cumulative drug uptake and tissue loading. 
 
Perhexiline has also been shown to have anti-inflammatory effects via the inhibition 
of superoxide formation by phagocytic NADPH oxidase in neutrophils (Kennedy et 
al., 2006) and to potentiate platelet responsiveness to nitric oxide via an increase in 
cyclic GMP (Willoughby et al., 2002). The relative importance of these mechanisms 
in the clinical effects of perhexiline therapy is yet to be established. 
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2.2.4 Pharmacokinetics 
The decline in the use of perhexiline was not due to a lack of efficacy; on the 
contrary, it was effective in the relief of angina but its highly variable metabolism led 
to severe toxicity in a small number of patients. Perhexiline is well absorbed orally, 
with a large volume of distribution but variable systemic bioavailability (Wright et al., 
1973). The major determinant of its oral clearance is hepatic metabolism with only a 
fraction of the dose eliminated unchanged in the urine. The primary metabolites of 
perhexiline are cis-OH-perhexiline and trans-OH-perhexiline, which in turn may be 
further oxidised to secondary dihydroxy derivatives. Formation of both cis- and trans-
OH-perhexiline is catalysed by cytochrome P450 2D6 (CYP2D6), a member of the 
microsomal mixed-function oxidase system (Davies et al., 2007); the saturability and 
genetic polymorphism of this enzyme has been identified as the main determinant of 
perhexiline clearance (Sallustio et al., 2002). Accordingly, the half-life of perhexiline 
may show a several hundred-fold variation between patients from just a few hours to 
over a month. On the other hand, there is relatively little intraindividual variability in 
the clearance of OH-perhexiline metabolites and so the ratio of the metabolites to the 
parent drug in the blood represents a useful clinical measure of perhexiline 
metabolism. This metabolic ratio (COH-Px/CPx) allows the separation of patients 
according to phenotypic metaboliser status, enabling the prediction of dosing 
requirements to maintain a steady-state within the therapeutic range and therefore 
prevention of the long-term effects of toxicity (table 3) (Sallustio et al., 2002). 
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Metaboliser status COH-Px/CPx ratio Predicted daily dose (mg/day) 
Ultra-rapid >20 300-500 
Extensive 2.5-20 100-250 
Intermediate 0.3-2.49 50-100 
Poor <0.3 10-25 
COH-Px indicates concentration of OH-perhexiline; CPx, concentration of perhexiline. 
 
Table 3. Perhexiline metaboliser status, metabolic ratio and predicted dose. 
 
Therapeutic drug monitoring has become the cornerstone of perhexiline therapy over 
the past 25 years. It has enabled patients to be maintained on effective therapy whilst 
preventing the toxicity previously associated with chronic use. The therapeutic range 
has been defined as a plasma perhexiline concentration of 0.15-0.6mg/L. Patients on 
long-term therapy undergo regular surveillance of plasma levels with dose titration 
according to a defined protocol (Horowitz et al., 1986, Lee et al., 2004). Personalised 
dosing may be used to account for variability in perhexiline pharmacokinetics 
between poor metabolisers with low clearance and high bioavailability and ultra-rapid 
metabolisers with high clearance and low bioavailability. Recent studies have also 
found differences in the stereoselective metabolism of perhexiline (+) and (–) 
enantiomers between metaboliser groups (Inglis et al., 2007, Davies et al., 2008) 
which may suggest a role for monitoring of the enantiomers rather than the current 
undifferentiated perhexiline concentration. 
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2.2.5 Pharmacogenomics 
The human CYP2D6 gene, part of the P450 gene superfamily, is comprised of nine 
exons and resides on the long arm of chromosome 22. It is thought to have emerged 
around 400 million years ago as tetrapods took to the land and required new 
enzymes to detoxify ingested plant metabolites (Gonzalez and Nebert, 1990). P450 
gene evolution has resulted in significant polymorphism, leading to marked variability 
in individual responses to drugs and toxins. Poor metabolisers of perhexiline possess 
two CYP2D6 null alleles and have no detectable enzymatic activity; intermediate 
metabolisers express low level residual function with at least one partially deficient 
allele. At the other end of the spectrum, ultra-rapid metabolisers have alleles carrying 
multiple copies of the gene resulting in excessive expression (Zanger et al., 2004). 
 
The prevalence of poor metabolisers is 7-10% in European Caucasians and 1-2% in 
African or East Asian populations (Gardiner and Begg, 2006). Many mutations of the 
CYP2D6 gene are recognised to activate or inactivate enzyme function (Ingelman-
Sundberg et al., 2011) and genotyping for the common variants has an accuracy of 
99% for differentiating poor and extensive metaboliser phenotypes (Sachse et al., 
1997). However, it has proven less useful for predicting future dosing as it excludes 
non-genetic factors affecting metabolism, including other drugs e.g. SSRIs, and does 
not account for alternative lower-affinity pathways, such as CYP3A. Therefore 
CYP2D6 genotyping is not a replacement for therapeutic drug monitoring but may be 
used to identify poor metabolisers who are at greater risk of toxicity (Barclay et al., 
2003, Davies et al., 2006a). On this basis, perhexiline has been suggested as a 
withdrawn drug that may be ‘rescued’ by genotype-based prescribing (Shah, 2006). 
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2.2.6 Adverse effects 
It has been known for many years that the toxic effects of perhexiline therapy are 
concentration-dependent. In poor metabolisers, the lack of CYP2D6 leads to steadily 
rising plasma levels with a standard dosing regimen. In intermediate metabolisers, 
there is a disproportionate change in plasma concentration compared to a change in 
dose; the unbound perhexiline concentration exceeds the Km for CYP2D6 within the 
clinical range, saturating its metabolism and predisposing to toxicity (Davies et al., 
2007). Early transient side-effects are related to acute elevation of plasma perhexiline 
concentration above 0.6mg/L and occur in 10%-28% of patients depending on dose 
(Philpott et al., 2004). Symptoms are principally nausea, dizziness and headache but 
may also include vomiting, diarrhoea, tremor, lethargy and insomnia; acute 
hypoglycaemia has also been reported in patients with diabetes mellitus (Sigma 
Pharmaceuticals, 2009). 
 
Chronic toxicity may occur after at least three months of continuous perhexiline 
therapy in susceptible individuals and is concentration-dependent. Serious adverse 
events are uncommon but include peripheral neuropathy, hepatitis, extrapyramidal 
dysfunction, muscle weakness, ataxia and weight loss (Sigma Pharmaceuticals, 
2009). Elevation of serum liver enzymes is common and must be monitored with 
long-term therapy. Sensory, motor and autonomic neuropathies have been reported 
with evidence of reduced nerve conduction velocity, denervation atrophy and 
demyelination. At a cellular level, these adverse effects are thought to be due to 
excessive inhibition of CPT-1, impairment of mitochondrial energy metabolism and 
upstream cytoplasmic accumulation of long-chain fatty acids (Ashrafian et al., 2007). 
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Toxicity can be prevented in long-term use by therapeutic drug monitoring and 
adjustment of dosing to achieve plasma levels within the therapeutic range (0.15-
0.6mg/L) (Horowitz et al., 1986, Cole et al., 1990). This strategy has been shown to 
maintain efficacy whilst avoiding almost all serious adverse effects (Horowitz et al., 
1995) in poor metabolisers over several years. 
 
2.2.7 Clinical use 
Perhexiline was originally marketed as a treatment for chronic angina pectoris and 
was found to be highly effective in patients who were either unsuitable or refractory to 
other agents, resulting in fewer angina attacks, improved exercise tolerance and 
reduced consumption of glyceryl trinitrate (Burns-Cox et al., 1971, White and Lowe, 
1983, Pilcher et al., 1985); although all of these early studies were limited by adverse 
effects. By dose adjustment according to plasma levels, Horowitz and colleagues 
(1986) were able to demonstrate a marked improvement in symptoms without long-
term toxicity. Cole et al. (1990) found perhexiline to be an effective therapy in patients 
with refractory angina who were unsuitable for coronary revascularisation; similarly, it 
was associated with marked improvement in symptoms in patients with severe aortic 
stenosis deemed unsuitable for aortic valve replacement (Unger et al., 1997). 
 
In recent years, metabolic manipulation with perhexiline has been shown to improve 
symptoms, left ventricular ejection fraction (LVEF) and maximal oxygen consumption 
(Vo2 max) in patients with chronic heart failure (Lee et al., 2005) and to enhance 
exercise capacity and ameliorate cardiac energetic impairment in symptomatic 
hypertrophic cardiomyopathy (Abozguia et al., 2010). Whilst patients on perhexiline 
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have previously undergone cardiac surgery (appendix 9.1), no studies to date have 
assessed whether it improves clinical markers of myocardial protection. 
 
Perhexiline is currently licensed for the treatment of refractory angina in Australia and 
New Zealand, subject to therapeutic monitoring of patients (Sigma Pharmaceuticals, 
2009). Whilst effective in the treatment of stable angina, unstable angina and acute 
coronary syndromes (Willoughby et al., 2002), its use is limited due to its narrow 
therapeutic index and variable pharmacokinetics. However, particularly at The Queen 
Elizabeth Hospital, Adelaide, it has been used off-label in patients with other cardiac 
conditions including diabetic or hypertrophic cardiomyopathy. In the United Kingdom, 
perhexiline is prescribed on a named-patient basis only and is restricted to a few 
specialist centres, often in the context of clinical trials (Phan et al., 2009). Currently, 
therapeutic drug monitoring of perhexiline is only performed in two centres. 
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2.3 Summary and hypotheses 
 
Myocardial protection enables the prolongation of ischaemic tolerance through the 
use of cardioplegia and hypothermia to produce elective cardiac arrest and facilitate 
surgery. However non-fatal perioperative events including low cardiac output episode 
due to inadequate protection significantly reduce late survival (Fremes et al., 2000). 
Modulation of metabolism offers a means to reduce ischaemia-reperfusion injury and 
improve function in the early postoperative period. GIK has been shown to improve 
postoperative haemodynamics and reduce myocardial injury in a meta-analysis of 33 
trials including 2113 patients (Fan et al., 2011); several potential mechanisms of 
action have been identified but their relative importance is unclear. However, it is not 
widely used in cardiac surgery today due to the lack of definitive randomised multi-
centre trials, the need for a standardised protocol and concerns over perioperative 
blood glucose control. In a systematic review of the literature, I found little evidence 
for the use of other metabolic therapies in myocardial protection. 
 
Perhexiline has been used to treat ischaemic heart disease and chronic heart failure. 
It is thought to induce a metabolic shift from fatty acids to glucose, increase efficiency 
of ATP production per mole of oxygen and improve coupling of glycolysis to glucose 
oxidation, resulting in a net reduction of myocardial proton burden during ischaemia. 
The available experimental evidence suggests that it may have a role in reducing 
myocardial ischaemia-reperfusion injury but this has never been tested in a clinical 
trial and so its application to cardiac surgery is unknown. 
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Coronary artery bypass graft surgery remains the predominant heart operation in 
Europe (Bridgewater et al., 2010) and the vast majority are still performed on 
cardiopulmonary bypass; hence it represents the largest pool of patients in whom to 
study myocardial protection and makes the findings widely and directly applicable to 
the greatest number of patients. The period of elective ischaemia with aortic cross-
clamping provides both a model for assessment of the effect of metabolic therapies 
on ischaemia-reperfusion and unique access to myocardial tissue to directly study 
the pharmacology of drugs in humans. 
 
In this thesis, I propose to test the following hypotheses: 
 
1. Preoperative oral loading with perhexiline maleate as an adjunct to cold blood 
cardioplegia during ischaemic arrest in patients undergoing CABG will improve 
markers of myocardial protection (Chapter 7). This will be reflected by a decreased 
incidence of low cardiac output episodes, reduced need for inotropic support and 
lower release of troponin in the perioperative period compared with controls. 
 
I conduct a prospective, two-centre, double-blind, randomised, placebo-controlled 
trial of preoperative oral perhexiline in patients undergoing CABG (Chapter 3) using 
validated clinical markers of myocardial stunning and ischaemia-reperfusion injury to 
evaluate its application to myocardial protection. 
 
2. Cardiac indices will also be higher in the perhexiline group prior to ischaemia due 
to improved metabolic efficiency (Chapter 7). This will be reflected by changes in 
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the myocardial metabolic profile favouring glucose metabolism and glycolytic flux 
through pyruvate to enter the citric acid cycle (Chapter 6). The short length of 
therapy will bring the benefits of CPT inhibition on metabolic efficiency without the 
potential risks of lipid accumulation caused by long-term inhibition of β-oxidation. 
 
I use two independent laboratory techniques, traditional enzymatic colourimetry and 
state-of-the-art Fourier transform ion cyclotron resonance mass spectrometry, to 
assess the effect of perhexiline therapy on carbohydrate and/or lipid metabolism in 
the atrial and ventricular myocardium prior to ischaemia. 
 
3. At least 80% of patients will be within the therapeutic range for serum perhexiline 
at the time of surgery with a standard dosing regimen of 200mg bis die for three 
days then 100mg bis die until surgery (Chapter 4). Patients may fall outside of the 
therapeutic range due to variable metabolism, side-effects or non-compliance. 
 
Following an evidence-based loading regime, I determine the serum concentration of 
perhexiline at the time of surgery and examine factors that may have influenced 
attainment of therapeutic levels including length of therapy and metaboliser status. 
 
4. Perhexiline is more concentrated in the human myocardium than in the serum 
reflecting cumulative drug uptake and tissue loading as previously shown in the rat 
heart (Chapter 5). Serum and myocardial levels will be closely correlated but may 
be reduced by insufficient length of therapy to reach steady-state or high serum 
concentrations with saturation pharmacokinetics. 
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I analyse atrial and ventricular biopsies obtained from patients in the trial using high 
performance liquid chromatography to determine the tissue concentration of 
perhexiline, correlate with serum levels and examine factors that may affect drug 
uptake. This work was conducted through a Wellcome Trust Training Award to visit 
the University of Adelaide, South Australia. 
 
5. The concentration of perhexiline in the myocardium following at least one week of 
therapy will be sufficient to significantly inhibit CPT-1 corresponding to inhibitory 
concentrations observed in the rat heart (Chapter 5) (Kennedy et al., 1996). 
 
I compare these novel human findings with those from studies of perhexiline in the rat 
heart to assess whether the concentration is likely to be sufficient for CPT-1 inhibition 
 
The subsequent chapters of this thesis are structured to address these hypotheses 
along a biological pathway from oral drug administration, attainment of a therapeutic 
serum concentration, uptake into the myocardium, modulation of myocardial 
metabolism and improvement in clinical markers of myocardial protection (figure 15). 
 
 
 
Figure 15. Structure of the subsequent chapters of this thesis. 
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3. METHODS 
 
Randomised controlled trials, alone or as part of a systematic review, provide the 
highest level of evidence for the effectiveness of an intervention and form the 
bedrock of evidence-based medicine (OCEBM, 2009). The International Conference 
on Harmonisation (www.ich.org) has developed tripartite guidelines for the scope, 
design, conduct, analysis and reporting of trials through a process of scientific 
consensus between regulatory authorities and the pharmaceutical industry in the 
United States, Europe and Japan. These international standards have been widely 
adopted into law to regulate clinical trials, maintain quality and ensure patient safety. 
 
In this chapter, I review the key ICH principles of clinical trial methodology including 
identifying research questions, avoiding bias, the intention-to-treat principle and the 
Consolidated Standards of Reporting Trials (CONSORT) statement. I relate these 
principles to the design, conduct and analysis of the CASPER trial, a multi-centre trial 
of perhexiline in myocardial protection on which this thesis is founded. 
 
3.1 Principles of clinical trial methodology 
 
The efficacy and safety of medicinal products should be demonstrated by clinical 
trials which follow the ethical and methodological principles of the Declaration of 
Helsinki (World Medical Association, 2008) and Good Clinical Practice (ICH, 1996). 
Such studies can be classified according to their objectives and timing during the 
process of drug development (table 4) (ICH, 1997). 
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Type of study Objectives Study examples 
Human Pharmacology  Assess tolerance 
 Describe PK and PD 
 Explore drug metabolism 
 Estimate drug activity 
 Dose-tolerance 
 Single or multi-dose 
 Drug interactions 
Therapeutic exploratory  Explore targeted 
indications 
 Estimate dosage 
 Provide basis for design 
of confirmatory studies 
 Well-defined population 
with pharmacological 
or  surrogate endpoints 
of clinical measures 
 Dose-response  
Therapeutic confirmatory  Demonstrate efficacy 
 Establish safety profile 
 Risk-benefit analysis 
 Establish dose-response 
 Controlled efficacy 
 Parallel dose-response 
 Clinical safety 
 Large simple trials 
Therapeutic use  Refine understanding of 
risk-benefit especially in 
special populations 
 Identify uncommon 
adverse drug reactions 
 Refine dosing proposals 
 Studies of comparative 
effectiveness 
 Mortality/morbidity 
 Additional endpoints 
 Pharmacoeconomics 
 ‘Real world’ trials 
PK indicates pharmacokinetics; PD, pharmacodynamics. 
 
Table 4. Classification of clinical drug studies according to objectives. 
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In addition, clinical studies can be described according to the temporal phase of drug 
development and whilst these typically track the objectives, they do not represent a 
fixed order for the conduct of research (ICH, 1997). 
 Phase I starts with the initial administration of the drug to humans and therefore 
are most typically Human Pharmacology studies. They are used to estimate the 
safety and tolerability of the drug, its pharmacokinetic (PK) and pharmacodynamic 
(PD) profile and may involve healthy volunteers. 
 Phase II studies are often therapeutic exploratory in which the primary objective is 
to investigate efficacy of the drug in patients. These studies are usually conducted 
in a selected group of relatively homogeneous patients and are used to determine 
potential endpoints, doses, regimens and target populations for Phase III trials. 
 Phase III is usually considered to start with the initiation of studies which 
demonstrate or confirm therapeutic benefit. These trials aim to confirm the safety 
and efficacy data from earlier phases and form the basis of marketing approval. 
They may also explore the drug’s use in a wider population, for a long period of 
time, in different stages of disease or in combination with other drugs. 
 Phase IV relates to therapeutic use and therefore begins with regulatory approval 
for a specific indication. These post-marketing studies may explore drug 
interactions, dose response, cost-benefit or acquisition of additional safety or 
epidemiological data. 
 
When appropriately designed, conducted and reported, randomised controlled trials 
represent the gold standard in evaluating healthcare interventions. However, 
complete, clear and transparent information on methodology and findings has often 
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been inadequately reported, leading to the CONSORT statement in 1996, updated in 
2001 and most recently in 2010 (Schulz et al., 2010). These guidelines include a 
checklist and flow diagram for the reporting of trials and therefore indirectly provide 
an impetus for improving trial design and conduct. 
 
3.1.1 Scope of a clinical trial 
Clinical trials should pose an important, clear and precise research question and all 
aspects of the trial should be conducted in order to safely and effectively answer this 
question. The hypothesis should be derived from a background of evidence 
supporting both the rationale for and the plausibility of the trial. Confirmatory trials 
test a pre-defined hypothesis as the primary objective in order to provide strong 
scientific evidence regarding the efficacy of a treatment (ICH, 1998). Adherence to 
protocol and standard operating procedures is therefore particularly important and 
any deviations should be documented, explained and potential effects scrutinised. 
 
The trial population should mirror the target population to enable generalisation of the 
results to the wider community, termed external validity. The inclusion and exclusion 
criteria should be considered to achieve a balance between maintaining homogeneity 
and restricting applicability including age, sex, ethnicity, co-morbidities and access to 
healthcare of the participants. Whilst no clinical trial can be wholly representative of 
future users due to the impact of geographical, temporal and logistical variables, the 
influence of such factors should be considered and minimised. 
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The primary endpoint should be a measurable variable which provides the most 
clinically relevant and convincing evidence directly related to the primary hypothesis 
of the trial (ICH, 1998). It should be an objective, reliable and validated measure of 
treatment benefit in the patient population and conform to the accepted norms and 
standards of the relevant field of research. The primary endpoint must be precisely 
defined and justified in the trial protocol and should be used to estimate the sample 
size. Secondary variables are used either to support the findings of the primary 
endpoint or as measurements of effects related to defined secondary objectives. 
 
3.1.2 Avoiding bias 
The ethical and scientific validity of a clinical trial is dependent upon its freedom from 
influences that may affect its design, execution or reporting. Bias may compromise a 
trial’s internal validity, the accuracy of its conclusions about the effect of the 
intervention on the trial subjects, or external validity, the applicability of the study to 
the wider population (Paradis, 2008). The two key techniques for avoiding the effects 
of bias in clinical trials are randomisation and blinding. 
 
Randomisation is the process of assigning participants to a treatment group such that 
the groups differ only by the intervention and the play of chance; if chance is found to 
be implausible by statistical analysis, then any observed differences in outcome can 
be attributed to the intervention. Whilst it does not guarantee a perfect balance 
between groups, it removes selection bias by obviating systematic differences due to 
known or unidentifiable factors other than the intervention and provides a sound 
statistical basis for the quantitative evaluation of treatment effect (ICH, 1998). The 
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CONSORT statement recommends that sequence generation, allocation 
concealment and implementation be reported for all randomised trials (Schulz et al., 
2010). There are several accepted mechanisms for generating randomisation 
sequences including simple, block, stratified and dynamic random allocation. 
Minimisation is a method of adaptive stratified sampling that aims to minimise the 
imbalance between treatment groups for a number of identified prognostic factors 
(Pocock and Simon, 1975); however it is controversial as the allocation of the next 
subject by the algorithm is dependent upon the allocation of previous subjects in a 
trade-off between balance and uncertainty (McEntegart, 2003). Concealment is the 
process used to implement the random allocation sequence such as sealed 
envelopes or a computer programme. Implementation refers to the people involved in 
generating the sequence, enrolling participants and assigning them to interventions. 
 
The process of randomisation facilitates blinding, the concealment of treatment 
assignment from one or more parties. It is intended to limit conscious or 
subconscious bias arising from the influence which the knowledge of treatment may 
have on the conduct and interpretation of a trial including recruitment and allocation 
of subjects, their subsequent care, the attitudes of subjects to treatments, 
assessment of endpoints, handling of withdrawals and exclusion of data from 
analysis (ICH, 1998). The gold standard is a double-blind trial in which neither the 
participant nor the investigators are aware of the allocated treatment arm until all 
such opportunities for bias have passed; if maintained, any potential expectation 
biases from patients or researchers are removed. If interim or safety analyses are 
performed, adequate standard operating procedures must be established to prevent 
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dissemination of treatment codes and compromise of internal validity. In order to 
maintain blinding, treatments must be indistinguishable in appearance, taste and 
immediately apparent consequences. Therefore, particularly in surgical interventions, 
blinding of one or both parties may be difficult or even impossible to achieve. 
 
Comparative trials in which patients are required to actively participate, such as 
reliably taking the drug under investigation, are also exposed to compliance bias. 
Differences in subject adherence to the protocol may be affected by an increased 
rate of side-effects in the treatment group and therefore precipitate withdrawal bias. 
An evaluation of patient compliance should be included in the protocol and actual 
usage documented if possible; a planned subgroup analysis may therefore be used 
to assess any impact on outcomes. 
 
Performance bias is an additional factor of particular importance in surgical trials. No 
two surgeons perform a procedure in exactly the same way nor does a surgeon 
repeat the same operation in an identical manner each time (Paradis, 2008). Whilst 
this potentially reduces internal validity by creating differences between patients in 
the same treatment group, it improves external validity by reflecting real-world 
variability in practice between surgeons and institutions. In a randomised trial, any 
detrimental effects may be controlled by including surgeon as a minimisation factor in 
the randomisation procedure, balancing any potential impact on the groups. 
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3.1.3 Clinical trial design 
The most common trial design is parallel groups in which subjects are randomised to 
one of two or more arms with each arm allocated a different treatment. Other designs 
include crossover, where all participants experience all arms of the trial in a 
randomised sequence and so act as their own controls, and factorial design, in which 
subjects are randomly allocated to combinations of treatments to examine their 
additive effects and positive or negative interactions (ICH, 1998). A multicentre trial 
enables an increased number of potential participants from a wider population, 
thereby improving both the efficiency of recruitment and the generalisation of the 
findings. However, it must be conducted according to a common protocol across 
participating sites with appropriate training of personnel and monitoring of conduct. 
 
The number of subjects participating in a clinical trial should have sufficient statistical 
power to provide a reliable answer to the primary research question. The sample size 
is determined by specifying: a primary variable, the test statistic, the null hypothesis, 
the probability of erroneously rejecting the null hypothesis (type I error), the 
probability of erroneously failing to reject the null hypothesis (type II error) and the 
approach to dealing with treatment withdrawals and protocol violations (ICH, 1998). 
In confirmatory trials, assumptions of treatment effect are usually based on published 
data from earlier trials or the minimum effect that has clinical relevance. 
Conventionally the probability of type I error is set at one-sided 2.5% or less whilst 
the probability of type II error is set at 10% or 20% in order to reduce the risk of 
incorrect and so misleading conclusions. 
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3.1.4 Conducting a clinical trial 
Obtaining informed consent is a statutory requirement for clinical trials. A favourable 
opinion must be obtained from a recognised body such as a NHS Research Ethics 
Committee for the use of the proposed Patient Information Sheet and Consent form, 
using clear, non-technical language. The seeking of consent in particular must 
adhere to the ethical principles of Good Clinical Practice (ICH, 1996). Consent must 
be given freely after the subject is informed of the nature, significance, implications 
and risk of the research and should be recorded in writing. The subject should be 
aware that they may decline participation or withdraw at any time. Special protection 
is afforded to vulnerable groups including children, prisoners and those without the 
mental capacity to give legal consent. 
 
In the UK, clinical trials are regulated by The Medicines for Human Use (Clinical 
Trials) Regulations 2004 (SI 1031) as amended, which implements the European 
Clinical Trials Directive (2001/20/EC) (MHRA, 2011). Accordingly, clinical trials of 
medicinal products in human subjects require authorisation by the competent 
authority, in addition to a favourable opinion from an ethics committee. The 
Medicines & Healthcare products Regulatory Authority (MHRA) is the governmental 
agency responsible for assessing applications from sponsors to conduct clinical trials 
of medicinal products and for issuing a clinical trial authorisation (CTA). All authorised 
trials are registered on the European Clinical Trials Database (EudraCT, 2011). 
During the conduct of a trial, the sponsor is responsible for safety reporting via the 
submission of Suspected Unexpected Serious Adverse Reactions (SUSARs) and 
Annual Safety Reports (ASRs) to the MHRA. 
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The updated Declaration of Helsinki states that (World Medical Association, 2008): 
‘Every clinical trial must be registered in a publically accessible database 
before recruitment of the first subject’ 
 
Registries, such as the US National Institutes of Health (www.ClinicalTrials.gov) or 
the International Standard Randomised Controlled Trial Number Register (ISRCTN) 
(www.controlled-trials.com), contain a minimum registration dataset defined by the 
World Health Organisation. This ensures that researchers, clinicians, funding bodies 
and potential participants are aware of current trials to inform decision-making, 
identify gaps in knowledge and avoid unnecessary duplication of research. 
 
During a clinical trial, there are two forms of monitoring: oversight of the quality of the 
trial, and comparing treatment outcomes through interim analyses. Monitoring the 
quality of the trial conduct includes ensuring adherence to the protocol, accuracy and 
completeness of data collection, the meeting of planned accrual targets, keeping 
patients in the trial and the appropriateness of design assumptions. This role may be 
performed by the sponsor or an independent group. On the other hand, any interim 
analyses of efficacy or safety data prior to the formal completion of the trial require 
access to unblinded comparative information and must be performed by an external 
independent group, the Data and Safety Monitoring Board (DSMB). The schedule of 
interim analyses and the modus operandi of the DSMB, including guidelines for 
stopping the trial early, should be clearly documented in the protocol; any deviation 
from this plan may flaw the results of the trial and weaken confidence in the 
conclusions drawn. 
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3.1.5 Analysis of a clinical trial and the intention-to-treat principle 
The principal features of the statistical analysis should be prespecified in the protocol 
including the way in which anticipated problems will be handled. The statistical 
analysis plan contains more technical and detailed procedures for executing the 
analysis of the primary and secondary endpoints and other data. The plan should be 
reviewed and updated if required following review of the dataset but prior to 
unblinding. The protocol should address anticipated problems prospectively, 
including how these may affect trial data, and specify procedures aimed at minimising 
irregularities in study conduct that may impair the analysis, including protocol 
violations, withdrawals and missing values (ICH, 1998). The frequency and type of all 
such irregularities should be documented in the clinical trial report and their potential 
influence of the trial results described. 
 
The intention-to-treat principle aims to analyse all randomised subjects in the groups 
to which they were originally allocated. Preservation of the initial randomisation is 
important to preserve an unbiased treatment allocation, the prognostic balance 
between the groups and confidence in the statistical analysis (Nuesch et al., 2009). 
However, there are some circumstances in which the exclusion of randomised 
subjects from the primary analysis is valid, avoiding bias and minimising random 
error (Fergusson et al., 2002); these include eligibility violations due to human error, 
failure to take at least one dose of the trial medication and the lack of any outcome 
data post-randomisation. Any such exclusions must always be justified and should 
not be influenced by knowledge of the assigned treatment. The CONSORT statement 
urges transparent reporting of the flow of participants through the various stages of a 
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trial, including a description of withdrawals and losses to follow-up with reasons for 
exclusions from the analysis (Schulz et al., 2010). In contrast, per protocol analyses 
allow exploration of the sensitivity of conclusions, particularly in superiority trials 
where intention-to-treat analysis alone may be seen as a conservative strategy and is 
more susceptible to type II error (ICH, 1998). Other statistical considerations include 
handling missing values, which represent a potential source of bias, identifying and 
dealing with outliers, selection of appropriate statistical tests, modelling and 
confidence intervals, and management of trial data. 
 
3.1.6 Reporting of a clinical trial 
The methodology and findings of all clinical trials should be publically reported 
according to prespecified criteria and standards. The CONSORT reporting criteria 
(Schulz et al., 2010) include the need for clear and detailed information on the 
hypotheses, trial design, participants, interventions, outcomes, sample size, 
randomisation, blinding, statistical methods, recruitment, baseline data, analysis, 
limitations, generalisability, interpretation, registration and funding. In particular, all 
subjects entered into the trial should be accounted for in the report, whether or not 
they were included in the analysis, through a CONSORT flow diagram which 
documents the progress of participants through the stages of enrolment, allocation, 
follow-up and analysis. Subjects excluded from the analysis, lost to follow up, 
withdrawn from treatment, or with a severe protocol violation should be identified and 
a detailed description provided, including reasons and relationship to the treatment 
and outcomes (ICH, 1998). The use of descriptive statistics is encouraged to 
illustrate clearly the important features of demographic and prognostic variables. 
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Efficacy and safety data should be presented through planned analyses with limited 
reliance on ad hoc analyses. The results of statistical tests should be presented 
precisely rather than with reference to critical thresholds to facilitate the inclusion of 
trial data in subsequent meta-analyses. 
 
The International Committee of Medical Journal Editors has published Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals (ICMJE, 2010). This 
document aims to reduce citation bias, the incomplete reporting of trial outcomes 
associated with statistical significance, publication bias, the selective reporting of 
positive trials favouring an intervention, and overlapping or redundant publication, 
through prospective trial registration and the use of reliable literature sources and 
standards for trial reporting. 
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3.2 Improving myocardial protection during Coronary Artery Surgery with 
Perhexiline: the CASPER trial 
 
A prospective, double-blind, randomised, placebo-controlled trial was conducted at 
two University teaching hospitals in the United Kingdom – the Queen Elizabeth 
Hospital (QEH), part of the University Hospitals Birmingham NHS Foundation Trust, 
and the Royal Sussex County Hospital (RSCH), a member of the Brighton & Sussex 
University Hospitals NHS Trust. The protocol was approved by the Cambridgeshire 1, 
South Birmingham and Brighton East Research Ethics Committees (REC: 
06/Q0104/141) and the UK Medicines & Healthcare products Regulatory Authority. 
The trial was registered with clinicaltrials.gov (NCT: 00845364), the European Clinical 
Trials Database (EudraCT: 2006-003164-62) and the UK Clinical Research Network 
(UKCRN: 5812). It was funded by grants from the British Heart Foundation (BHF: 
PG/06/044/20703) and Sussex Heart Charity, and sponsored by University Hospitals 
Birmingham NHS Foundation Trust (UHB: RRK3217). In this section, I discuss the 
design, conduct, endpoints and proposed analysis of the CASPER trial in relation to 
the ICH principles of clinical trial methodology and Good Clinical Practice. 
 
3.2.1 Inclusion & exclusion criteria 
The criteria for inclusion in this trial were: adult patients undergoing first-time, 
isolated, CABG for multi-vessel coronary artery disease; therefore, patients with 
single vessel disease, proposed combined procedures (such as valve surgery, 
radiofrequency ablation or left ventricular remodelling) or previous cardiac surgery 
were not included. 
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The following exclusion criteria were applied (Sigma Pharmaceuticals, 2009): 
 Known hypersensitivity to perhexiline 
 History of porphyria: Perhexiline is deemed unsafe in porphyria as it may 
precipitate a symptomatic attack. 
 Hepatic impairment: Perhexiline is cleared from the body via extensive hepatic 
metabolism by the cytochrome P450 2D6 mixed-function oxidase system which is 
readily saturable within the clinical dose range. Evidence of impaired liver function 
is therefore a documented contraindication to prevent rapid drug toxicity. 
 Renal impairment: The metabolites of perhexiline are mainly excreted in the urine. 
Patients with significant renal impairment, defined as serum creatinine > 200 
μmol/L, were therefore excluded. 
 Recent amiodarone therapy: In addition to its Class III anti-arrhythmic effects, 
amiodarone is a partial inhibitor of cardiac mitochondrial CPT-1 and may therefore 
exert cardioprotective effects via the same mechanism as perhexiline (Kennedy et 
al., 1996). It also inhibits hepatic cytochrome P450 isoenzymes, reducing the 
systemic clearance of perhexiline and predisposing to toxicity. 
 Diabetes mellitus: Perhexiline should be administered with caution in diabetic 
patients as it may precipitate hypoglycaemia, particularly with concurrent use of 
insulin or a sulfonylurea. Fasting blood sugar levels fall by around 30% over the 
first three days and most trial patients were starting therapy unsupervised in the 
community. 
 Peripheral neuropathy: Perhexiline toxicity has been linked with denervation 
atrophy and demyelination; patients with pre-existing disease were excluded. 
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 Pregnancy or breast-feeding: There is limited data on the use of perhexiline in 
pregnancy and it is not known whether it is excreted in breast milk. Any effects on 
the foetus and newborn infant are also unknown. 
 Atrial fibrillation: The irregularity of heart rate and variation in stroke volume in 
atrial fibrillation produces inconsistent and irreproducible measurements of cardiac 
output as determined with a pulmonary artery catheter by the thermodilution 
technique. In addition, the loss of coordinated atrial transit diminishes left 
ventricular end-diastolic volume in the absence of ventricular dysfunction. 
Therefore atrial fibrillation would be likely to introduce both type I and type II errors 
in the measurement of clinical endpoints through actual and observed alterations 
in cardiac function. 
 Emergency surgery: Defined as requiring potentially life-saving surgery prior to 
8am the following day, these patients had insufficient time for adequate loading 
with perhexiline and therefore could not be included. 
 Ethical considerations: The application for ethical approval did not seek to include 
patients lacking capacity to consent for themselves or those in the custody of HM 
Prison Service; these patients were therefore excluded from the trial.  
 Significant deviation from protocol required on clinical grounds: A small number of 
patients have known co-morbidities that would mandate significant deviations from 
the trial protocol. For example, sickle-cell disease (or trait) and cryoglobulinaemia 
are contraindications to the cardiopulmonary bypass, cardioplegia and cardiac 
output measurement techniques used in this trial. Any such patients were 
therefore identified and excluded on an individual basis. 
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Patients taking Selective Serotonin Reuptake Inhibitors (SSRIs), such as fluoxetine 
or paroxetine, were not excluded from the trial. Cases of perhexiline toxicity have 
been reported with co-administration of these agents due to competition for 
cytochrome P450 CYP2D6 microsomal enzymes (Alderman et al., 1997); however 
the low dose and short duration of perhexiline therapy used in this trial were deemed 
not to be prohibitory to concurrent use (Frenneaux, 2007). 
 
3.2.2 Patient recruitment 
Suitable patients were identified from the NHS waiting lists of nine Consultant 
Cardiac Surgeons involved in the trial through two referral pathways: those referred 
for routine elective surgery and those warranting urgent inpatient surgery, defined as 
requiring definitive intervention during the current hospital admission. The latter 
included many patients who had recently been admitted to hospital due to a 
myocardial infarction; these patients often require further investigations and 
optimisation prior to surgery, providing a window of opportunity for recruitment and 
instigation of trial therapy. If the time between the opportunity for recruitment to the 
trial and the predicted date of surgery was less than five days, the patient was not 
approached unless surgery was subsequently delayed beyond this time. Patients 
who were referred through the normal NHS pathway but were later invited for surgery 
at a private institution as part of a waiting list initiative were either excluded or 
withdrawn due to the lack of sponsor/ethical approval for this hospital as a trial site. 
Patients were invited to participate in the trial with a site-specific patient information 
sheet (appendix 9.2) and given at least 24 hours to consider their involvement. All 
patients gave written informed consent prior to being enrolled (appendix 9.3). 
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3.2.3 Randomisation 
Once written informed consent had been obtained, patients were randomised to 
either the perhexiline or placebo arm of the trial. A password-protected, encrypted 
Microsoft Access database containing the randomisation code was designed by Dr 
Melanie J. Calvert and Professor Nick Freemantle and used to generate a random 
allocation sequence. The randomiser allocated treatment in a 1:1 ratio and used 
minimisation as a method of adaptive stratified sampling in order to reduce any 
imbalance between treatment groups for three identified factors: consultant surgeon; 
operation status (elective or urgent); and left ventricular systolic function (good ≥ 
50%, moderate 30-49%, poor < 30% according to standard criteria). The patient 
details were entered by myself (or later Mr Senanayake) and the programme 
allocated a number corresponding to the bottle of tablets to be supplied to the 
patient; it also had the facility to allocate a second bottle in the same arm of the trial 
to the same patient whilst maintaining allocation concealment. The database was 
reviewed at regular intervals by Dr Calvert who remained unblinded to ensure that it 
was functioning satisfactorily; she also had access to the allocation sequence as a 
mechanism for breaking the code if required in the case of a serious adverse event. 
 
3.2.4 Investigational Medicinal Product 
Perhexiline and placebo tablets (Sigma Pharmaceuticals, Baulkham Hills, Australia) 
were manufactured in accordance with standards of Good Manufacturing Practice 
equivalent to those applied in the European Union and supplied with a Certificate of 
Analysis. All tablets were identical in appearance: white to off-white, 8.5mm in 
diameter and labelled ‘PEXSIG’. Perhexiline has a provisional shelf-life of two years 
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(Sigma Pharmaceuticals, 2009) and was therefore imported into the UK in batches to 
undergo Qualified Person (QP) release (Bilcare GCS, Crickhowell, UK). The 
Investigational Medicinal Product (IMP) was dispensed into bottles of 34 tablets and 
labelled consecutively between 1 and 600 according to the randomisation schedule. 
Bottles were stored under standard conditions in the hospital pharmacy until 
allocated to a named patient. 
 
A standardised one-size-fits-all loading and maintenance regime was employed. 
Each patient received 200mg bis die for three days followed by 100mg bis die until 
surgery. This dosing regime was developed in cooperation with Professor John D. 
Horowitz at The Queen Elizabeth Hospital (TQEH), Adelaide who has the world’s 
largest clinical experience with perhexiline. It had previously been used in over one 
thousand patients with a 10% incidence of transient nausea but patient compliance of 
over 95% and no serious adverse events related to toxicity (appendix 9.4). It was 
therefore deemed the most suitable for prompt, effective yet tolerable drug loading in 
the community. However, if a patient had not had surgery by 31 days after 
commencing the IMP, it was discontinued; including the loading period, this equated 
to two full bottles of tablets. 
 
Initially, it was intended that interim plasma perhexiline levels would be measured in 
patients who took the IMP for more than two weeks prior to their date of surgery. This 
would have enabled dosing adjustment by an independent, unblinded colleague to 
maximise the number of patients within the therapeutic range at the time of surgery. 
A similar number of patients in the placebo group would also have been tested to 
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maintain blinding. However, the logistical limitations of the test availability limited its 
application; perhexiline therapeutic drug monitoring is only performed at two centres 
in the UK and the assay is only run once per week. There was insufficient funding to 
establish the assay ad hoc in Birmingham. Therefore, interim monitoring was not 
used rather dose adjustment was guided by patient-reported nausea and/or dizziness 
which have been shown to be strongly predictive of the accumulation of perhexiline 
beyond the therapeutic range during short-term therapy (Stewart et al., 1996). 
 
Patients were provided with access to a dedicated 24-hour mobile telephone helpline 
for advice and support. If patients reported potential side-effects from the trial 
therapy, they were offered up to three options in sequence until an acceptable 
solution was found: to continue at the current dose if tolerable and see whether the 
symptoms settled with time; to half the dose to one tablet per day and see whether 
the symptoms settled with time; to stop the trial medication. Routine telephone follow-
up enquiries were made to ensure that symptoms had settled. 
 
On admission for surgery, all patients were specifically questioned regarding the 
occurrence of potential side-effects and deviation from the dosing regimen in a 
standard, open manner to avoid an observer-expectancy effect. Even if the patient 
had stopped the IMP, either following discussion or spontaneously, they continued in 
the trial unless they specifically declined and withdrew. Compliance with trial therapy 
was assessed retrospectively by taking blood at the time of surgery and measuring 
serum perhexiline levels in all patients at the end of the trial. 
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On the morning of surgery, the IMP was taken as usual at approximately 07:00, along 
with pre-medication for patients on the morning operating list. Trial patients 
underwent surgery on both morning and afternoon operating lists and therefore blood 
for perhexiline levels was taken either between 08:00-09:00 (C1-C2) or 13:00-15:00 
(C6-C8). As perhexiline and OH-perhexiline have a long half-life in humans, the 
within-day variability in plasma perhexiline concentrations is small, with a mean 16% 
difference between peak (around C4) and trough (C0) levels in steady-state patients 
(Jones et al., 2004). The timing of surgery would therefore not be expected to 
significantly affect the measurement of perhexiline concentrations. 
 
3.2.5 Perioperative protocols 
Anaesthesia, cardiopulmonary bypass, myocardial protection and surgical techniques 
were standardised. The protocols were similar to those used in previous trials in our 
department (Quinn et al., 2006, Ranasinghe et al., 2006, Howell et al., 2011) in order 
to promote process familiarity and thereby reduce human error. 
 
Anaesthesia: A standard pre-medication of temazepam, ranitidine and 
metoclopramide was given. Anaesthesia was induced using intravenous etomidate, 
fentanyl and pancuronium and maintained with propofol, alfentanil and 
supplementary isoflurane; other volatile anaesthetic agents were not permitted. 
Invasive monitoring lines were inserted to obtain radial artery, central venous and 
pulmonary artery pressure readings. Phenylepherine was administered in aliquots to 
maintain a mean arterial pressure of 60-70mmHg. Intravenous antibiotics and a bolus 
of mannitol were given prior to sternotomy according to the unit protocol. An anti-
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fibrinolytic agent, either aprotinin or tranexamic acid, was given at the surgeon’s 
request. Anticoagulation was achieved with heparin prior to the institution of CPB and 
reversed with protamine after the termination of CPB. Standard monitoring was 
performed throughout including haemodynamic variables, urine output, blood gas 
analysis and measurement of activated clotting time. 
 
Operative procedure: Coronary artery bypass graft surgery was conducted in a 
standard manner. After transfer to the operating theatre, the surgical checklist was 
completed, the patient was prepped and draped, and the chest opened through a 
median sternotomy. Internal mammary artery, radial artery and saphenous vein 
conduits were harvested simultaneously as required. Cardiopulmonary bypass 
between the right atrium and the ascending aorta was instituted at 34°C with a roller 
pump, hollow-fibre membrane oxygenator and asanguineous prime. An aortic cross-
clamp was applied to the proximal ascending aorta and intermittent antegrade cold 
blood St. Thomas’ Hospital Solution No.2 cardioplegia (Martindale Pharma, 
Brentwood, UK) given via the aortic root for myocardial protection: 12ml/kg for 
induction and 6ml/kg for maintenance at intervals of approximately 20 minutes. 
Supplemental retrograde or ‘hot shot’ terminal cardioplegia were not permitted. Distal 
anastomoses were constructed during a single cross-clamp period (ischaemic time) 
and proximal anastomoses were made with partial aortic occlusion following removal 
of the aortic cross-clamp. After rewarming with a 37°C maximal heat-exchanger, CPB 
was discontinued at 36-37°C nasopharyngeal temperature. In the event of difficulty 
separating from CPB or marked haemodynamic instability, subjective and objective 
measures of ventricular function were made and inotropic support instituted at the 
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discretion of the operating surgeon. Intraoperative ventricular tachyarrhythmias were 
treated with internal cardioversion. Intravenous glycopyrollate, atropine and atrial or 
dual chamber epicardial pacing wires were used to achieve a target heart rate of 70 
to 110 beats per minute. Drains were placed in the mediastinum and open pleural 
cavities. Once haemodynamic stability and haemostasis had been achieved, the 
chest was closed with sternal wires in a standard manner and the patient transferred 
to the Cardiac Intensive Care Unit (ICU). 
 
Postoperative care: The following target parameters were used to guide patient 
management in the early postoperative period: heart rate of 70-110 beats per minute 
in sinus rhythm, paced AAI, DDD or VVI, in order of preference; mean arterial 
pressure (MAP) of 65-85mmHg; central venous pressure (CVP) of 8-12mmHg; 
pulmonary artery wedge pressure (PAWP) of 12-16mmHg; and a cardiac index ≥ 
2.2L/min/m2. These parameters were adjusted on an individual patient basis 
according to intraoperative observations of changes in haemodynamic variables 
particularly in response to fluid volume. If the cardiac index remained < 2.2L/min/m2 
despite correction of heart rate, filling pressures and appropriate vasoconstriction 
with phenylepherine, the patient was deemed likely to be in a state of low cardiac 
output and inotropic support was commenced. The first-line inotrope used in this trial 
was an infusion of dopamine at a dose of 5µg/kg/min; subsequent escalation of 
inotropic support was at the discretion of the clinical team but would usually involve 
adrenaline or enoximone as required. Any decision on chest reopening for suspected 
cardiac tamponade, cardiac arrest or excessive bleeding was taken by the clinical 
team and the findings documented. 
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If the patient was deemed to be in a state of vasodilatation despite a phenylepherine 
infusion reaching its therapeutic ceiling, noradrenaline was used as the second-line 
vasoconstrictor followed by vasopressin. Hypertension with a sustained MAP > 
85mmHg was treated with glyceryl trinitrate infusion once potential causes such as 
inadequate sedation or analgesia were excluded. Atrial arrhythmias were managed 
with stepwise correction of electrolyte imbalance, amiodarone and DC cardioversion. 
 
Other clinical variables and management targets were as standard for the unit and 
defined in the clinical protocol including urine output ≥ 0.5ml/kg/hr, serum potassium 
4.5-5.5mmol/L, haemoglobin ≥ 8g/dL and blood glucose 4-7mmol/L, with insulin 
commenced on a sliding-scale if above 10mmol/L. Arterial blood gas analyses were 
performed regularly and extubation was driven by a nurse-led protocol. Routine 
Intensive Care and hospital discharge criteria were used and applied at the discretion 
of the clinical team. The patient’s involvement in the trial ceased once discharged 
from the immediate care of our department to home, convalescence, another 
department or hospital, or upon death, whichever occurred sooner. 
 
3.2.6 Trial investigations 
Clinical data for each patient was prospectively recorded on a specific data collection 
sheet including demographics, risk factors, medications, perhexiline therapy, 
operative data, cardiac output studies, blood gas analyses, inotrope and 
vasoconstrictor requirements, intra-aortic balloon pump usage, volume requirements, 
arrhythmias, intensive care data, blood results, complications, discharge data and 
any significant deviations from the trial protocol. 
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Cardiac output studies: A pulmonary artery catheter enabled invasive assessment of 
haemodynamic variables and the thermodilution technique was used to measure 
cardiac function. Baseline readings were obtained with the patient under general 
anaesthesia but prior to sternotomy. Following weaning from CPB, further 
measurements were taken before and approximately ten minutes after the 
administration of protamine, and then at two, four, six, nine and 12 hours after 
reperfusion of the myocardium, marked by the release of the aortic cross-clamp. At 
each time point, the following variables were recorded: heart rate, rhythm, cardiac 
output, mean systemic blood pressure, central venous pressure, mean pulmonary 
artery pressure and pulmonary artery wedge pressure. 
 
Blood samples: Preoperative baseline samples for serum perhexiline (plain tube) and 
troponin-T (clot activator & gel separator) were obtained in the anaesthetic room after 
insertion of the arterial line. Postoperative blood for troponin-T was drawn at six, 12 
and 24 hours after removal of the aortic cross-clamp. Blood taken during the night-
time was refrigerated at 4°C and processed the next morning. Sample tubes were 
centrifuged at 3000rpm for five minutes, the supernatant decanted into cryotubes and 
frozen at -80°C in our remotely-monitored ultra-low temperature freezers at QEH, 
Birmingham and RSCH, Brighton. Perhexiline and OH-perhexiline concentrations in 
serum were measured by HPLC using a previously described technique (Sallustio et 
al., 2002) by the Clinical Pharmacology Laboratory, TQEH, Adelaide. Serum troponin 
was measured using the Elecsys Troponin-T assay (Roche Diagnostics, Burgess Hill, 
UK) by the Department of Clinical Biochemistry, QEH, Birmingham. 
 
105 
 
Tissue biopsies: Atrial and ventricular biopsies were obtained during surgery at QEH, 
Birmingham and promptly snap-frozen in liquid nitrogen. The right atrial appendage 
was truncated during venous cannulation for CPB; in selected patients, it was divided 
in two: one portion was snap-frozen, the other mounted on a cork disk, embedded in 
Tissue-Tek Optimum Cutting Temperature (OCT) compound (Sakura, Netherlands) 
and frozen in isopentane pre-cooled to approximately -40°C with dry ice. Transmural 
Tru-Cut needle (Allegiance, McGaw Park, IL) biopsies of the left ventricular free-wall 
between the left anterior descending artery and the first diagonal branch were taken 
at three time points: pre-ischaemia (on CPB but before application of the aortic cross-
clamp), end ischaemia (before cross-clamp removal or local reperfusion through an 
anastomosed internal mammary artery graft) and reperfusion (approximately 10-15 
minutes after cross-clamp removal). Once frozen, all samples were stored at -80°C. 
 
Electrocardiograms: Serial standard 12-lead electrocardiogram (ECG) tracings were 
obtained at four time points: preoperative baseline, within two hours of arrival on ICU, 
and on the first and fourth postoperative days. 
 
3.2.7 Outcome measures 
The primary endpoint was an episode of low cardiac output in the first six hours after 
removal of the aortic cross-clamp, defined as hypotension (MAP < 65mmHg) with a 
cardiac index < 2.2L/min/m2 in the presence of adequate filling pressures (CVP 8-
12mmHg or PCWP 12-16mmHg) and heart rate (> 75bpm) where systolic blood 
pressure < 90mmHg and/or inotropic support  intra-aortic balloon pump for > 60 
minutes was required to maintain such a clinical picture. A blinded endpoints 
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committee was convened at regular intervals to adjudicate on borderline cases, 
comprising Professor Pagano, Mr Rooney, Mr Ranasinghe, Mr Howell and myself. 
 
The secondary endpoints were: 
 Cardiac index at six and 12 hours after removal of the aortic cross-clamp: absolute 
values and corrected for change in cardiac index from baseline. 
 Prevalence of inotrope usage in the first six and 12 hours after removal of the 
aortic cross-clamp 
 Cardiac troponin-T release in the first 24 hours: peak ranked according to quintile 
and area under the concentration-time curve (AUC) 
 ECG evidence of new myocardial injury, defined as the presence of new Q waves 
of ≥ 2mm in depth in two contiguous leads, new bundle branch block or loss of R 
wave progression, analysed by Dr Lynne K. Williams, a blinded cardiologist 
 Length of stay in the ICU and in the hospital 
 
The haemodynamic endpoints of low cardiac output and cardiac index were chosen 
as surrogate measures of cardiac contractility to reflect the degree of clinical recovery 
of myocardial function and stunning. Following cardiac surgery, around one-in-three 
patients have a period of detectable dysfunction due to myocardial stunning, most of 
whom require inotropes to support the heart during its recovery (Arnold et al., 1985). 
An episode of non-fatal low output syndrome in the early postoperative period has 
also been shown to be associated with a significant reduction in late survival 
following CABG (Fremes et al., 2000). By improving metabolic efficiency and the 
resilience to ischaemia-reperfusion, this trial aims to reduce myocardial stunning and 
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improve contractile function in the perioperative period. As the nadir in early cardiac 
contractility invariably occurs within the first six hours of reperfusion (Hearse et al., 
1981), this was chosen as the timeframe for the primary endpoint. Cardiac output is 
the product of heart rate and stroke volume, which is itself influenced by preload, 
afterload and contractility. By optimising these variables (with the exception of 
contractility unless clinically necessary) by pacing, intravascular fluid replacement or 
vasoconstriction to achieve predetermined targets, comparison of cardiac function 
could be made between patients and groups. These endpoints for myocardial 
stunning were used in our previously published trials of myocardial protection during 
cardiac surgery in Birmingham (Quinn et al., 2006, Howell et al., 2011) and in a meta-
analysis of GIK (Bothe et al., 2004), and have therefore been both internally and 
externally validated. 
 
The identification of perioperative myocardial injury is complicated despite recent 
consensus guidelines on diagnosis of myocardial infarction (Thygesen et al., 2007): 
‘Biomarker values more than five times the 99th percentile of the normal 
reference range during the first 72 hours following CABG, when associated with 
the appearance of new pathological Q-waves or new left bundle-branch block 
(LBBB), or angiographically documented new graft or native coronary artery 
occlusion, or imaging evidence of new loss of viable myocardium should be 
considered as diagnostic of a CABG-related myocardial infarction (type 5 MI).’ 
 
Cardiac troponin-T has been shown to be superior to CK-MB for the prediction of 
complications following cardiac surgery (Januzzi et al., 2002). However, interpretation 
of troponin release is more complex than in other causes of myocardial injury. The 
concentration of serum troponin in the early postoperative period is almost universally 
elevated compared to baseline; it is released in response to irreversible myocardial 
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necrosis but rather than the acute regional infarction that occurs with coronary 
occlusion, it usually represents diffuse myocardial injury (Januzzi, 2011). Diagnosed 
according to the consensus guidelines, myocardial infarction occurs in just 2% of 
patients following CABG (Mohammed et al., 2009) although the AUC for serum 
troponin at 24 hours has been shown to correlate strongly with the mass of new 
myocyte necrosis on delayed-enhancement cardiac magnetic resonance (Pegg et al., 
2011). Recent studies have shown that postoperative troponin release is a strong 
independent predictor of ICU stay, major adverse cardiac events (MACE), and short-, 
medium- and long-term survival after cardiac surgery (Croal et al., 2006, Lurati Buse 
et al., 2009). In clinical practice, the use of multiple troponin assays with considerable 
heterogeneity in analytical sensitivity, precision and reference ranges, has led to 
difficulties in determining a threshold for significant myocardial injury (Mohammed et 
al., 2009). Januzzi and colleagues (2002) found that a troponin-T level in the highest 
quintile within a population was the strongest predictor of outcomes, avoiding the 
need for an absolute cut-off for internal comparisons. In our trial, the troponin-T 
subunit was measured up to 24 hours following release of the aortic cross-clamp as 
this approach is supported by the evidence described and the assay was already in 
routine clinical use at QEH, Birmingham. 
 
ECG changes following cardiac surgery are common and not necessarily diagnostic 
for ischaemia (Yokoyama et al., 2000). However, when new pathological Q waves 
appear in territories other than those identified before surgery, myocardial infarction 
should be considered, particularly if associated with elevated biomarkers, new wall 
motion abnormalities or haemodynamic instability (Thygesen et al., 2007). 
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3.2.8 Power calculations and statistical analysis 
It was hypothesised that the preoperative use of perhexiline would reduce the 
incidence of a low cardiac output episode (LCOE) compared with controls. The 
sample size was estimated by extrapolating pooled data from our recently completed 
MESSAGE and MESSAGE-2 trials (Quinn et al., 2006, Ranasinghe et al., 2006) in 
which patients undergoing CABG were randomised to GIK or placebo; a reduction of 
50% in the incidence of LCOE was detected in the GIK (19%) group compared with 
controls (37%). To achieve a similar difference in incidence between groups, with α 
0.05 and 1-β 0.9, required a total of 280 patients randomised 1:1 between groups 
and provided sufficient statistical power to examine all secondary outcome measures. 
 
A statistical analysis plan (appendix 9.5) was developed before starting the trial and 
refined during blinded review in accordance with ICH Statistical Principles for Clinical 
Trials (ICH, 1998). Analysis of the main outcome measures was performed according 
to the intention-to-treat principle on all eligible subjects who had data on the primary 
outcome; patients who were randomised, dosed but failed to undergo surgery on 
CPB and reach the collection of outcome data were excluded. A planned exploratory 
analysis of the primary outcome compared patients in the perhexiline arm who had 
reached the lower threshold of the therapeutic range (0.15mg/L) at the time of 
surgery with propensity score-matched controls. Propensity scoring was based on 
age, ethnicity, weight, days of trial therapy, left ventricular function and priority of 
surgery and an optimal matching approach was applied using the dist macro for SAS 
(Bergstralh and Kosanke, 2003). 
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Analysis was performed using SAS (version 9.2, SAS Institute Inc., Cary, NC) and 
SPSS software (version 17.0, SPSS Inc., Chicago, IL). Continuous data was 
assessed for normality and presented as mean (standard error of the mean) or 
median (interquartile range). Normally distributed data were analysed by Student’s t-
test or by analysis of variance (ANOVA) whilst skewed data were analysed with 
Mann-Whitney U-test. Categorical data were analysed by Fisher’s exact test. The 
primary analysis was conducted using a non-linear mixed model. All statistical tests 
were two-sided unless stated and deemed to be statistically significant at p < 0.05. 
Analyses were undertaken stratified for baseline left ventricular function and 
elective/urgent status; Consultant Surgeon was accounted for as a random effect. In 
the event of death before assignment of the primary endpoint, a LCOE was assigned. 
Missing data for all other outcomes was identified and excluded from the analysis. An 
outline of the statistical tests used in this thesis is contained in appendix 9.6. 
 
3.2.9 Data and Safety Monitoring Board and adverse event reporting 
An independent Data and Safety Monitoring Board (DSMB) comprising Professor 
Freemantle (Chair), Dr Jordan and Dr Lipkin met at predetermined milestones in 
recruitment. Data were reviewed on the primary and safety endpoints after 50, 125 
and 225 patients had undergone surgery and been discharged. A truncated modified 
O’Brien-Fleming alpha spending plan was used to preserve the overall one-sided 
type I error rate for efficacy at the 0.025 level. A non-symmetrical power function was 
used for safety to increase the likelihood of stopping early for harm (figure 16). The 
following were defined as Serious Adverse Events (SAE) and reported to the DSMB 
within 48 hours of diagnosis: death, stroke, renal failure requiring replacement 
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therapy, and any additional surgical procedures, including reopening of the chest, 
laparotomy or limb amputation, with the exception of tracheostomy. A mechanism 
was in place for the reporting of suspected unexpected serious adverse reactions 
(SUSAR) to the MHRA via their eSUSAR website (www.esusar.mhra.gov.uk). Annual 
safety reports (ASR) were submitted to the MHRA and Research Ethics Committee. 
 
  
Figure 16. Stopping boundaries to control alpha for benefit and harm. 
 
In this chapter, I have described the ICH principles for conducting a randomised 
controlled clinical trial through its scope, design, administration, analysis and 
reporting. I related the application of these standards to the conduct of the CASPER 
trial, a multi-centre trial of perhexiline in myocardial protection, on which this thesis is 
founded. I justified the selection of inclusion & exclusion criteria, IMP dosing and 
primary & secondary endpoints. Finally, I explained the patient pathway through the 
trial, the use of perioperative protocols, the acquisition of blood and biopsies, the 
analysis of clinical data and procedures for the monitoring of patient safety. 
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4. RESULTS 
 
The CASPER trial was given ethical and regulatory approval in January 2007. 
Recruitment commenced at the Queen Elizabeth Hospital, Birmingham in February 
that year and the first patient underwent surgery in May. Following approval of a 
substantial amendment, the trial was expanded to a second site at the Royal Sussex 
County Hospital, Brighton from April 2009. The final patient completed the trial 
pathway in April 2010 after the target recruitment of at least 280 eligible patients had 
been successfully passed. 
 
In this chapter, I describe the recruitment of patients to the trial across both sites, 
document the baseline and operative demographics of the trial population and 
discuss the serum concentration of perhexiline at the time of surgery in relation to its 
pharmacokinetics. The myocardial pharmacokinetics, biochemical and metabolomic 
effects of perhexiline, and the clinical outcome measures of the trial will be discussed 
in subsequent chapters. 
 
4.1 Trial recruitment and CONSORT flow diagram 
 
The CONSORT flow diagram (figure 17) documents the number of trial participants 
who were enrolled, randomly assigned, received intended treatment and analysed for 
the primary outcome. At each stage, there were a number of exclusions and losses, 
the justifications for which are as follows: 
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Figure 17. CONSORT flow diagram of trial recruitment. 
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Eight hundred and seven patients met the inclusion criteria and were assessed for 
eligibility. Of these, 480 patients were excluded – 243 (30.1%) met one or more of the 
exclusion criteria, including ten patients who had both diabetes and renal impairment, 
148 (18.3%) declined participation in the trial and 89 (11.0%) were excluded for other 
reasons: 48 patients underwent surgery at short notice before it was possible for 
them to be recruited to the trial; 20 patients underwent surgery at a non-NHS hospital 
(BMI The Priory Hospital, Edgbaston) as part of an initiative to reduce NHS waiting 
times; 11 patients were not able to be contacted by telephone or post prior to 
admission for surgery; five patients fell outside the scope of ethical approval for the 
trial (three with severe learning difficulties, two from an HM Prison); and five patients 
had other medical conditions that were judged to necessitate significant deviation 
from the protocol (three with Sickle-cell disease or trait, one with Cryoglobulinaemia, 
one with Hermansky-Pudlak syndrome, a platelet storage pool defect). 
 
Three hundred and twenty seven patients were randomised – 162 to receive 
perhexiline and 165 to receive placebo – of whom 33 did not receive the intervention. 
 
 In the perhexiline group, 145 patients received the intervention and 17 did not: six 
patients withdrew consent after randomisation but before starting the IMP; six 
patients had surgery at short notice prior to starting the IMP; three patients 
underwent surgery at a non-NHS hospital without starting the IMP; and two 
patients were undergoing further investigations with no proposed date for surgery 
when the trial ended. 
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 In the placebo group, 149 patients received the intervention and 16 did not: Four 
patients withdrew consent after randomisation but before starting the IMP; two 
patients underwent surgery at a non-NHS hospital without starting the IMP; one 
patient developed a new medical condition and did not proceed to surgery; one 
patient had surgery at short notice prior to starting the IMP; three patients were 
undergoing further investigations with no proposed date for surgery when the trial 
ended; and five patients were excluded for non-medical reasons (three patients 
withdrawn by Consultant Surgeons for personal reasons and two patients had their 
care transferred to a Consultant who was not participating in the trial). 
 
Two hundred and ninety four patients received the intervention, of whom eight were 
subsequently excluded from the analysis. 
 
 In the perhexiline group, 139 patients were included in the analysis and six were 
not: one patient died as an inpatient prior to surgery (see below); two patients 
were converted to off-pump coronary artery bypass (OPCAB) surgery at the 
discretion of the operating surgeon and so did not undergo aortic cross-clamping; 
one patient did not proceed to surgery as planned following further discussion on 
the risk-benefits of an operation; one patient withdrew consent after starting the 
IMP but before surgery; and in one patient, investigators were unable to float the 
pulmonary artery catheter and therefore unable to measure cardiac output. 
 In the placebo group, 147 patients were included in the analysis and two were not: 
one patient did not proceed to surgery as planned; and one patient withdrew 
consent after starting the IMP but before surgery. 
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One patient died prior to surgery whilst taking the IMP and this was reported to the 
sponsor and ethics committee as a SAE. The patient had been admitted with a non-
ST elevation myocardial infarction and poor left ventricular function, was referred for 
urgent surgical revascularisation and was expeditiously recruited to the trial. 
However, two days prior to his scheduled surgery, he suffered a VF arrest on the 
ward, precipitating emergency transfer to the catheterisation laboratory. Despite 
immediate treatment, he was not able to be resuscitated and died from a further 
myocardial infarction. 
 
Two hundred and eighty six patients were included in the intention-to-treat analysis, 
representing 87.5% of those randomised and 97.3% of those receiving the 
intervention. These represent all consenting patients who underwent cardiac surgery 
with a period of ischaemia-reperfusion in whom the primary outcome was 
measurable, analysed in the original groups to which they were randomly assigned, 
regardless of the need for additional procedures or whether or not they actually took 
the IMP. Baseline patient demographic and operative variables are shown in tables 5 
and 6, respectively. Five trial patients underwent an additional procedure: in the 
perhexiline group, one patient had a mitral valve replacement after failed repair; in 
the control group, three patients had a mitral valve repair and one had an aortic valve 
replacement. 
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 Control (n=147) Perhexiline (n=139) 
Age (years), median (IQR) * 65.7 (60.2-73.6) 66.1 (59.4-73.2) 
Male, n (%) * 134 (91.2) 128 (92.1) 
Race, n (%)   
 Caucasian 136 (92.5) 133 (95.7) 
 South Asian 10 (6.8) 5 (3.6) 
 Black 1 (0.7) 1 (0.7) 
Body Mass Index (kg/m
2
), median (IQR) 27.8 (25.4-30.7) 28.0 (25.1-30.3) 
CCS angina score, n (%)   
 0 7 (4.8) 12 (8.6) 
 I 14 (9.5) 9 (6.5) 
 II 71 (48.3) 70 (50.4) 
 III 43 (29.3) 39 (28.1) 
 IV 12 (8.2) 9 (6.5) 
NYHA functional class, n (%)   
 I 59 (40.1) 58 (41.7) 
 II 79 (53.7) 68 (48.9) 
 III 9 (6.1) 13 (9.4) 
 IV 0 (0) 0 (0) 
Previous MI, n (%) 48 (32.7) 49 (35.3) 
Previous coronary stenting, n (%) 10 (6.8) 13 (9.4) 
Left main stem disease ≥ 50%, n (%) 47 (32.0) 54 (38.9) 
Left ventricular function, n (%) *   
 Good, ≥ 50% 122 (83.0) 118 (84.9) 
 Moderate, 30-49% 24 (16.3) 20 (14.4) 
 Poor, <30% 1 (0.7) 1 (0.7) 
Urgent non-elective, n (%) 23 (15.7) 19 (13.7) 
Hypertension, n (%) 89 (60.5) 90 (64.8) 
Hypercholesterolaemia, n (%) 109 (74.2) 94 (67.6) 
Family history of IHD, n (%) 60 (40.8) 56 (40.3) 
Smoking status on admission, n (%)   
 Non-smoker 55 (37.4) 38 (27.3) 
 Ex-smoker 76 (51.7) 87 (62.6) 
 Current smoker 16 (10.9) 14 (10.1) 
Pulmonary disease, n (%) * 12 (8.2) 17 (12.2) 
Extra-cardiac arteriopathy, n (%) * 10 (6.8) 14 (10.1) 
Neurological dysfunction, n (%) * 4 (2.7) 2 (1.4) 
Unstable angina, n (%) * 1 (0.7) 1 (0.7) 
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Recent MI, ≤ 90 days, n (%) * 17 (11.6) 19 (13.7) 
Pre-operative IABP, n (%) * 0 (0) 1 (0.7) 
Medications, n (%)   
 Aspirin 139 (94.6) 131 (94.2) 
 Clopidogrel 38 (25.9) 35 (25.2) 
 ACE inhibitor or ARB 96 (65.3) 90 (64.8) 
 Statin 139 (94.6) 129 (92.8) 
 β-adrenergic antagonist 121 (82.3) 99 (71.2) 
 Calcium channel antagonist  47 (32.0) 48 (34.5) 
 Long-acting oral nitrate 47 (32.0) 46 (33.1) 
 Potassium channel blocker 41 (27.9) 32 (23.0) 
 Diuretic 22 (15.0) 24 (17.3) 
Number of anti-anginal agents, n (%)   
 None 2 (1.4) 3 (2.2) 
 One 65 (44.2) 68 (48.9) 
 Two 55 (37.4) 48 (34.5) 
 Three 19 (12.9) 15 (10.8) 
 Four or more 6 (4.1) 5 (3.6) 
Haemoglobin (g/dL), median (IQR) 14.2 (13.4-14.9) 14.4 (13.5-15.2) 
Creatinine (µmol/L), median (IQR) * 98 (85-110) 105 (91-119) 
eGFR, MDRD (ml/min), median (IQR) 68.9 (61.0-81.4) 64.8 (54.8-74.5) 
EuroSCORE, median (IQR)   
 Additive EuroSCORE 3 (1-4) 3 (1-4) 
 Logistic EuroSCORE 1.82 (1.07-2.94) 1.82 (1.23-3.06) 
CCS, Canadian Cardiovascular Society; NYHA, New York Heart Association; MI, myocardial infarction; 
IHD, ischaemic heart disease; IABP, intra-aortic balloon pump; ACE, angiotensin converting enzyme; 
ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; MDRD, Modification 
of Diet in Renal Disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation. 
* factored into EuroSCORE calculation 
 
 
Table 5. Baseline patient demographics. 
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 Control (n=147) Perhexiline (n=139) 
Number of grafts, mean (SD) 3.29 (0.82) 3.30 (0.73) 
IMA graft used, n (%) 136 (92.5) 132 (95.0) 
Incomplete revascularisation, n (%) 13 (8.8) 12 (8.6) 
Additional procedure, n (%) 4 (2.7) 1 (0.7) 
Operation performed by trainee, n (%) 50 (34.0) 38 (27.3) 
CPB time (min), median (IQR) 110 (90-134) 109 (93-131) 
Reinstitution of CPB, n (%) 6 (4.1) 3 (2.2) 
XC time (min), median (IQR) 57 (45-72) 56 (45-70) 
Cardioplegia (ml), mean (SD) 1999 (520) 2018 (484) 
VF/VT on reperfusion, n (%) 3 (2.0) 3 (2.2) 
Anti-fibrinolytic agent, n (%) 100 (68.0) 97 (69.8) 
Volume of cell-salvaged blood (ml), mean (SD) 499 (355) 487 (328) 
Intra-aortic balloon pump used, n (%) 21 (14.3) 10 (7.2) 
 Pre-op for unstable angina 0 (0) 1 (0.7) 
 Pre-op elective in theatre e.g. LMS, poor LV 6 (4.1) 3 (2.2) 
 Pre-CPB non-elective e.g. ischaemia, unstable 0 (0) 2 (1.4) 
 Before off CPB, anticipating problems 4 (2.7) 1 (0.7) 
 Post-CPB, emergency e.g. LCOE, post-arrest 8 (5.4) 2 (1.4) 
 On ICU, emergency e.g. LCOE, post-arrest 3 (2.0) 1 (0.7) 
IMA indicates internal mammary artery; CPB, cardiopulmonary bypass; XC, aortic cross-clamp; VF, 
ventricular fibrillation; VT, ventricular tachycardia; LMS, left main stem coronary stenosis; LV, left 
ventricle; ICU, intensive care unit; LCOE, low cardiac output episode. 
 
 
Table 6. Intraoperative variables. 
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4.2 Serum perhexiline concentration at the time of surgery 
 
The therapeutic range for perhexiline has been defined as a serum concentration of 
0.15-0.6mg/L (Horowitz et al., 1986). Therapeutic drug monitoring to maintain serum 
levels within this target range confers clinical benefit without toxicity (Cole et al., 
1990). In this trial, the IMP was prescribed according to a standardised one-size-fits-
all loading and maintenance regime: 200mg bis die for three days followed by 100mg 
bis die until surgery. In over one thousand patients taking perhexiline, this regime has 
a previously reported incidence of transient nausea of 10% but patient compliance of 
over 95% and no serious toxicity (appendix 9.4). Patients commenced the IMP at 
least five days before the planned date of surgery to set a minimum level of 
perhexiline exposure in the treatment group and thereby maximise the number of 
patients in the therapeutic range. 
 
Serum perhexiline concentration at the time of surgery was determined in 280/286 
(97.9%) patients analysed in the trial using high-performance liquid chromatography 
(HPLC). Samples were processed in batches by the routine therapeutic drug 
monitoring service provided by the Department of Clinical Pharmacology at The 
Queen Elizabeth Hospital, Adelaide. Serum perhexiline was measured in 135/139 
(97.1%) patients in the treatment group. The median serum concentration was 
0.26mg/L (IQR 0.14-0.48) with a range of 0 to 2.19mg/L and was not normally 
distributed (Kolmogorov-Smirnov test, D=0.18, p<0.001). 98 (72.6%) patients were 
above the lower threshold of the therapeutic range (0.15mg/L), with 19 (14.1%) 
patients also above the upper threshold (0.6mg/L). In the placebo group, 145/147 
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(98.6%) patients were assessed and all had a serum perhexiline level of zero, 
confirming the difference between the groups. 
 
Metaboliser phenotype was determined by the serum OH-perhexiline to perhexiline 
concentration ratio (COH-Px/CPx) and classified according to published criteria (table 3) 
(Sallustio et al., 2002, Zanger et al., 2004). Of 132 patients, eight (6.1%) were poor 
(mean CPx 1.26mg/L), 28 (21.2%) were intermediate (mean CPx 0.65mg/L), 87 
(65.9%) were extensive (mean CPx 0.25mg/L) and nine (6.8%) were ultra-rapid (mean 
CPx 0.06mg/L) metabolisers (figure 18); the other three patients in the treatment 
group in whom it was measured had no detectable serum perhexiline and therefore 
their metaboliser phenotype remains unknown. 
 
 
Figure 18. Frequency distribution of patients within metaboliser groups. 
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This distribution of metabolic ratios is broadly reflective of the local population, with a 
reported poor metaboliser prevalence of 7-10% in European Caucasians and 1-2% in 
those of African or East Asian decent (Gardiner and Begg, 2006). Serum perhexiline 
and metaboliser status are not independent variables and therefore it was 
unsurprising that the Spearman’s rank coefficient was found to be -0.75 (p<0.001), 
suggesting a strong correlation. The log transformation of serum COH-Px/CPx was 
calculated and found to have a bimodal distribution in the population (figure 19) with 
the lowest ratios to the left representing the poor metabolisers; these findings are 
similar to those of previous studies on the pharmacokinetics of perhexiline (Sallustio 
et al., 2002). 
 
 
Figure 19. Frequency distribution of serum log COH-Px/CPx in 132 patients. 
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During the trial, 18 patients reported potential side-effects consistent with perhexiline 
toxicity:  nausea (12), dizziness (8), headache (3), vomiting (2) and altered sensation 
in legs (1) (table 7). Six of 139 (4.3%) patients in the perhexiline group reported non-
compliance with the protocol due to side-effects: four stopped the IMP prior to 
surgery and two reduced the dose. At the time of surgery, six patients were above, 
seven patients within and only two patients below the therapeutic range; of note, 
three patients reporting side-effects were found to be in the control group, all of 
whom had continued as per protocol. Overall, 15/139 (10.8%) patients in the 
perhexiline group reported side-effects prior to surgery with the one-size-fits-all 
regime, of whom five were poor metabolisers (5/8, 63%). On the other hand, three 
poor metabolisers denied any new symptoms despite serum perhexiline levels more 
than twice the upper limit of the therapeutic range. No patients withdrew from the trial 
due to side-effects and no such symptoms persisted beyond discharge from hospital. 
 
There were twelve other known deviations from the IMP protocol, four of which were 
in patients randomised to perhexiline: three patients were no longer taking the IMP at 
the time of surgery due to delays in rescheduling their operations; one patient was 
not given the IMP consistently due to confusion among the nurses on a hospital ward 
(CPx zero, COH-Px 0.6mg/L). Furthermore, two other patients reported taking the IMP 
as per protocol but were found to have a perhexiline level of zero with either a trace 
or no OH-perhexiline suggesting a lack of compliance. 
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ID Symptoms Reported deviation CPx (mg/L) Phenotype 
19 Nausea Stopped for 3 days 0.08 Extensive 
24 Nausea Reduced for 5 days 0.28 Extensive 
42 Nausea & vomiting Stopped for 3 days 0.46 Poor 
49 Severe dizziness Continued 1.46 Intermediate 
67 Dizziness Reduced for 5 days 1.18 Poor 
68 Nausea & headache Continued 0.29 Extensive 
73 Dizziness Continued 0.34 Intermediate 
87 Nausea Continued 0.07 Extensive 
88 Dizziness & nausea Stopped for 4 days 0.59 Poor 
91 Nausea & vomiting Continued 0.64 Poor 
117 Burning sensation in legs Continued 0 Control 
153 Dizziness & nausea Continued 1.36 Poor 
154 Headache, nausea, dizziness Stopped for 3 days 0.43 Intermediate 
177 Headache Continued 0 Control 
185 Nausea Continued 0 Control 
229 Dizziness Continued 1.75 Intermediate 
234 Nausea & dizziness Continued 0.47 Extensive 
268 Nausea Continued 1.58 Intermediate 
CPx indicates serum concentration of perhexiline. 
 
 
Table 7. Patient-reported side-effects and deviations from protocol. 
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In this trial, it was intended that the length of therapy with the IMP would be at least 
five days (ten doses), including three days at the loading dose, to enable subjects 
receiving perhexiline to reach the therapeutic range. The maximum length of therapy 
was 31 days (62 doses) corresponding to two bottles of 34 tablets each. Overall, 46 
(16%) of the 286 trial patients exceeded 28 doses and required a second bottle, 19 of 
whom were in the perhexiline arm. Of the 130 patients in the treatment group who 
reported still taking the IMP and in whom serum perhexiline was measured, 120 
(92.3%) had taken ten or more consecutive doses prior to surgery. The remaining ten 
patients had taken nine (7, 5.4%), eight (1, 0.8%) or seven (2, 1.5%) doses. Median 
length of therapy was 9.5 days (19 doses) with a range of 3.5 to 30.5 days (7-61 
doses) and was not normally distributed (D=0.16, p<0.001) but rather skewed 
towards one week of therapy (figure 20). 
 
 
Figure 20. Frequency distribution of length of therapy in the perhexiline group. 
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The relationship between serum perhexiline and length of therapy was measured in 
the 130 perhexiline patients using Spearman’s rank correlation with an rs coefficient 
of 0.13 (p 0.14), suggesting a very weak correlation. The analysis was repeated in 
the 87 extensive metabolisers and showed no correlation, with a coefficient of 0.03 (p 
0.80). This suggests that after a minimum period, length of therapy did not 
significantly affect serum perhexiline concentration, which was strongly influenced by 
other factors such as metaboliser status and compliance with treatment. Figure 21 
highlights the distribution of serum perhexiline measurements across the metaboliser 
groups with all poor metabolisers above and all ultra-rapid metabolisers below the 
therapeutic range (0.15 to 0.6mg/L). 
 
 
Shading indicates therapeutic range. ● Poor, ● Intermediate, ● Extensive, ● Ultra-rapid metabolisers. 
 
Figure 21. Plot of serum perhexiline versus length of therapy in 130 patients. 
127 
 
Overall, 37 (27.4%) patients randomised to perhexiline were found to be below the 
therapeutic range at the time of surgery: nine patients were ultra-rapid metabolisers, 
with metabolic ratios from 20.2 to 37.0; two patients had reported side-effects, one of 
whom had stopped the IMP, the other had apparently continued; one patient was not 
given the IMP due to nursing errors; and two patients are highly likely to have been 
non-compliant as both CPx and COH-Px were negligible. Serum perhexiline was not 
available in the three patients who were no longer taking the IMP due to rescheduling 
delays. Of the remaining 23 patients, three had taken the IMP for less than five days 
(ten doses) but the median length of therapy for this cohort was eight days (17 
doses). All were classified as extensive metabolisers with metabolic ratios ranging 
from 5.7 to 18.3. There is no clear explanation for the sub-therapeutic concentrations 
in these patients but it may be related to undeclared non-compliance, particularly in 
those with a low metabolic ratio, or other as yet unidentified factors. An exploratory 
analysis of the primary endpoint will evaluate whether sub-therapeutic serum levels 
impacted on the clinical effect of perhexiline. 
 
In this chapter, I have detailed the recruitment of patients to the CASPER trial in a 
CONSORT flow-diagram, justified the reasons for excluding patients from the trial 
and documented the baseline and operative demographics of the trial population. I 
have reported the measurement of serum perhexiline in relation to metaboliser 
status, side-effects, protocol deviations and length of therapy. I have also sought to 
explain why more than one quarter of the perhexiline group were found to be sub-
therapeutic at the time of surgery. 
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5. PERHEXILINE PHARMACOKINETICS IN THE MYOCARDIUM 
 
5.1 Introduction 
 
In clinical practice, the principles of pharmacokinetics determine the dosage of each 
drug prescribed and its effects on an individual patient. If the dose is too low, it will be 
ineffective; if too high, it may cause side effects due to toxicity and reduce patient 
compliance leading to inefficient treatment and complications. Most drugs reach their 
active site through untargeted delivery in the circulation and the concentration in the 
blood is determined by several pharmacokinetic parameters, principally absorption, 
distribution and clearance. However, in order for a drug to be effective, it must reach 
its target tissue in sufficient concentration to influence a biological process either via 
stimulation or inhibition. The half maximal inhibitory concentration (IC50) is a measure 
of the effectiveness of a drug and indicates the concentration required at the site of 
action to reduce the activity of the process by 50% in vitro. The IC50 can be used to 
predict the effect of a particular drug or to compare the potency of two antagonists. 
 
Drug distribution to a tissue depends upon its perfusion, drug binding, regional pH, 
partitioning and the permeability of cell membranes. Many drugs have an intracellular 
site of action and enter the cell either by passive transcellular diffusion or by active 
carrier-mediated transport across the membrane. Factors affecting drug uptake into 
the myocardium include tachycardia, sepsis, shock and circulatory volume overload, 
which all increase uptake, and ischaemia which inhibits drug uptake (Horowitz and 
Powell, 1986). A model of drug uptake into the myocardium has been proposed 
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(Lullmann et al., 1979), comprising four compartments: the freely accessible 
extracellular space, a low-capacity lipid barrier (the sarcolemma) and two larger 
capacity compartments within the cell: cell water and intracellular binding sites (figure 
22). Binding to macromolecules such as proteins, phospholipids or nucleic acids may 
lead to its progressive accumulation, reaching a concentration many times higher 
than in plasma. Some drugs require substantial tissue uptake before reaching IC50 
and their effects are delayed according to the rate of intracellular accumulation.  
 
 
 
Figure 22. Compartments of drug uptake into the myocardium. 
 
Historically, there have been difficulties in balancing the clinical effectiveness of 
perhexiline with significant toxicity due to marked inter-individual variation in its 
pharmacokinetics, principally differences in elimination by genetic polymorphisms of 
CYP2D6. Severe adverse events can be avoided by therapeutic drug monitoring to 
maintain the plasma concentration within a defined therapeutic range (Horowitz et al., 
1986). Perhexiline has been shown to accumulate in the rat myocardium, reaching 
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levels 20-fold higher than in the corresponding plasma and to inhibit mitochondrial 
uptake of fatty acids via CPT-1 in a concentration-dependent manner with an IC50 of 
77µmol/L in rat heart homogenate (Kennedy et al., 1996). However, some biological 
effects of perhexiline are delayed and this has been attributed to a gradual tissue 
accumulation to reach an intracellular concentration that significantly inhibits CPT-1 
activity (Willoughby et al., 2002, Unger et al., 2005). Due to the practical difficulties in 
obtaining myocardial biopsies from patients who have traditionally been treated with 
perhexiline, no previous studies have addressed its uptake by the human heart. 
 
High-performance liquid chromatography (HPLC) is a chromatographic technique 
used in analytical chemistry to identify, quantify and purify the individual components 
of a mixture of compounds (Snyder et al., 2010). A small volume of the mixture is 
dissolved in a stream of mobile phase which is pumped through a densely packed 
column containing the stationary phase. The constituents of the mixture travel at 
different speeds depending on their differential partitioning between phases causing 
them to separate. The detection sensitivity and separation selectivity of an HPLC 
column depend upon its internal diameter, particle size, pore size and pump 
pressure. Retention time within the column depends upon the strength of interactions 
with the stationary phase, the ratio of solvents used, the flow rate of the mobile phase 
and temperature; these variables may be modified to enhance mixture separation. A 
detector measures changes in the absorption and emission of ultraviolet light near 
the far end of the column to provide a retention time of each constituent and generate 
a plot of analyte peaks against time. The area under each peak is used to quantify 
the concentration of the analyte in the sample. 
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In this chapter, I measure the concentration of perhexiline in biopsies of human atrial 
and ventricular myocardium obtained from patients in the treatment arm of the 
CASPER trial using HPLC. I correlate these findings with serum perhexiline levels at 
the time of surgery and examine factors that may affect steady-state uptake into the 
myocardium. Finally, I compare the human pharmacokinetic findings with data from 
an animal model to assess how the ventricular concentration of perhexiline in vivo in 
patients corresponds to that required for CPT-1 inhibition in the rat myocardium. 
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5.2 Materials & methods 
 
The experiments described in this chapter were conducted in the laboratory of 
Associate Professor Benedetta C. Sallustio at the Basil Hetzel Institute, University of 
Adelaide using techniques previously validated in an animal model (Licari, 2010) 
adapted from a published method (Davies et al., 2006b). Serum and tissue samples 
obtained at QEH, Birmingham were shipped to Adelaide on dry-ice in two batches by 
Marken UK, specialists in cold-chain logistics. I performed all of the experiments 
described in this chapter during my Wellcome Trust Research Training Award visit. In 
this section, I describe the laboratory methods including the reagents and standards, 
tissue specimens, perhexiline extraction technique and chromatography used to 
determine the concentration of perhexiline in the atrial and ventricular myocardium. 
 
5.2.1 Reagents and standards 
The following reagents were used in the extraction of perhexiline and HPLC: 
 Methanol, n-hexane and ethyl acetate (all Merk-Hipersolv grade) 
 HPLC glass-distilled water 
 2.0M NaOH: 8.0g of NaOH dissolved in 100mL of distilled water. 
 0.5M NaOH: 5.0g of NaOH dissolved in 250mL of distilled water. 
 10% Ethyl acetate in n-Hexane: To a 250mL measuring cylinder, 25mL of ethyl 
acetate was added and topped up to full volume with n-hexane, stored at 2-8°C. 
 0.05% (R)-(-)-1-(1-Napthyl)ethyl isocyanate (derivitising agent) in acetone: 5 µL of 
1-NEIC dissolved in 10mL of acetone in a nitrogen environment, stored at 2-8°C. 
 0.1M HCl: 4.3ml of concentrated HCl was added to 500mL of distilled water. 
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The following standard stock solutions were used: 
 Perhexiline racemic stock (100mg/L): 7.09mg of perhexiline maleate (Sigma, MW 
393, equivalent to 5mg of perhexiline base, MW 277) was weighed and transferred 
to a 50mL volumetric flask. 5mL of methanol was added to completely dissolve the 
solid, made up to volume with 0.1M HCl and mixed well to ensure solution. 
 Perhexiline standard solution (10mg/L, 0.5mg/L): In a 50mL volumetric flask, 5mL 
of racemic perhexiline 100mg/L solution was added and made up to full volume 
with 0.1M HCl to give a 10mg/L racemic stock solution. 1mL batches were 
aliquoted into disposable glass culture tubes, capped and stored frozen. On the 
day of the assay, one tube was thawed at 37°C. To prepare a 0.5mg/L racemic 
stock solution, after mixing well, it was diluted 1 in 20 with 0.1M HCl. 
 Prenylamine stock solution (10mg/L, internal standard): 10mg of prenylamine 
(Sigma) was weighed out and transferred to a 100mL volumetric flask. 10mL of 
methanol was added to dissolve the solid and made up to volume with 0.1M HCl. It 
was diluted 1 in 10 with 0.1M HCl to give a 10mg/L stock solution, stored at 2-8°C. 
 Quality control specimens: Fresh perhexiline 100mg/L racemic stock solution was 
prepared as above. To make a 1.50mg/L racemic (0.75mg/L enantiomers) QC 
batch, 300µL of 100mg/L stock was added to a 20mL volumetric flask and made 
up to volume with control right atrial homogenate. To make a 0.80mg/L racemic 
(0.40mg/L enantiomers) QC batch, 160µL of 100mg/L stock was added to a 20mL 
volumetric flask and made up to volume with control atrial homogenate. To make a 
0.06mg/L racemic (0.03mg/L enantiomers) QC batch, 120µL of 10mg/L stock was 
added to a 20mL volumetric flask and made up to volume with control atrial 
homogenate. 700µL of each QC solution was transferred to Eppendorf tubes. 
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5.2.2 Tissue specimens 
As described previously, atrial and ventricular biopsies were obtained during surgery 
and promptly snap-frozen in liquid nitrogen. The right atrial appendage was truncated 
during venous cannulation for CPB. Transmural Tru-Cut needle (Allegiance, McGaw 
Park, IL) biopsies of the left ventricular free-wall between the left anterior descending 
artery and the first diagonal branch were taken at three time points but only the pre-
ischaemia biopsy (on CPB but before application of the aortic cross-clamp) was used 
in this experiment. Once frozen, all samples were stored at -80°C until analysis, 
except during shipping to Adelaide on dry-ice. 
 
Right atrial biopsies were mechanically digested in 0.15M phosphate buffer solution 
(pH 6.0) using a homogeniser and a tissue grinder to form a suspension; a fine tissue 
grinder alone was used for the left ventricular biopsies which had far lower masses. 
Atrial and ventricular biopsies from patients in the perhexiline arm constituted the 
experimental groups. Atrial biopsies from patients in the control arm, with proven zero 
serum perhexiline concentrations, were also prepared for generating standard curves 
and quality control (QC) samples. 
 
5.2.3 Perhexiline extraction 
Biopsies were analysed in batches of approximately 25 samples. A standard curve 
and quality control samples were prepared for each batch using 0.5mL of control right 
atrial homogenate in 15mL screw-cap disposable glass tubes (table 8). Prenylamine 
was added to all samples, except the blank, as an internal standard to enable 
reverse quantification of sample perhexiline concentration. 
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No. Perhexiline 0.1M HCl Control Racemic Px stock Prenylamine 
 (mg/L)  atrium 10mg/L 0.5mg/L 10mg/L 
1 2.00 - 500 200 - 50 
2 1.00 100 500 100 - 50 
3 0.50 150 500 50 - 50 
4 0.20 180 500 20 - 50 
5 0.10 - 500 - 200 50 
6 0.05 100 500 - 100 50 
7 0.02 160 500 - 40 50 
8 0.01 180 500 - 20 50 
9 0 200 500 - - 50 
10 Blank 250 500 - - - 
11+ ? 200 QC and patient specimens 50 
HCl indicates hydrochloric acid; Px, perhexiline; QC, quality control. All volumes in µL. 
 
Table 8. Preparation of HPLC standard curve, control and patient specimens. 
 
For each QC solution and patient specimen, 0.5mL of homogenised tissue was used. 
50µL of 10mg/L prenylamine was added to all tubes except Blank (No.10) and 
vortexed briefly. 50µL of 2M NaOH was added to all tubes and vortexed briefly. 4mL 
of a solution of 10% ethyl acetate in n-hexane was added and mixed on a horizontal 
shaker for 15 minutes at 100opm. All tubes were centrifuged for 15 minutes at 
2500rpm and 10°C. The aqueous layer was frozen in a dry ice/ethanol bath and 
discarded whilst the organic layer was transferred to 5mL disposable glass tubes. 
Samples were evaporated at room temperature in an evacuated centrifuge. 
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To the dry residue, 200µL of derivitising agent (1-NEIC in acetone) was added and 
vortexed briefly then incubated at room temperature for 5 minutes. 200µL of 0.5M 
NaOH was added and vortexed briefly then incubated at room temperature for 5 
minutes. 3mL of 10% ethyl acetate in n-hexane was added, the tubes capped and 
vortexed for 5 minutes. All tubes were centrifuged for 3 minutes at 2500rpm and 
10°C. The aqueous layer was frozen in a dry ice/ ethanol bath and discarded whilst 
the organic layer was quickly transferred to clean 5mL disposable glass tubes. 
Samples were evaporated at room temperature in an evacuated centrifuge. The dry 
residue in all tubes was reconstituted in 150µL of a mixture of 82% methanol and 
18% water and 100µL injected into the HPLC column. 
 
5.2.4 Chromatography 
Analyses were conducted on an Agilent 1100 series HPLC apparatus (Agilent 
Technologies, Forest Hill, VA, Australia) operated by Chemstation for LC 3D 
software, as previously reported (Davies et al., 2006b). The hardware consisted of a 
model G1322A degasser, a model G1311A pump generating flow at 1ml/min, a 
model G1313A autosampler and a model G1321A fluorescence detector with 
excitation and emission wavelengths of 218 and 334nm, respectively. Resolution of 
the diasteromers was achieved using a Merck Purospher RP-18E (5µm, 125mm x 
4mm) column at ambient temperature. With gradient elution, the mobile phase was 
composed of 82% methanol and 18% water for the first 11.5 minutes, then increased 
to 86% methanol in a linear gradient over 1 minute, maintained at this concentration 
for a further 15.5 minutes, then reduced back to 82% methanol over 1 minute and 
continued at this concentration for the remaining 3 minutes of each sample run time. 
137 
 
The calibration curves of the concentrations of each enantiomer against the peak 
area ratios between the analyte and the first peak of the internal standard were 
constructed using linear regression (Davies et al., 2006b). Precision and accuracy 
were evaluated using the coefficient of variation (CV) and the bias of the measured 
concentration versus the known spiked concentration, respectively; a CV and bias of 
+/- 15% was considered acceptable. Inter-assay quality control was assessed by 
analysing aliquots from three separate QC pools spiked with 0.03, 0.4 and 0.75mg/l 
of perhexiline enantiomers. Due to the lack of UV absorbance and fluorescence of 
underivatised perhexiline and the unavailability of pure derivatised perhexiline, it was 
not possible to determine the absolute extraction efficiency of this method. 
 
5.2.5 Statistical analysis 
Data is presented as mean (standard deviation) or median (interquartile range). The 
concentration of perhexiline is reported as the sum of the two enantiomers measured. 
The normality of data was assessed using the Kolmogorov-Smirnov test. Spearman’s 
rank test was used to correlate non-parametric data. The relationship between 
variables was modelled using simple and multiple linear regression in SPSS. An 
outline of the statistical tests used in this thesis is contained in appendix 9.6. 
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5.3 Results 
 
The concentration of perhexiline in right atrial wall biopsies was measured in 94/139 
(67.6%) patients in the treatment group (table 9), for whom serum perhexiline was 
also available; the mean mass of atrial tissue analysed was 85mg (range 10-458mg). 
Pre-ischaemia left ventricular biopsies from 28/139 (20.1%) patients in the treatment 
group, in whom serum and atrial perhexiline had also been determined, were 
analysed; the mean mass of ventricular specimens was 3.6mg (range 1.6-15mg). 
Poor metabolisers were excluded as they were unlikely to have reached steady-state. 
 
Variable Perhexiline (n = 94) 
Serum perhexiline, median (IQR), mg/L 0.24 (0.12-0.44) 
Serum OH-perhexiline, median (IQR), mg/L 1.18 (0.96-1.52) 
Metaboliser status, n (%)  
 Intermediate 18 (19.1) 
 Extensive 68 (72.3) 
 Ultra-rapid 8 (8.5) 
Length of therapy, median (IQR), d 8.5 (6.5-12.5) 
Age, mean (SD), y 64.3 (8.9) 
Weight, mean (SD), kg 84.2 (15.0) 
Pre-treatment heart rate, mean (SD) 60 (10) 
Pre-ischaemia cardiac index, mean (SD), L/min/m
2
 2.13 (0.60) 
Preoperative medications, n (%)  
 ACE inhibitor or ARB 60 (63.8) 
 Statin 87 (92.6) 
 β-adrenergic antagonist 66 (70.2) 
 Calcium channel antagonist  34 (36.2) 
 Long-acting oral nitrate 32 (34.0) 
 Potassium channel blocker 20 (21.3) 
ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker. 
 
Table 9. Characteristics of 94 patients providing atrial biopsies for analysis. 
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Analysis of each biopsy using HPLC generated a plot of UV light against retention 
time with identifiable peaks representing the concentration of perhexiline (figure 23). 
 
 
 
Peaks 1 & 2 correspond to the diasteromers of derivatised prenylamine, the internal standard. Peaks 3 
& 4 correspond to the diasteromers of derivatised (+) and (–) perhexiline, respectively; the sum of 
these two peaks gives the total concentration of perhexiline in the specimen (Davies et al., 2006b). 
 
Figure 23. Representative chromatogram of a patient sample. 
 
5.3.1 Atrial perhexiline concentration 
The median atrial concentration was 6.02mg/Kg (IQR 2.70-9.06) with a range of 0.74 
to 28.6mg/Kg and was not normally distributed (D=0.16, p<0.001). Paired atrial and 
serum perhexiline concentrations were compared using Spearman’s rank correlation 
finding an rs coefficient of 0.91 (p<0.001), suggesting a very strong correlation. Linear 
regression was performed using atrial perhexiline as the dependent variable and 
serum perhexiline as the independent variable. The R value of 0.87, R2 of 0.76 and 
F-ratio of 279 (p<0.001) suggest that serum perhexiline is highly predictive of atrial 
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concentration, explaining 76% of the variation in measured atrial concentration (figure 
24). Unsurprisingly, atrial perhexiline and metaboliser status were also strongly 
correlated with an rs of -0.71 (p<0.001). The median atrial-serum perhexiline ratio 
was 21.5 (IQR 18.1-27.1) with a range from 4.9 to 55.6 and was not normally 
distributed (D=0.10, p=0.03). 
 
 
Figure 24. Plot of atrial against serum perhexiline concentrations. 
 
Stepwise multiple linear regression was performed using serum perhexiline, OH-
perhexiline, length of therapy, age, weight, heart rate, left ventricular function, pre-
sternotomy cardiac index and concurrent mediations as potential predictors of atrial 
concentration. A model containing serum perhexiline (β 0.82, p<0.001), age (β 0.14, 
p<0.01), heart rate (β -0.17, p<0.01) and weight (β -0.15, p<0.01) achieved an R 
value of 0.91, R2 of 0.82 and F-ratio of 99.2 (p<0.001); it should be noted that serum 
perhexiline alone has already been shown to have an R2 of 0.76. Length of therapy 
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had no impact on the model suggesting that similar to serum perhexiline, atrial drug 
concentration was not significantly affected by the length of therapy beyond five days 
and that most patients had reached a steady-state of atrial drug uptake. 
 
5.3.2 Ventricular perhexiline concentration 
The median ventricular concentration was 10.0mg/Kg (IQR 5.76-13.1) with a range of 
3.05 to 35.7mg/Kg and did not fit a normal distribution model (D=0.19, p<0.01). 
Median length of therapy in the 28 patients with ventricular biopsies was 9.5 days 
(IQR 7.0-14.0). Linear regression was used to assess the impact of serum 
perhexiline on the measured concentration in the ventricular myocardium with an R 
value of 0.85, R2 of 0.73 and F-ratio of 69.1 (p<0.001) (figure 25). Repeating the 
analysis for the predictive value of atrial concentration found an R of 0.88, R2 of 0.77 
and F-ratio of 86.6 (p<0.001) (figure 26). The ventricular-serum perhexiline ratio had 
a median of 34.9 (IQR 24.5-55.2) with a range of 16.7 to 89.3. The ventricular-atrial 
ratio had a median of 1.67 (IQR 1.39-2.22) with a range from 0.9 to 5.0. 
 
Stepwise multiple linear regression was used to identify predictors of the ventricular 
concentration. Unsurprisingly, serum perhexiline concentration (β 0.71, p<0.001) 
remained the leading predictor but the model was improved by the addition of length 
of therapy (β 0.26, p<0.01) and OH-perhexiline (β -0.23, p 0.02), achieving an R 
value of 0.92, R2 of 0.85 and F-ratio of 43.8 (p<0.001). The presence of length of 
therapy in the model suggests that unlike perhexiline uptake into the atrium, the 
concentration in the ventricular myocardium had not yet reached steady-state by the 
time of surgery. Therefore, the concentration measured in these ventricular biopsies 
may not reflect that achievable with a longer period of therapy. 
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Figure 25. Plot of ventricular against serum perhexiline concentrations. 
 
 
 
Figure 26. Plot of ventricular against atrial perhexiline concentrations. 
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5.4 Discussion 
 
This study is the first to measure the myocardial concentration of perhexiline in 
humans. In patients undergoing cardiac surgery, I have demonstrated that it is highly 
concentrated in the human myocardium compared with serum, approximately 20-fold 
in the right atrium and 35-fold in the left ventricle, after median nine days of therapy. 
These observations reflect closely the 20-fold accumulation previously observed 
following acute exposure to perhexiline in the rat (Kennedy et al., 1996). Despite a 
low serum concentration, there is progressive accumulation of perhexiline in the 
myocardium, potentially leading to a high tissue concentration at its site of action. 
 
On multivariate analysis, serum perhexiline concentration was the strongest predictor 
of myocardial concentration confirming that drug uptake is concentration-dependent 
(Horowitz and Powell, 1986). Uptake of perhexiline appeared to have linear kinetics 
implying that the mechanism is not saturable within the therapeutic range and that 
either it is not carrier-mediated or the unbound serum concentration of perhexiline is 
well below the Km of any transporters. Atrial concentration was also correlated with 
increasing age and inversely with heart rate and weight, although the relationship 
with weight may be mediated by lower serum levels. Increasing concentration with 
age is a novel finding and likely to reflect unmeasured factors such as myocardial 
uptake, efflux, metabolic capacity, protein binding and serum:myocardial partitioning. 
On the other hand, the inverse correlation with heart rate was an unexpected finding; 
it has previously been suggested that myocardial drug uptake is increased by 
tachycardia (Lullmann et al., 1979) although increased myocardial mechanical work 
may have been a confounding factor. 
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The hypothesis that cumulative drug uptake in the myocardium may be influenced by 
mechanical work (Lloyd and Taylor, 1976, Lullmann et al., 1980) is supported by the 
finding that perhexiline was more concentrated in the ventricle than in the atrium. A 
similar observation has been reported in patients on long-term digoxin therapy 
undergoing mitral valve surgery in whom the drug concentration was 41-times higher 
in atria and 77-times higher in left ventricular papillary muscle than in plasma 
(Carruthers et al., 1975). Both the serum and atrial perhexiline concentration were 
strongly predictive of the ventricular level; the slightly higher predictive value of the 
atrial concentration (R2 0.77) is likely to reflect one or more unidentified factors that 
affect myocardial drug uptake per se and were therefore already taken into account. 
However, length of therapy was found to be a predictor of the ventricular but not the 
atrial perhexiline concentration. Despite greater drug accumulation in the ventricle, it 
may not have yet reached a steady-state following a median 9.5 days of therapy. 
This suggests that the rate of perhexiline uptake into the myocardium of the ventricle 
may be protracted, with a larger volume of distribution and slower drug metabolism 
than in the atrium and delayed equilibration between serum and tissue. With a longer 
period of exposure, an even higher concentration may have been achieved in the 
ventricular myocardium and improved correlation with atrial levels. 
 
Little is known regarding the uptake of drugs into the human myocardium at steady-
state; most studies have examined changes in compartments following acute drug 
administration (Horowitz and Powell, 1986). Gradual accumulation in the myocardium 
may be due to high tissue binding with or without an active cellular uptake 
mechanism. The availability of intracellular binding sites may be affected by disease 
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states e.g. ischaemia, other drugs and metabolites, including OH-perhexiline, and 
contribute to inter-individual variability in perhexiline uptake and efficacy. 
 
Whilst this study has shown that perhexiline is markedly concentrated in the human 
myocardium compared with serum, is it sufficient to significantly inhibit CPT function? 
In the rat heart, Kennedy et al. (2000) examined the effect of perhexiline on CPT-1 
and -2 inhibition at varying concentrations (figure 27) and found the IC50 in isolated 
cardiac mitochondria to be 77µmol/L (21.3mg/L) with no significant differences 
between intact mitochondrial and homogenate preparations. 
 
 
 
 
 
 
 
 
 
 
 
Intact mitochondria (■      ■), pellet (ӿ      ӿ) and supernatant (▲      ▲) preparations after Tween-20.  
 
Figure 27. Concentration response curve for the inhibition of CPT-1 in the rat.2 
                                            
2
 Reprinted from Kennedy JA, Kiosoglous AJ, Murphy GA, Pelle M, Horowitz JD. Effect of Perhexiline 
and Oxfenicine on Myocardial Function and Metabolism during Low-Flow Ischemia/Reperfusion in the 
Isolated Rat Heart. Journal of Cardiovascular Pharmacology, 36(6), 794-801, Copyright (2000), with 
permission from Wolters Kluwer Health. 
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In the current study, only 2/28 (7.1%) patients had a ventricular perhexiline 
concentration above 77µmol/L (21.3mg/L), one of whom had significantly toxic serum 
levels and the other was at the upper limit of the therapeutic range. This raises the 
possibility that the myocardial concentration of perhexiline may have been insufficient 
to significantly inhibit CPT-1 at the time of surgery, although there are a number of 
important caveats. The degree of interspecies preservation of enzyme function, 
binding sites and susceptibility to perhexiline inhibition is unknown. There were also 
important methodological differences between the in vitro rat mitochondria and the ex 
vivo human homogenate affecting the exposure of CPT-1 on the outer mitochondrial 
membrane to perhexiline. These include the availability of cellular binding sites, the 
proportion of unbound drug in the myocardium, the length of exposure to perhexiline, 
the solvent extraction technique and potential drug compartmentalisation within the 
sarcolemma, cytosol and mitochondria. Total tissue concentration may not reflect 
drug concentration at its site of pharmacological action. On the other hand, the 
concentration-dependent inhibition of CPT was similar across the intact mitochondria, 
pellet and supernatant preparations with no significant difference in IC50 values 
(Kennedy et al., 2000). The concentration of perhexiline measured in the ventricular 
biopsies from trial patients was in the same order of magnitude as that used in the rat 
studies. Indeed as it falls close to the steep section of the sigmoid log curve, small 
changes in concentration would lead to large changes in the degree of enzyme 
inhibition. Direct comparisons of perhexiline concentrations and IC50 between models 
should therefore be regarded as hypothesis-generating rather than definitive 
evidence. 
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Further improving our understanding of drug uptake into the myocardium will provide 
insights into the relationship between efficacy and toxicity, inform drug design, enable 
targeted delivery in disease states such as ischaemia and facilitate an individualised 
approach to therapeutics. It also provides a platform for physiologically-based 
pharmacokinetic modelling (PBPK), a mathematical technique for assessing system 
dynamics that utilises a multi-compartment model to improve understanding of the 
interactions of a drug and its metabolites across compartments. 
 
In this chapter, I have demonstrated the utility of myocardial biopsies for the 
elucidation of steady-state drug uptake in the heart. I have shown that perhexiline is 
highly concentrated in the myocardium and whilst there is a strong correlation with 
plasma levels, other factors such as heart rate and age may modulate the uptake 
process. However, it appears that the ventricular concentration of perhexiline had not 
reached steady-state by the time of surgery using the trial dosing regimen; the 
concentration may have risen further with a longer period of exposure. Whilst the 
level achieved in the ventricular myocardium was in the correct order of magnitude 
for CPT-1 inhibition according to the rat model, it remains unknown whether at 
steady-state, the concentration would be sufficient to significantly affect the flux 
through cellular metabolic pathways in humans. 
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6. METABOLIC PRECONDITIONING WITH PERHEXILINE 
 
6.1 Introduction 
 
The myocardium is the most metabolically active tissue in the body for weight. Its 
major source of ATP is mitochondrial oxidative metabolism which is tightly controlled 
to meet the contractile and homeostatic needs of the heart. As discussed previously, 
energy is derived from a variety of competing substrates taken up from the blood 
(Taegtmeyer, 2007). Substrate utilisation is primarily regulated locally by the glucose-
fatty acid cycle whereby the availability of fatty acids undergoing β-oxidation inhibits 
the PDH complex, decreasing the entry of pyruvate into the citric acid cycle and 
leading to preferential oxidation of fatty acids over glucose. Malonyl-CoA acts as the 
endogenous regulator, decreasing mitochondrial uptake of fatty acids through potent 
CPT-1 inhibition (Ussher and Lopaschuk, 2008). In ischaemia, a rise in circulating 
FFA further uncouples glycolysis from glucose oxidation and the fate of pyruvate is 
switched to lactate production, maintaining ATP production via anaerobic metabolism 
at the expense of worsening acidosis and reduced contractile function (Depre et al., 
1999). Upon reperfusion, β-oxidation of FFA is accelerated to meet the increased 
energy demands of the cell to the detriment of glucose oxidation. High levels of 
circulating FFA during reperfusion have been shown to contribute to myocardial 
ischaemia-reperfusion injury through PDH complex inhibition (Lopaschuk et al., 1994) 
leading to worsening cellular acidosis, calcium overload and oxidative stress which 
may precipitate cell death (Crompton, 1999) and impairment of contractile function. 
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Pharmacological modulation of myocardial metabolism aims to induce a shift in 
substrate utilisation from fatty acids to glucose, increasing oxidative energy efficiency 
and decreasing the harmful effects of β-oxidation during ischaemia-reperfusion 
(Taegtmeyer, 2002). Reduced suppression of the PDH complex maintains the entry 
of glycolytic pyruvate into the citric acid cycle, decreases lactate and proton 
production, and downregulates mitochondrial uncoupling proteins thereby restoring 
the efficacy of oxidative phosphorylation and electron transport (Lopaschuk et al., 
2010). The enhanced energetic status of the cell is postulated to activate pro-survival 
pathways and reduce the impact of ischaemia, translating into enhanced recovery of 
cardiac function during reperfusion. GIK has been shown to enhance myocardial 
protection during cardiac surgery (Fan et al., 2011) and many metabolic mechanisms 
have been proposed including a reduction in circulating FFA and their β-oxidation, 
glycogen loading, increased glycolytic ATP production, repletion of depleted energy 
cycles by anaplerosis and improved efficacy of ATP production from glucose 
oxidation (Doenst et al., 2003a). Indeed, our group has shown that perioperative GIK 
significantly increases pre-ischaemia atrial glycogen content and markedly 
suppresses plasma FFA concentrations during reperfusion (Howell, 2010). 
 
Perhexiline has been shown to inhibit mitochondrial CPT in rat heart mitochondria, 
leading to reduced uptake and β-oxidation of long-chain fatty acids (Kennedy et al., 
1996). In a subsequent study using the Langendorff isolated perfused heart model, 
Kennedy and colleagues (2000) found that perhexiline inhibited the release of lactate 
from the myocardium during normal flow but had no effect of pre-ischaemic glycogen 
content. Tissue levels of malonyl-CoA were similar to controls despite an increase in 
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acetyl-CoA with perhexiline (216nmol/g v 143 nmol/g, p<0.05) which may represent 
increased availability of substrate for the citric acid cycle. There was no significant 
difference in myocardial long-chain acyl-carnitine consistent with the simultaneous 
inhibition of both CPT-1 and -2 with perhexiline. Whilst this study demonstrated 
reduced diastolic dysfunction during ischaemia, perhexiline had no beneficial effect 
on the recovery of myocardial systolic function on reperfusion and concerns were 
raised over whether the length of pre-exposure to perhexiline had been sufficient to 
achieve a high level of cellular accumulation and maximise CPT inhibition. 
 
In the previous chapter, I demonstrated that after a median 8.5 days (IQR 6.5-12.5) 
of treatment, there had been uptake and accumulation of perhexiline in the 
myocardium of patients undergoing surgery to within the same order of magnitude 
required for the effective inhibition of CPT in the rat. According to its proposed 
mechanism of action, CPT inhibition by perhexiline should produce significant 
changes in myocardial carbohydrate and lipid metabolism. Preoperative treatment is 
proposed to enable short-term metabolic optimisation prior to ischaemia by 
maintaining the oxidative coupling of glucose to improve myocardial protection 
without the potential risks of lipid accumulation associated with long-term therapy. 
The fate of glucose may be assessed by its storage (glycogen), flux through 
glycolysis (G6P, pyruvate) and anaerobic metabolism (lactate), and lipid metabolism 
by the concentration of myocardial triacylglycerol and phospholipid. Substrate 
availability prior to ischaemia is determined by serum glucose, lactate, lipids and 
ketones whilst the lipid profile during reperfusion has been shown to affect metabolic 
and functional recovery (Lopaschuk et al., 1994). 
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In this chapter, I perform laboratory experiments on human tissue to directly examine 
the impact of perhexiline on myocardial metabolism. I use traditional biochemical 
methods to measure the effect of perhexiline on carbohydrate and lipid intermediates 
in serum and atrial myocardium and the effect of surgery on the serum lipid profile. In 
collaboration with colleagues in Biosciences, I analyse the metabolomic profile of left 
ventricular biopsies obtained prior to ischaemia from patients on perhexiline therapy 
compared with controls using state of the art ultra-high resolution mass spectrometry. 
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6.2 Traditional biochemical analysis 
 
6.2.1 Materials & methods 
The experiments described in this section were conducted in collaboration with Dr 
David Hauton at the Institute for Biomedical Research, University of Birmingham. The 
concentrations of carbohydrates and lipids in human tissue and serum samples were 
determined principally by enzymatic colourimetry. In this technique, the analyte is 
degraded by a specific enzyme to produce an intermediate which reacts with an 
additive to form a coloured complex; the resulting colour absorbance of the solution is 
proportional to the concentration of the analyte according to Beer-Lambert’s law: 
Absorbance (A) = molar absorptivity (ε) x path length (l) x molar concentration (c) 
in which path length and absorptivity are known. Absorbance was measured using a 
Labsystems Multiskan spectrophotometer (Thermo Fisher Scientific, Loughborough, 
UK) at predefined wavelengths. All solvents and reagents were of analytical grade. 
 
Tissue and serum specimens 
Serum samples and atrial biopsies were obtained during surgery from trial patients at 
QEH, Birmingham. Serum samples were collected at induction of anaesthesia and 
six hours after removal of the aortic cross-clamp. The right atrial appendage was 
truncated during venous cannulation for CPB and any macroscopic epicardial fat 
removed; in selected patients, it was divided in two: one portion was promptly snap-
frozen in liquid nitrogen, the other mounted on a cork disk, embedded in Tissue-Tek 
Optimum Cutting Temperature (OCT) compound (Sakura) and frozen in isopentane 
pre-cooled to approximately -40°C with dry ice. All samples were stored at -80°C. 
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Serum biochemical analyses 
Fasted serum samples collected at induction of anaesthesia were tested for glucose 
(Thermo-Electron, Melbourne, Australia), insulin (Mercodia, Uppsala, Sweden), FFA 
(Wako Chemicals, Neuss, Germany), TAG and β-hydroxybutyrate (Randox, Crumlin, 
UK) using commercial assay kits according to the instructions. Serum samples 
collected during reperfusion at six hours after removal of the aortic cross-clamp were 
analysed for FFA and TAG. 
 
Myocardial glycogen 
Tissue glycogen content was determined by isolation using conventional alkali 
digestion and ethanol precipitation, followed by hydrolysis and spectrophotometric 
assay of the glucose product (Lavery et al., 2007). Briefly, right atrial biopsies were 
pulverised under liquid nitrogen, an aliquot of 50-100mg tissue weighted into an 
Eppendorf tube and 200µL of 2M KOH added. The tissue/alkali mixture was heated 
at 70°C for two hours and shaken occasionally to aid digestion. After cooling, 1ml 
(five volumes) of absolute ethanol was added to promote the precipitation of 
glycogen, left on ice for 30 minutes then centrifuged for 2 minutes at 13,000rpm. To 
recover the glycogen, the supernatant was decanted off, leaving a pellet which was 
allowed to dry before 200µL of distilled water was added and mixed thoroughly to 
redissolve. The washing process was repeated twice before redissolving the pellet in 
500µL of acetate buffer containing 100mM sodium acetate at pH 4.5. To this solution, 
50µL of α-amyloglucosidase (50mg/ml) from Aspergillus niger (Sigma-Aldrich, Poole, 
UK) in acetate buffer was added and left overnight at room temperature to digest the 
glycogen into free glucose units. 
154 
 
To a 96-well plate, 6µL of each sample or standard and 450µL of glucose oxidase 
reagent (Thermo-Electron) were added in duplicate and mixed thoroughly. After 10 
minutes, glucose concentrations were determined by enzymatic colourimetry with 
absorbances read at 490nm. Standard curves were constructed and the glucose 
concentration of each sample calculated using its linear regression as a reference. 
Concentrations were expressed as glucose units from glycogen per mass of tissue. 
 
Myocardial carbohydrate metabolites 
The extraction of carbohydrate metabolites was performed by the method of Hohorst 
(1963). Briefly, 30-50mg of right atrial tissue was weighted into Eppendorf tubes and 
400µL of 0.6M perchloric acid added. Samples were homogenised using glass beads 
(100µL equivalent volume) in a Mini-Beadbeater (BioSpec Products, Bartlesville, OK) 
in short bursts to prevent sample overheating, neutralised with 330µL of 0.5M KOH 
(pH ~8.0), centrifuged for two minutes at 5000rpm and the supernatant recovered. 
Metabolite concentrations were determined using enzymatic colourimetric techniques 
as outlined below with absorbances read on a spectrophotometer at 340nm. 
Standard curves were constructed and concentrations calculated using its linear 
regression as a reference. Concentrations were recorded per unit mass of tissue. 
 
Tissue pyruvate and lactate were estimated using the methods of Neville and Gelder 
(1971). Briefly, for pyruvate 50µL of supernatant or standard were added in duplicate 
to a 96-well plate. To each well were added 200µL of 0.1M tris-HCl buffer solution, 
50µL of NADH solution (5mg/ml) and 10µL of lactate dehydrogenase solution 
(10mg/ml) and mixed well. The assay was run at room temperature to completion of 
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NADH consumption. For lactate, 50µL of supernatant or standard were added in 
duplicate to a 96-well plate. 200µL of NAD solution (10mg/ml) in buffer and 10µL of 
lactate dehydrogenase solution (10mg/ml) were added to each well and mixed well. 
The assay was run at room temperature to completion of NADH production. 
 
Tissue glucose-6-phosphate (G6P) concentration was estimated using the method 
described by Hohorst (1963). Briefly, 200µL of supernatant or standard were added 
in duplicate to a 96-well plate. 200µL of NADP solution (10mg/ml) in buffer and 10µL 
of glucose-6-phosphate dehydrogenase solution (10mg/ml) were added to each well, 
mixed thoroughly and run at room temperature to completion of NADPH production. 
 
Myocardial lipids 
Lipids were extracted from atrial biopsies using the method described by Folch et al. 
(1957). In brief, 50-100mg of right atrium was weighed out, ground to a fine powder 
by pestle and mortar under liquid nitrogen, added to 20ml of Folch solvent 
(chloroform/methanol in a 2:1 ratio) in an extraction tube and shaken vigorously. 5ml 
of distilled water was added to break the solvent phases, mixed well and the solution 
left to separate into two phases. The lower, solvent fraction was recovered, 
transferred to a clean dry test tube and evaporated to dryness under a stream of inert 
gas in a fume cupboard. The residue was resuspended in 500µL of absolute ethanol 
and the concentrations of various lipids determined as follows. 
 
The triacylglycerol (TAG) content was estimated by the Trinder method using a 
commercial assay (Randox) according to the kit instructions. Briefly, 10µL of lipid 
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suspension or standard were added in duplicate to a 96-well plate with 200µL of 
reagent, containing lipases, glycerol kinase, glycerol-3-phosphate oxidase and 
peroxidase. TAG concentrations were determined by the method of Jacobs & 
Vandemark (1960) using enzymatic colourimetry with absorbances read at 492nm, 
using the standard as a reference and recorded per unit mass of tissue. 
 
The phospholipid content of atrial samples was estimated using a commercial assay 
(Sentinel, Milan, Italy) according to the kit instructions. Briefly, 5µL of lipid suspension 
or standard were added to 500µL of enzyme reagent, containing phospholipases, 
choline oxidase and peroxidase, in Eppendorf tubes and 200µL aliquots transferred 
in duplicate to a 96-well plate. Phospholipid concentrations were determined using 
enzymatic colourimetry with absorbances read at 520nm, using the standard as a 
reference and recorded per unit mass of tissue. 
 
Histological sectioning and staining for lipids 
Atrial biopsies embedded in OCT were transferred to a cryostat maintained at -20°C. 
Samples were mounted perpendicular to the cutting blade and sequential 10µm 
sections were carefully cut from a representative depth to provide the maximum 
surface area of atrial muscle. Sections were applied to polylysine-coated histology 
slides in duplicate and stored at -20°C until analysis. Myocardial lipid content was 
estimated by Oil Red O staining using a method adapted from Koopman et al. (2001). 
Briefly, sections were air dried for 30 minutes, outlined with a wax pen and fixed by 
immersion in 3.7% formalin (Sigma-Aldrich) for 30 minutes. Slides were rinsed in 
phosphate buffer solution (PBS) thrice for 30 seconds each and laid flat. 200µL of Oil 
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Red O stain (Oil Red O 300mg/L in 60% triethyl phosphate) was layered onto the 
specimens and incubated at room temperature for 15 minutes. Slides were rinsed 
again in PBS thrice for 30 seconds then in water for 10 minutes and cover slips 
applied with 50% glycerol. An AxioScope darkfield fluorescent microscope (Zeiss, 
Germany) with a monochromator and Texas Red filter was used to view the slides. 
Digital images were captured of four different x400 magnification fields per slide with 
AxioCam and the area of lipid staining was quantified by RGB colour thresholding 
using ImageJ image processing software (NIH, Bethesda, MD). 
 
Statistical analysis 
Data is presented as mean (standard deviation) or median (interquartile range). 
Mean values of the treatment and control groups were compared using independent 
Student’s t-tests. Spearman’s rank correlation was used to compare non-parametric 
data. All analyses were conducted blinded to the group allocation. An outline of the 
statistical tests used in this thesis is contained in appendix 9.6. 
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6.2.2 Results 
 
Serum analyses 
Biochemical analyses were performed on serum from 35 patients: 16 in the treatment 
group, 19 in the control group; the perhexiline group had a median serum perhexiline 
level of 0.37mg/L (IQR 0.19-0.62) after 12.5 days of therapy (IQR 10.5-14.0). There 
were no differences in mean glucose, insulin, β-hydroxybutyrate or TAG pre-
ischaemia at induction of anaesthesia although FFA were found to be significantly 
higher in the perhexiline group than in the control group (p<0.001) (table 10). 
 
 Control (n=19) Perhexiline (n=16) p value 
Glucose, mmol/L 6.81 (1.75) 6.91 (2.17) 0.88 
Triacylglycerol, mmol/L 0.14 (0.07) 0.16 (0.10) 0.45 
Free fatty acids, mmol/L 0.50 (0.13) 0.75 (0.08) <0.001 
β-hydroxybutyrate, mmol/L 0.57 (0.25) 0.67 (0.46) 0.44 
Insulin, nmol/L 0.27 (0.11) 0.32 (0.13) 0.32 
 
Table 10. Serum metabolite and insulin concentrations pre-ischaemia. 
 
At six hours after release of the aortic cross-clamp, the difference in serum FFA had 
been lost: 0.73mmol/L (SD 0.15) in the perhexiline group and 0.70mmol/L (SD 0.21) 
in the control group (p 0.64). Serum TAG was approximately 7-fold higher than pre-
ischaemia (p<0.001) but again there was no difference between groups at six hours: 
1.06mmol/L (SD 0.53) in the perhexiline group versus 1.10mmol/L (SD 0.38) in the 
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control group (p 0.79) (figure 28). There was a strong negative correlation between 
serum TAG concentration at six hours and age (rs -0.53, p 0.002) but no correlation 
with body mass index (rs -0.01, p 0.95). 
 
 
Figure 28. Serum lipid profile pre-ischaemia and at six hours into reperfusion. 
 
Myocardial carbohydrates 
Atrial glycogen concentration was measured in atrial biopsies from 101 patients: 50 in 
the treatment group, 51 in the control group; those in the perhexiline group had a 
median serum perhexiline level of 0.31mg/L (IQR 0.13-0.50) after 8.5 days of therapy 
(IQR 6.5-11.5). Groups were remarkably similar with a mean glycogen concentration 
of 4.74µmol/100g (SD 1.74) in the perhexiline group versus 4.73µmol/100g (SD 1.63) 
in the control group (p 0.97). There was no correlation between atrial glycogen and 
serum perhexiline (rs 0.02), days of therapy (rs 0.02), body mass index (rs 0.05) or 
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baseline cardiac index (rs 0.13, p 0.18) although there was a moderate negative 
correlation with age (rs -0.37, p<0.001). 
 
The concentration of carbohydrate metabolites was measured in right atrial biopsies 
from 18 patients: seven in the treatment group, 11 in the control group; those in the 
perhexiline group had a median serum perhexiline level of 0.45mg/L after 12.5 days 
of therapy. There were no significant differences in the mean concentrations of 
lactate (Px: 47.2µmol/g, SD 16.3; control: 45.9µmol/g, SD 26.1, p 0.89), pyruvate (Px: 
11.0µmol/g, SD 2.85; control: 12.5µmol/g, SD 6.53, p 0.53) or G6P (Px: 6.54µmol/g, 
SD 1.33; control: 6.62µmol/g, SD 2.97, p 0.93) between groups (figure 29). There 
was also no difference in the lactate-pyruvate ratio between groups: 4.65 (SD 0.91) in 
the perhexiline group versus 3.93 (SD 0.44) in the control group (p 0.50). 
 
 
Figure 29. Lactate, pyruvate and G6P concentrations in right atrium. 
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Myocardial lipids 
TAG and phospholipids were measured in atrial biopsies from 25 patients: 12 in the 
perhexiline group, 13 in the control group; the perhexiline group had a median serum 
perhexiline level of 0.35mg/L (IQR 0.14-0.58) after 12 days (IQR 10.5-13.5). There 
were no significant differences in the mean concentrations of TAG (Px: 31.2µmol/g, 
SD 18.1; control: 45.4µmol/g, SD 34.8, p 0.21) or phospholipid (Px: 12.9µmol/g, SD 
8.5; control: 15.0µmol/g, SD 8.8, p 0.54) (figure 30). There was no correlation with 
serum perhexiline (rs -0.34, p 0.28) although the sample size was small (n=12). 
 
 
Figure 30. Triacylglycerol and phospholipid concentrations in right atrium. 
 
Histology was performed on atrial biopsies frozen in OCT from 13 patients: five in the 
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control group (p 0.20) (figure 32). However, there was marked inter-individual 
variation, particularly in the control group with a 7-fold difference between the highest 
and lowest percentages of tissue staining. In addition, on light microscopy, lipid 
droplets were often visualised on the surface of the sections suggesting that there 
may have been contamination from residual epicardial adipose tissue. 
 
 
 
 
 
 
 
 
 a b 
 
Figure 31. Oil Red O staining of (a) control and (b) perhexiline atrium (x400). 
 
 
Figure 32. Area of Oil Red O staining of control and perhexiline atrium.  
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6.3 Metabolomic analysis 
 
6.3.1 Metabolomics: understanding the biochemical network 
Metabolomics is the measurement of small molecules within a cell, tissue, biofluid or 
organism and represents a paradigm shift in metabolic research (Griffin et al., 2011), 
attempting to profile the complexity of metabolic networks rather than focusing on 
single pathways. It tells a story downstream of other functional-genomic approaches 
(figure 33), providing a snap-shot of cellular physiology to demonstrate actual 
changes in biological systems rather than their mechanisms of regulation. Over the 
last decade, metabolomics has rapidly grown in importance for the understanding of 
systems biology and the discovery of new biomarkers of disease. 
 
 
 Genomics Transcriptomics Proteomics Metabolomics 
 
Figure 33. The spectrum of functional-genomic analyses. 
 
The Human Metabolome Database already contains over 8,500 metabolites that are 
found in human tissues and biofluids at concentrations over 1 µmolar (Wishart et al., 
2009). No single analytical tool can measure all of the metabolites that exist over a 
wide range of molecular masses, polarities and concentrations. The two most 
commonly used techniques are nuclear magnetic resonance (NMR) spectroscopy 
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and mass spectrometry (MS). NMR utilises the property of certain nuclei, including 
1H, 13C and 31P, to spin when placed inside a magnetic field; the frequency at which a 
nucleus resonates is determined by coupling with adjacent nuclei and its chemical 
environment enabling a high specificity for determining chemical structure. Whilst it is 
a fast, simple test with high analytical reproducibility, NMR lacks sensitivity for 
metabolites at low biological concentrations. On the other hand, MS has an ionisation 
source, an ion trap, a mass analyser and a detector to measure the mass-to-charge 
ratio (m/z) of positive or negative ions in the mixture. Highly sensitive and specific, it 
generates a vast quantity of data in the form of a mass spectrum (figure 34) with 
each peak representing the relative abundance of molecules with a particular m/z. 
 
 
Figure 34. Representative FT-ICR mass spectrum with SIM-stitching method.3 
 
                                            
3
 Reprinted with permission from Southam AD, Payne TG, Cooper HJ, Arvanitis TN, Viant MR. 
Dynamic range and mass accuracy of wide-scan direct infusion nanoelectrospray Fourier Transform 
Ion Cyclotron Resonance Mass Spectrometry-based metabolomics increased by spectral stitching 
method. Analytical Chemistry, 79(12), 4595-4602. Copyright 2007 American Chemical Society. 
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Fourier transform ion cyclotron resonance (FT-ICR) MS measures mass by detecting 
the image current produced by ions cyclotroning in a magnetic field and is a 
particularly powerful tool for analysing complex metabolite mixtures due to its ultra-
high mass resolution and accuracy (Southam et al., 2007). In principle, this enables 
the empirical formula of many low molecular weight metabolites to be unambiguously 
identified based upon mass alone. Positive and negative ions can be evaluated but to 
detect molecules with functional groups that readily lose a proton, e.g. carbohydrates 
and oligonucleotides, negative ion mode is used. Direct infusion nanoelectrospray is 
a technique that has high reproducibility of the m/z-dependent axis, shorter analysis 
times and substantially reduced differential ionisation of metabolites. There are only a 
few laboratories in the world that currently have expertise in these technologies. 
 
FT-ICR mass spectra require extensive data processing. Multiple narrow overlapping 
spectra are collected and analysed in selected ion monitoring (SIM) mode; spectra 
are then combined by SIM-stitching to produce a spectrum with high mass accuracy 
across a wide mass range (Southam et al., 2007). This technique generates a single 
spectral fingerprint for each biological sample, facilitating peak characterisation, data 
handling and multivariate analysis. Other stages of data processing include filtering, 
normalisation, false discovery rate (FDR) control and peak identification through an 
algorithm enhanced with knowledge of metabolic pathways (Weber and Viant, 2010). 
 
In this section, I report an overview of the techniques used to analyse the myocardial 
metabolome of pre-ischaemia left ventricular biopsies and compare the negative ion 
mode profiles of patients in the perhexiline and placebo groups of the clinical trial.  
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6.3.2 Methods 
The experiments described in this section were conducted in the laboratory of 
Professor Mark R. Viant in the School of Biosciences at the University of 
Birmingham. Methods for the metabolomic analysis of human myocardial biopsies 
using a state-of-the-art FT-ICR mass spectrometer have been refined by our group to 
reduce mass variation and signal-to-noise ratio and to improve confidence of 
metabolite peak identification. 
 
Tissue specimens 
Transmural Tru-Cut needle (Allegiance, McGaw Park, IL) biopsies of the left 
ventricular free-wall between the left anterior descending artery and the first diagonal 
branch were taken at three time points, as described previously, but only the baseline 
pre-ischaemia biopsy (on CPB but before application of the aortic cross-clamp) was 
used in this experiment. Biopsies were promptly snap-frozen in liquid nitrogen and 
stored at -80°C until analysis. 
 
Metabolite extraction 
Metabolites were extracted using a methanol:water:chloroform solvent system (Wu et 
al., 2008). A blank was prepared using the same extraction method except that no 
biopsy material was added. Samples were dried using a centrifugal concentrator 
(Thermo Savant, Holbrook, NY) and stored at -80°C. Each dried polar extract was re-
dissolved in 60μL of 80:20 methanol:water containing 20mM ammonium acetate for 
negative ion analysis, vortexed and centrifuged at 10,000-g prior to MS. QC samples 
were prepared by pooling an equal aliquot of each sample. 
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Mass spectrometry 
MS analyses were conducted using a hybrid 7-Tesla linear ion trap FT-ICR mass 
spectrometer (LTQ FT Ultra, Thermo Fisher Scientific, Germany) equipped with a 
Triversa chip-based nanoelectrospray ion source (Advion Biosciences, NY) using 
conditions as described previously (Weber et al., 2011). Three mass spectra were 
collected for each sample using a selected-ion-monitoring (SIM) stitching method 
from m/z 70 to 740 in negative ion mode (Southam et al., 2007, Weber et al., 2011), 
processed (Payne et al., 2009, Hrydziuszko and Viant, 2011), normalised and 
generalised-log transformed as reported previously (Dieterle et al., 2006, Parsons et 
al., 2007). This produced a peak intensity matrix representing the metabolic profile of 
each extracted biopsy. Using MI-Pack software (Weber and Viant, 2010), m/z 
measurements were putatively annotated. 
 
Statistical analysis 
Student’s t-tests were conducted on the non-generalised log-transformed peak 
intensity matrix, using an FDR of 5% to correct for multiple testing, to determine if 
individual peaks changed significantly between the two groups (Benjamini and 
Hochberg, 1995). In addition, principal components analyses (PCA) and partial least 
squares discriminant analyses (PLS-DA) were conducted to discover metabolic 
differences between the groups (Nicholson et al., 2002). Internal cross-validation with 
venetian blinds was applied to assess for over-fitting of the optimal PLS-DA model. 
An outline of the statistical tests used in this thesis is contained in appendix 9.6. 
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6.3.3 Results 
Polar extracts from pre-ischemia left ventricular biopsies were analysed from 43 
patients: perhexiline n=22, control n=21. All biopsies from the perhexiline group were 
from patients above the lower end of the therapeutic range (median 0.36mg/L, IQR 
0.24-0.58). The median spectral relative standard deviation (RSD), a benchmark to 
assess reproducibility in metabolomics (Parsons et al., 2009), for each sample 
analysed in triplicate by MS was relatively small and consistent across all samples 
(mean 11.6%, SD 1.6%). 
 
After data processing, the final intensity matrix consisted of 4039 peak intensity 
measurements for each sample. All peaks were examined using univariate statistics 
to determine if any changed intensity significantly in response to perhexiline therapy 
(table 11). No significant peak intensity changes were found with FDR 5% correction. 
 
Number of m/z 
measurements 
p value criteria 
<0.01 <0.05 <0.5 
Before FDR correction at 5% 4 19 142 
After FDR correction at 5% 0 0 0 
m/z indicates mass-to-charge ratio; FDR, false discovery rate. 
 
Table 11. m/z measurements changing significantly following Student’s t-test. 
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Multivariate PCA was used to reduce the dimensionality of the data and visualise the 
metabolic similarities and differences between groups; the PCA scores plot showed 
no differential grouping along the PC1 and PC2 axes suggesting that there was no 
metabolic response to perhexiline (figure 35). Clustering of the eight QC samples 
demonstrates the consistency in MS instrument performance over time. 
 
 
Perhexiline (□) and control (●) left ventricular extracts and quality control (x) samples. 
Figure 35. PCA scores plot from analysis of negative ion mass spectra. 
 
In addition, PLS-DA was conducted to maximise separation of the metabolic profiles. 
Control and treatment samples were minimally separated and the associated mean 
classification error rates of the model for predicting class membership were high at 
43% and 47%, respectively, again suggesting no metabolic differences between 
groups (figure 36). More than 200 m/z measurements in the FT-ICR MS dataset were 
assigned to at least one putative named metabolite including ATP, creatine, 
phosphocreatine, glycolytic and citric acid cycle intermediates (appendix 9.7). 
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Perhexiline (□) and control (●) left ventricular extracts and quality control (x) samples. 
Figure 36. PLS-DA scores plot from analysis of negative ion mass spectra. 
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6.4 Discussion 
 
The metabolic effects of perhexiline were first documented in a rat heart model and 
appear to involve a metabolic shift from β-oxidation of fatty acids to glucose utilisation 
through inhibition of CPT-1 (Kennedy et al., 1996). In patients, metabolism has been 
assessed indirectly using non-invasive (31P magnetic resonance spectroscopy) 
(Abozguia et al., 2010) and invasive (coronary sinus catheter) (Beadle et al., 2011) 
techniques to determine cardiac energetics, respiratory quotient and mechanical 
efficiency. However, the studies presented in this chapter are the first to directly 
examine the effect of perhexiline on the human myocardium. Indeed, I believe that 
this analysis of left ventricular biopsies is the first to investigate the effects of any 
drug on the human myocardium using MS metabolomics. 
 
On serum analysis, the concentration of FFA at the time of anaesthesia was found to 
be significantly higher in patients treated with perhexiline compared with controls with 
no differences in TAG, glucose, β-hydroxybutyrate or insulin. At six hours into 
reperfusion, there was no difference between groups for serum FFA or TAG but the 
concentration of TAG was seven-fold higher than pre-ischaemia. Cardiac surgery is 
known to precipitate a marked rise in FFA due to endogenous and exogenous 
catecholamine release and the administration of heparin. Exposure of the post-
ischaemic heart to high levels of FFA during reperfusion inhibits the PDH complex 
and uncouples glucose oxidation (Lopaschuk et al., 1994). The marked rise in serum 
TAG at six hours represents the lag phase of FFA release with uptake by the liver, re-
esterification and export back into the blood. Perhexiline did not appear to suppress 
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the serum surge in FFA during reperfusion and indeed, pre-ischaemia levels were 
higher than in controls. As perhexiline is a competitive inhibitor of CPT-1, any 
potential inhibition may have been reduced even before ischaemia and would almost 
certainly have been overwhelmed during reperfusion. 
 
In the atrial myocardium, there were no significant differences in pre-ischaemia 
glycogen, lactate, pyruvate, glucose-6-phosphate, triacylglycerol or phospholipid 
between groups. However, significant variation within the groups suggests that the 
concentration of metabolites is determined by factors other than perhexiline therapy, 
despite likely reaching steady-state atrial concentrations. These results concur with 
another recent study conducted in Birmingham. In a double-blind trial, cardiac 
energetics and substrate utilisation were assessed in patients with non-ischaemic 
dilated cardiomyopathy using 31P magnetic resonance spectroscopy (Beadle et al., 
2011). Perhexiline was found to significantly improve the myocardial PCr/ATP ratio 
and NYHA functional class compared with controls. However, preliminary invasive 
data suggests no improvement in efficiency or change in respiratory quotient across 
the myocardium between the aorta and the coronary sinus (Beadle, 2011). 
 
Furthermore, on studying the polar metabolome of the left ventricle prior to ischemia 
using ultra-high resolution MS, I found that the metabolic profiles of patients on 
perhexiline therapy were indistinguishable from controls. This metabolomic analysis 
demonstrates that perhexiline has no significant effect on the myocardial metabolome 
including any of the intermediates of energy transfer, glycolysis or the citric acid cycle 
(appendix 9.7). 
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The experiments presented in this chapter independently demonstrate that in 
patients with ischaemic heart disease undergoing cardiac surgery following treatment 
with perhexiline, there is no evidence of a shift in myocardial metabolism. The lack of 
upregulation of glucose pathways or cellular accumulation of lipid intermediates 
suggests that there was no significant inhibition of CPT-1 in the heart. Rather than its 
primary mechanism of action, CPT-1 inhibition may occur only after prolonged 
accumulation of the drug in the myocardium which was not evident following a short 
period of therapy; any metabolic effects of perhexiline may therefore contribute only 
to its toxic rather than its therapeutic effects. The possibility that perhexiline exerts 
anti-ischaemic effects predominantly via a CPT-independent pathway has been 
raised previously. Unger et al. (2005) observed a temporal dissociation between its 
effects on cardiac efficiency and metabolism in the rat. Other potential mechanisms 
of action include inhibition of neutrophil superoxide formation (Kennedy et al., 2006) 
and potentiation of platelet responsiveness to nitric oxide (Willoughby et al., 2002). 
 
In this chapter, I found that perhexiline does not appear to suppress the surge in 
serum FFA associated with reperfusion in cardiac surgery. I observed no significant 
difference in the concentration of any carbohydrate or lipid intermediates in the right 
atrial myocardium prior to ischaemia with perhexiline. I presented novel human data 
suggesting that treatment with perhexiline has no significant effect on the MS-visible 
polar myocardial metabolome in vivo at therapeutic serum concentrations. These 
findings support the suggestion that perhexiline acts via a pathway that is largely or 
entirely independent of myocardial CPT-1 inhibition (Unger et al., 2005). Further 
evidence is required to elucidate its mechanism of action in the human heart. 
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7. RESULTS OF THE CLINICAL TRIAL 
 
Three hundred and twenty seven patients undergoing coronary artery bypass graft 
(CABG) surgery at two centres were recruited to the trial and randomised to 
perhexiline or placebo between February 2007 and April 2010. Of these, 286 patients 
for whom data on the primary endpoint was available, were included in the analysis 
on an intention-to-treat basis: 139 in the treatment arm and 147 in the control arm. In 
the treatment arm, 98/135 (72.6%) patients were shown to be within or above the 
therapeutic range for serum perhexiline at the time of surgery; in the remaining four 
patients, it was not measured. Perhexiline was not detected in any patients in the 
control arm, confirming the difference between the groups. 
 
In this chapter, I document the clinical findings of the trial according to the primary 
and secondary endpoints as defined in the statistical analysis plan (appendix 9.5). I 
perform an exploratory analysis to examine the primary endpoint in patients above 
the lower threshold of the therapeutic range against propensity score-matched 
controls, thereby excluding those who were sub-therapeutic. I assess the impact of 
serum perhexiline concentration on cardiac index, review the safety endpoints used 
to monitor the trial and report other postoperative outcomes. Finally, I discuss the 
impact of these findings on the use of perhexiline in patients undergoing cardiac 
surgery and explore potential explanations for the results of the trial, in particular the 
potential effect of perhexiline on the pre-ischaemia cardiac index. 
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7.1 Primary outcome 
 
The primary endpoint was an episode of low cardiac output in the first six hours after 
removal of the aortic cross-clamp, defined as hypotension (mean arterial pressure < 
65mmHg) with a cardiac index < 2.2L/min/m2 in the presence of adequate filling 
pressures (CVP 8-12mmHg or PCWP 12-16mmHg) and heart rate (> 75bpm) where 
systolic blood pressure < 90mmHg and/or inotropic support  intra-aortic balloon 
pump for > 60 minutes was required to maintain such a clinical picture; this was 
adjudicated in borderline cases by a blinded endpoints committee. 
 
An episode of low cardiac output was diagnosed in 102 (35.7%) of the 286 patients 
analysed; however, there was no significant difference in incidence between the two 
groups: 51 (36.7%) in the perhexiline arm and 51 (34.7%) in the control arm (OR 
0.92, 95% CI 0.56 to 1.50, p 0.74). In the exploratory analysis, patients in the 
treatment arm who were above the lower threshold of the therapeutic range for 
serum perhexiline (≥ 0.15mg/L) at the time of surgery were compared with propensity 
score matched controls (n=97 in each group) (table 12). There was no significant 
difference in the incidence of low cardiac output episodes in these groups: 38 
(39.2%) in the perhexiline arm and 31 (32.0%) in the control arm (OR 0.73, 95% CI 
0.40 to 1.33, p 0.30). A further analysis was performed to assess the effect of 
perhexiline on the incidence of an episode of low cardiac output in several 
prespecified sub-groups and found no significant heterogeneity between groups 
(figure 37). 
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0.2 0.5 1 2 5
Logistic EuroSCORE > 4 0.74 (0.21, 2.64)
Urgent surgery 1.33 (0.40, 4.47)
LVEF < 50% 1.00 (0.30, 3.35)
Age > 70 years 0.70 (0.32, 1.52)
Serum perhexil ine > 0.15mg/L 0.73 (0.40, 1.33)
Overall 0.92 (0.56, 1.50)
 Control (n=97) Perhexiline (n=97) 
Age (years), median (IQR) 65 (59-72) 66 (60-73) 
Weight (kg), median (IQR) 80 (72-88) 80 (72-88) 
Serum perhexiline (mg/L), median (IQR) 0 0.39 (0.23-0.56) 
Left ventricular function, n (%)   
 Good, ≥ 50% 79 (81.4) 81 (83.5) 
 Moderate, 30-49% 17 (17.5) 15 (15.5) 
 Poor, <30% 1 (1.0) 1 (1.0) 
Urgent surgery, n (%) 14 (14.4) 12 (12.4) 
 
Table 12. Propensity score-matched groups for exploratory analysis. 
 
 
 Odds ratio (95% CI) 
 
 
 
 
 
 
 
 
 ← Favours placebo Favours perhexiline → 
 
Figure 37. Forest plot for sub-group analyses of the primary outcome. 
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7.2 Secondary outcomes 
 
7.2.1 Cardiac Index 
Cardiac output was measured before ischaemia and at intervals following release of 
the aortic cross-clamp using a pulmonary artery catheter and indexed to body surface 
area (figure 38). At six hours following reperfusion, the mean cardiac index was 
significantly lower in the perhexiline group (2.51L/min/m2, SD 0.43) than in the control 
group (2.70L/min/m2, SD 0.54) (Difference in Means 0.17, 95% CI 0.05 to 0.29, p 
0.005). By 12 hours, there was no difference between the groups: 2.73L/min/m2 (SD 
0.54) in the perhexiline arm versus 2.79L/min/m2 (SD 0.48) in the control arm (DiM 
0.58, 95% CI -0.06 to 0.18, p 0.34). 
 
 
Figure 38. Mean cardiac index during the period of haemodynamic monitoring. 
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Pre-ischaemia Control (n=145) Perhexiline (n=135) DiM (95% CI) p value 
Heart rate (beats/min) 58 (10.8) 56 (9.0) 1.94 (-0.41-4.28) 0.11 
CVP (mmHg) 11 (3.9) 10 (3.9) 0.92 (-0.003-1.83) 0.05 
PAWP (mmHg) 13 (4.4) 12 (4.3) 1.08 (0.06-2.10) 0.04 
MAP (mmHg) 74 (10.2) 72 (9.3) 1.79 (-0.52-4.09) 0.13 
Cardiac index (L/min/m
2
) 2.31 (0.53) 2.09 (0.57) 0.22 (0.09-0.35) 0.001 
 
6 hours of reperfusion Control (n=144) Perhexiline (n=135) DiM (95% CI) p value 
Heart rate (beats/min) 94 (7.4) 93 (6.9) 0.61 (-1.08-2.30) 0.48 
CVP (mmHg) 9 (3.0) 9 (3.4) -0.19 (-0.94-0.55) 0.61 
PAWP (mmHg) 10 (3.4) 9 (3.2) 0.77 (0-1.55) 0.05 
MAP (mmHg) 71 (7.7) 72 (8.7) -1.02 (-2.96-0.92) 0.30 
Cardiac index (L/min/m
2
) 2.70 (0.54) 2.51 (0.43) 0.17 (0.05-0.29) 0.005 
 
12 hours of reperfusion Control (n=142) Perhexiline (n=135) DiM (95% CI) p value 
Heart rate (beats/min) 93 (7.9) 93 (6.9) 0.54 (-1.23-2.31) 0.55 
CVP (mmHg) 9 (3.1) 8 (2.9) 0.56 (-0.17-1.24) 0.14 
PAWP (mmHg) 10 (3.0) 9 (2.9) 0.43 (-0.26-1.12) 0.22 
MAP (mmHg) 74 (9.2) 73 (9.5) 0.56 (-1.65-2.77) 0.62 
Cardiac index (L/min/m
2
) 2.79 (0.48) 2.73 (0.54) 0.58 (-0.06-0.18) 0.34 
CVP, central venous pressure; PAWP, pulmonary artery wedge pressure; MAP, mean arterial pressure. 
 
 
Table 13. Haemodynamic variables before and after ischaemia/reperfusion. 
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However, the cardiac index measured prior to ischaemia was also found to be 
significantly lower in the perhexiline group (2.09L/min/m2, SD 0.57) than the control 
group (2.31L/min/m2, SD 0.53) (DiM 0.22, 95% CI 0.09 to 0.35, p 0.001). Using 
repeated-measures with pre-ischaemia cardiac index as a covariate, cardiac index 
was not significantly affected by perhexiline therapy, F (3.57, 896.9) = 1.02, p 0.40. 
No significant relationship between serum perhexiline concentration and pre-
ischaemia cardiac index was observed on univariate analysis (β -0.05, 95% CI -0.30 
to 0.20, p 0.69). There was little difference between the groups in terms of heart rate, 
filling pressures (CVP and PAWP) or afterload (MAP); there was a trend towards 
lower filling pressures in the perhexiline group but this was statistically significantly 
(p≤0.05) only for the PAWP pre-ischaemia and at six hours (table 13). 
 
7.2.2 Inotrope usage after reperfusion 
The use of inotropic support in the perioperative period was indicated if the cardiac 
index remained < 2.2L/min/m2 despite correction of other haemodynamic variables to 
within predetermined limits according to the trial protocol, although the decisions on 
commencement and escalation of inotropes were ultimately at the discretion of the 
clinical team. There was no difference in the prevalence of inotropic support in the 
first six hours after reperfusion: perhexiline 39/139 (28.1%) versus control 36/147 
(24.5%) (OR 0.84, 95% CI 0.49 to 1.44, p 0.52). However, by 12 hours, inotrope use 
was significantly more frequent in the perhexiline group (67, 48.2%) versus the 
control group (50, 34.0%) (OR 0.55, 95% CI 0.34 to 0.89, p 0.015). Of note, there 
were no differences between groups in the dose requirements for phenylepherine (p 
0.26), noradrenaline (p 0.12) or insulin (p 0.43) in the first 12 hours. 
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7.2.3 Serum troponin-T and ECG evidence of new myocardial injury 
Troponin-T is an established marker of irreversible myocyte necrosis and a valuable 
predictor of complications after cardiac surgery. ECG changes are common although 
the appearance of new pathological Q waves is suggestive of myocardial infarction. 
In this trial, there was no difference between groups in peak troponin-T concentration 
in the first 24 hours: 0.78ng/ml (SD 0.71) in the perhexiline patients versus 0.89ng/ml 
(SD 0.92) in the control patients (DiM 0.11, 95% CI -0.09 to 0.30, p 0.28). Similarly, 
there was no difference in the number of patients in the highest quintile of peak 
troponin-T (≥1.18ng/ml): 25/134 (18.7%) in the perhexiline group versus 32/143 
(22.4%) in the control group (p 0.46). There was also no significant difference in area 
under the concentration-time curve in the first 24 hours between groups: perhexiline 
3.98ng.hr/ml (SD 3.79) versus control 4.71ng.hr/ml (SD 5.32) (p 0.12) (figure 39). 
 
 
Figure 39. Mean concentration-time curves for the release of troponin-T. 
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There was no difference in the frequency of ECG changes consistent with new 
myocardial injury: 23/139 (16.6%) in the perhexiline arm versus 25/147 (17.0%) in the 
control arm (OR 1.02, 95% CI 0.55 to 1.92, p 0.94); nor the composite endpoint of a 
rise in troponin-T or ECG evidence of injury: 50/139 (36.0%) in the perhexiline arm 
versus 55/147 (37.4%) in the control arm (OR 1.06, 95% CI 0.65 to 1.73, p 0.82). 
 
7.2.4 Length of stay 
There was no significant difference in mean length of stay on the Intensive Care Unit 
between the perhexiline group (102 hours, SD 150) and the control group (105 hours, 
SD 134) (DiM 3.37, 95% CI -29.9 to 36.7, p 0.84). Likewise, there was no difference 
in mean hospital length of stay: perhexiline 9.2 days (SD 6.9) versus control 9.9 days 
(SD 9.8) (DiM 0.73, 95% CI -1.27 to 2.73, p 0.47). 
 
 
  
182 
 
7.3 Safety outcomes 
 
The safety of the trial was reviewed at regular intervals by the Data & Safety 
Monitoring Board (DSMB). The primary and secondary endpoints were evaluated in 
addition to Serious Adverse Events: death; stroke; renal replacement therapy; and 
any additional surgical procedures, including chest reopening but with the exception 
of tracheostomy. A non-symmetrical power function was used to increase likelihood 
of stopping early for harm. Following all three scheduled DSMB meetings, the board 
were content for the trial to continue as planned. No extraordinary DSMB meetings 
were held and the overall frequency of SAEs during the trial is shown in table 14. 
 
 Control (n=147) Perhexiline (n=139) 
Death, n (%) 2 (1.4) 2 (1.4) 
Stroke, n (%) 1 (0.7) 3 (2.2) 
Renal replacement therapy, n (%) 2 (1.4) 3 (2.2) 
Chest reopening follow surgery, n (%) * 13 (8.8) 9 (6.5) 
 Bleeding, n (%) 11 (7.5) 6 (6.5) 
 LCOE/tamponade, n (%) 1 (0.7) 1 (0.7) 
 Arrest, n (%) 1 (0.7) 2 (1.5) 
 Use of CPB, n (%) 1 (0.7) 1 (0.7) 
Other operation, n (%) 1 (0.7) 0 
LCOE, low cardiac output episode; CPB, cardiopulmonary bypass. * Not significant Fisher’s exact test. 
 
Table 14. Frequency of serious adverse events reported during the trial. 
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7.4 Other outcomes 
 
 Control (n=147) Perhexiline (n=139) 
Neurological injury   
 Type I – stroke or TIA, n (%) 2 (1.4) 3 (2.2) 
 Type II e.g. confusion, disorientation, n (%) 10 (6.8) 15 (10.8) 
Any respiratory complication, n (%) 34 (23.1) 33 (23.7) 
Pneumonia, n (%) 14 (9.5) 15 (10.8) 
Reintubated, n (%) 4 (2.7) 2 (1.4) 
Tracheostomy, n (%) 4 (2.7) 4 (2.9) 
Peak creatinine (µmol/L), median (IQR) 102 (90-119) 109 (94-128) 
AKIN score for change in renal function   
 0 126 (85.7) 121 (87.1) 
 1 16 (10.9) 13 (9.4) 
 2 0 2 (1.4) 
 3 5 (3.4) 3 (2.2) 
Any abdominal complication, n (%) 4 (2.7) 5 (3.6) 
Gastrointestinal bleed, n (%) 2 (1.4) 2 (1.4) 
Prolonged paralytic ileus, n (%) 2 (1.4) 0 
Any treated infective episode, n (%) * 25 (17.0) 27 (19.4) 
Sternal wound infection   
 Superficial infection/dehiscence, n (%) 4 (2.7) 5 (3.6) 
 Deep infection requiring surgery, n (%) 1 (0.7) 0 
Leg wound complication, n (%) 7 (4.8) 2 (1.4) 
Atrial fibrillation/flutter, n (%) * 66 (44.9) 55 (39.6) 
Chest tube drainage at 12 hours (ml), mean (SD) 704 (448) 700 (498) 
Transfusion of blood (units), mean (SD) 2.0 (2.6) 2.3 (2.6) 
Discharge destination   
 Home, n (%) 138 (93.9) 130 (93.5) 
 Convalescence, n (%) 6 (4.1) 5 (3.6) 
 Other hospital or department, n (%) 1 (0.7) 2 (1.4) 
TIA, transient ischaemic attack; AKIN, Acute Kidney Injury Network * Not significant Fisher’s exact test 
 
Table 15. Postoperative outcomes and complications. 
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7.5 Discussion 
 
In this prospective, double-blind, randomised, placebo-controlled trial conducted at 
two centres in the United Kingdom, preoperative administration of oral perhexiline to 
patients undergoing non-emergent surgical revascularisation on cardiopulmonary 
bypass with cold blood cardioplegic arrest did not improve clinical markers of 
myocardial protection. The recruitment target of at least 280 patients randomised in a 
1:1 ratio to perhexiline or placebo was met. There was no difference in the primary 
outcome, the incidence of a low cardiac output episode and this lack of effect 
persisted once patients with a sub-therapeutic serum perhexiline concentration were 
removed from the analysis. With the exception of cardiac index at six hours, no 
significant differences were seen for the secondary endpoints, safety outcomes or 
other postoperative variables. 
 
Cardiac output is the product of heart rate and stroke volume, which itself is 
determined by preload, afterload and contractility; by clinically optimising heart rate, 
filling pressures and mean arterial pressure, cardiac index becomes a surrogate 
measure of contractility. Therefore, any divergence in cardiac index between the 
groups following ischaemia-reperfusion should reflect the degree of clinical recovery 
of myocardial function and stunning. A significant difference in cardiac index at six 
hours, a secondary endpoint, was found but favoured the control group. A similar 
difference in cardiac index was present pre-ischaemia and once this was taken into 
account as a covariate in ANOVA, the difference at six hours became non-significant. 
Whilst the other haemodynamic variables (heart rate, CVP and MAP) were within 
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protocol limits, pulmonary artery wedge pressure (PAWP) was consistently a mean of 
9-10mmHg in both groups, below the generalised, pre-defined target range of 12-
16mmHg; there was a statistically significant difference in PAWP at six hours but this 
is unlikely to have been clinically important as the difference in means was only 
1mmHg. The observation that the difference in cardiac index between groups was 
present pre-ischaemia suggests two possibilities: 
 
The difference in cardiac index was due to chance, bias or confounding.  
Countering this argument are the strength of the statistical findings and aspects of 
study design intended to enhance validity. The low p value of 0.001 means that there 
is 1 in 1000 probability that the observed difference between the groups is due to 
chance; a large number of patients (n=286) were entered into the trial and the 
baseline demographics of the two groups appear similar. To avoid selection bias and 
confounding factors, patients were randomly allocated using minimisation, an 
adaptive stratified sampling method to reduce imbalance; this included left ventricular 
function although it was not precisely quantified on echocardiogram prior to 
commencing trial therapy. Cardiac output was measured using a validated, 
reproducible technique, other physiological variables determining cardiac output were 
actively controlled and both trial participants and investigators were blinded to 
address measurement bias. The trial was analysed on an intention-to-treat basis, 
including all 286/294 (97.3%) patients who started the IMP in whom the primary 
endpoint was available, in order to reduce analysis bias. Perhaps most importantly, 
no difference between groups was observed for the primary endpoint, other 
secondary outcomes, safety endpoints or any other postoperative variable. 
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The difference in cardiac index was due to a negative inotropic effect of perhexiline.  
Despite a weak calcium channel inhibitory effect (Horowitz et al., 1986), perhexiline 
has not previously been found to be negatively inotropic although no previous studies 
involved anaesthesia or surgery. In a working rat heart model, Unger and colleagues 
(2005) demonstrated that pre-exposure to perhexiline led to a significant increase in 
heart rate (20%, p<0.05), cardiac output (31%, p<0.01) and cardiac work (29%, 
p<0.05). In a randomised controlled trial of short-term perhexiline therapy in patients 
with chronic heart failure, Lee et al. (2005) found improvements in left ventricular 
ejection fraction and resting/peak stress myocardial function. Recent data from our 
department using magnetic resonance and echocardiography to assess the effect of 
perhexiline in patients with non-ischaemic cardiac failure has also shown an 
improvement in cardiac energetics but not ventricular function (Beadle, 2011). 
Furthermore, if perhexiline was responsible for reducing cardiac output in the study 
population, it would be expected to be exposure-dependent but no correlation was 
observed between serum perhexiline concentration and pre-ischaemia cardiac index. 
High levels of serum FFA are known to reduce cardiac efficiency (Murray et al., 2004) 
and as shown in the previous chapter, FFA concentrations prior to ischaemia were 
significantly higher in the perhexiline group (0.75mmol/L, SD 0.08) than in the control 
group (0.50mmol/L, SD 0.08). However, on linear regression, serum FFA did not 
predict pre-ischaemia cardiac index (R2 0.09, F-ratio 3.28, p 0.08). 
 
A convincing explanation for the finding of a lower mean pre-ischaemia cardiac index 
with perhexiline remains elusive. Cardiac index remained lower in the perhexiline 
group at six hours but by 12 hours, the difference was lost. This late convergence 
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may be explained by a higher frequency of inotrope use in the perhexiline group. The 
two outcomes are not independent as institution of inotropic support was prompted 
by a low cardiac index and its use leads to an elevation in the observed contractility; 
the increased use of inotropes between six and 12 hours may have been a delayed 
response to the nadir in cardiac index around six hours (figure 38). 
 
The release of troponin-T was consistently lower in the perhexiline group when 
assessed by peak value, number of patients in the highest quintile, repeated-
measures ANOVA and area under the concentration-time curve; however, none of 
these measures were significant. A previous trial of myocardial protection in our 
department (REMOTE) was powered to detect a reduction in AUC for troponin-T in a 
similar cohort of patients and required 120 subjects (Rahman et al., 2010). Therefore, 
it is unlikely that the failure to reach significance for troponin-T in this trial was due to 
it being underpowered. All other secondary endpoints demonstrated no significant 
difference between groups including predefined safety outcomes (table 14) or other 
complications (table 15). 
 
In the trial protocol, all outcome measures reflected potential differences between the 
groups in the early postoperative period and data collection was completed upon 
death or discharge from the Department of Cardiothoracic Surgery. It did not address 
any long-term benefits that perioperative perhexiline may bestow upon ventricular 
dysfunction. Whilst the trial was not designed to measure long-term outcomes, any 
significant effect on myocardial protection would seem unlikely given that no 
advantage was discernible in the early postoperative period. 
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This study is the first high quality, adequately-powered trial to examine the role of a 
preoperative oral direct metabolic modulator on clinical outcomes of ischaemia-
reperfusion in the setting of myocardial protection during cardiac surgery. Our 
previous trial of GIK in patients undergoing CABG used a similar perioperative 
protocol and outcome measures but found higher cardiac indices, a lower incidence 
of LCOE, lower inotrope usage and reduced early release of troponin in the treatment 
group (Quinn et al., 2006); these findings supported the results of two meta-analyses 
which found an improvement in perioperative haemodynamics in patients treated with 
GIK (Bothe et al., 2004, Fan et al., 2011). In this trial, perhexiline failed to improve 
any of the clinical markers of recovery in myocardial function after cardioplegic arrest. 
Our findings do not support the use of preoperative perhexiline as an adjunct to 
myocardial protection in patients undergoing coronary artery bypass graft surgery. 
 
In this chapter, I reported the clinical results of the CASPER trial, including a 
statistical analysis of the primary, secondary, safety and other outcomes. I 
demonstrated that the lack of effect of perhexiline was not influenced by patients who 
failed to reach the lower threshold of the therapeutic range using propensity score-
matched controls. I also found that serum perhexiline concentration had no direct 
impact on cardiac index either before or after ischaemia-reperfusion. I discussed the 
endpoint analysis but failed to explain why the pre-ischaemia cardiac index was 
significantly lower in the perhexiline group. In the final chapter of my thesis, I will 
draw together the results of the clinical trial with those of preceding chapters to 
present a coherent biological argument on why the trial proved negative. 
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8. CONCLUSIONS 
 
‘Surgery of the heart has probably reached the limits set by nature to all 
surgery; no new method, and no new discovery, can overcome the natural 
difficulties that attend a wound of the heart.’ 
(Paget, 1896) 
 
Over the last sixty years, cardiac surgery has evolved; it is no longer an 
experimental, last-ditch option for fatal diseases performed by courageous pioneers 
(Miller, 2000); it has progressed through the age of discovery, when artificial valves 
were crafted in the garage or hand-sewn at the kitchen table (Starr, 1986); and it has 
seen the industrial revolution of coronary surgery to successfully treat the twentieth 
century epidemic of ischaemic heart disease in the developed world. Today cardiac 
surgery offers widely-accessible, reproducible, evidence-based and increasingly safe 
treatment options. It drives a global market of multi-billion dollar companies producing 
a range of precision engineered products that have been implanted millions of times 
(Gott et al., 2003). Surgical revascularisation remains the gold-standard for the 
treatment of multi-vessel coronary artery disease (Kolh et al., 2010) whilst advances 
in transplantation, mechanical assist and surgery for congenital heart disease offer 
improving survival for otherwise incurable conditions. But even 116 years after 
Paget’s premature epitaph for the speciality, significant challenges remain across the 
spectrum of cardiac surgery. Myocardial protection research was vogue in the early 
decades but with the advent of effective cardioplegia, enthusiasm cooled. The 
changing scope of surgical procedures and demographics of the patients has made it 
clear that this is not a problem solved; preserving the ischaemic heart remains an 
important discipline of scientific endeavour. 
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In this thesis, I have traced the historical development of cardiac surgery and the 
quest for effective myocardial protection. I have outlined the metabolic pathways that 
produce cellular energy, their substrates and regulators. I have explored the rapidly 
evolving field of ischaemia-reperfusion injury and the development of protective 
strategies from hypothermia to cardioplegia to ischaemic conditioning. I have 
evaluated the clinical use of metabolic therapies with a systematic review of the 
literature. I have recalled the troubled story of perhexiline, its long road to redemption 
and its potential role in myocardial protection. And I have drawn together hypotheses 
to examine its pharmacokinetics in the heart, directly elucidate its metabolic effects in 
humans and test its novel clinical application in patients undergoing cardiac surgery. 
 
In this final chapter, I focus on my hypotheses and review the evidence generated in 
this thesis to assess whether they can be supported or refuted. I draw conclusions 
from each of the experiments performed to determine how this work adds to the 
literature on perhexiline and its application to myocardial protection during cardiac 
surgery. I reflect on my experience of conducting a randomised controlled trial and 
discuss the limitations of the clinical and laboratory experiments presented. Finally, I 
present areas of future study, building on the foundation of this thesis to adapt the 
concepts and techniques gained to address new research questions. 
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8.1 The pharmacokinetics of perhexiline 
 
‘At least 80% of patients will be within the therapeutic range for serum perhexiline at 
the time of surgery with a standard dosing regimen of 200mg bis die for three days 
then 100mg bis die until surgery (Chapter 4). Patients may fall outside of the 
therapeutic range due to variable metabolism, side-effects or non-compliance.’ 
 
At the time of surgery, only 72.6% of patients in the treatment group were above the 
lower threshold of the therapeutic range for serum perhexiline, despite following 
expert advice on the optimal loading and maintenance dosing regimen. High inter-
individual variation in the metabolism of perhexiline was one factor, with all of the 
ultra-rapid metabolisers found to be sub-therapeutic (6.8%). Some patients had either 
known or suspected non-compliance with therapy (6.5%), often due to dosing errors 
or side-effects, particularly in the poor metabolisers. A small proportion of patients 
(7.7%) had less than five days of therapy and three (2.2%) had long finished the IMP 
by the time of their delayed surgery. However, in the remaining patients, there was 
no clear explanation for falling below the therapeutic range. 
 
‘Perhexiline is more concentrated in the human myocardium than in the serum 
reflecting cumulative drug uptake and tissue loading as previously shown in the rat 
heart (Chapter 5). Serum and myocardial levels will be closely correlated but may be 
reduced by insufficient time to reach steady-state or high serum concentrations with 
saturation pharmacokinetics.’ 
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The experiments conducted during my research fellowship in Adelaide are the first to 
measure the myocardial concentration of perhexiline in humans. I confirmed that 
perhexiline is highly concentrated in the atrial and ventricular myocardium of patients. 
There was a strong correlation with serum levels but other factors such as heart rate 
and age may modulate drug uptake and accumulation. The ventricular concentration 
was significantly higher than that in the atrium suggesting that contractile work may 
also affect compartmentalisation. However, it appears not to have reached steady-
state by the time of surgery and this may have impacted on any metabolic effects and 
therefore any potential benefit in myocardial protection. 
 
‘The concentration of perhexiline in the myocardium following at least one week of 
therapy will be sufficient to significantly inhibit CPT-1 corresponding to the inhibitory 
concentrations observed in the rat heart (Chapter 5).’ 
 
Despite apparently not reaching steady-state, the level achieved in the left ventricular 
myocardium appears to have been in the correct order of magnitude for CPT-1 
inhibition according to the studies in the rat heart by Kennedy et al. (1996, 2000). 
However, CPT-1 inhibition may not represent a clinically important mechanism of 
action in the human myocardium even at steady-state and therapeutic plasma levels. 
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8.2 The metabolic effects of perhexiline 
 
‘Improved metabolic efficiency with perhexiline will be reflected by changes in the 
myocardial metabolic profile favouring glucose metabolism and glycolytic flux through 
pyruvate to enter the citric acid cycle (Chapter 6). The short length of therapy will 
bring the benefits of CPT inhibition on metabolic efficiency without the potential risks 
of lipid accumulation caused by long-term inhibition of β-oxidation.’ 
 
On analysis of myocardial biopsies obtained from patients during the trial, using both 
traditional biochemical techniques and state of the art FT-ICR MS metabolomics, I 
found no evidence for a metabolic switch from fatty acids to glucose with perhexiline. 
There was neither an increase in carbohydrate intermediates nor lipid accumulation 
within the myocardium. Indeed, the polar negative ion metabolomic profiles of 
patients on perhexiline and placebo were indistinguishable; perhexiline had no 
significant effect on the myocardial metabolome including the intermediates of energy 
transfer, glycolysis or the citric acid cycle. This lack of upregulation in glucose 
metabolism may account for the absence of clinical benefit in myocardial protection 
and suggests that the mechanism of action of perhexiline in vivo in humans may not 
be primarily metabolic. These findings are supported by recent data from another 
double-blind trial in Birmingham in which no difference in cardiac efficiency or 
respiratory quotient across the myocardium was found following four weeks of dose-
adjusted perhexiline therapy (Beadle, 2011). 
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It is conceivable that CPT inhibition may be responsible for the side-effects and long-
term toxicity of perhexiline rather than its therapeutic anti-ischaemic effects. A chronic 
rise in the tissue perhexiline concentration may lead to progressive inhibition of β-
oxidation and accumulation of TAG, phospholipids and other products of fatty acid 
metabolism, including the pro-apoptotic ceramide. Lipotoxicity is known to have 
deleterious effect on cardiac function and has been implicated in the pathogenesis of 
diabetic cardiomyopathy (Brindley et al., 2010). Whilst it was reassuring to find that 
there was no rise in myocardial lipid content in the trial, the maximum length of 
therapy was only 31 days. For patients undergoing cardiac surgery at least, the 
promise of short-term gain without long-term risk from perhexiline therapy was 
obviated by the lack of actual clinical benefit. 
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8.3 The role of perhexiline in myocardial protection 
 
‘Preoperative oral loading with perhexiline maleate as an adjunct to cold blood 
cardioplegia during ischaemic arrest in patients undergoing CABG will improve 
markers of myocardial protection (Chapter 7). This will be reflected by a decreased 
incidence of low cardiac output episodes, reduced need for inotropic support and 
lower release of troponin in the perioperative period compared with controls. Cardiac 
indices will also be higher in the perhexiline group prior to ischaemia.’ 
 
In the CASPER trial, preoperative administration of oral perhexiline as an adjunct to 
cold blood cardioplegia failed to improve any of the clinical markers of myocardial 
protection, providing no evidence to support its routine use in patients undergoing 
non-emergent coronary artery bypass graft surgery. Perhexiline has been shown to 
be an effective agent in the treatment of angina pectoris (Cole et al., 1990) and heart 
failure (Lee et al., 2005) but appears to offer no protection against the detrimental 
effects of ischaemia-reperfusion. The only previous study of perhexiline in this setting 
found improvement in diastolic dysfunction during ischaemia but similarly no benefit 
in recovery of systolic function on reperfusion in a rat model (Kennedy et al., 2000). 
 
So why was the CASPER trial a negative trial? A large number of patients were 
recruited (n=286) and it was adequately powered to detect its primary and secondary 
endpoints but found absolutely no difference between groups (OR 0.92, 95% CI 0.56-
1.50, p 0.74). An exploratory analysis with propensity score-matched controls 
confirmed that the finding was not significantly weakened by sub-therapeutic patients. 
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The mean pre-ischaemia cardiac index was found to be lower in the treatment group 
but even when taken into account, there was no difference in postoperative 
myocardial contractility. It is apparent that perhexiline did not significantly inhibit CPT-
1 at the time of surgery in these patients either due to not reaching steady-state in 
the ventricular myocardium or because that is not its mechanism of action; no change 
was demonstrated in myocardial metabolism prior to ischaemia using two different 
biochemical approaches. Any potential inhibition of CPT-1 may have been negated 
by the higher serum FFA levels prior to ischaemia in the perhexiline group. In any 
case, this would almost certainly have been overcome by the surge of FFA entering 
the myocardium on reperfusion which was not suppressed by perhexiline therapy, 
evidenced by the similarly raised TAG profiles at six hours. 
 
In conclusion, this trial does not detract from the principal that metabolic drugs have a 
role in improving myocardial protection during cardiac surgery rather perhexiline is 
not such an agent. In contrast, GIK has multiple metabolic and non-metabolic actions 
including increased availability of glucose, suppression of plasma fatty acids during 
reperfusion and activation of pro-survival pathways. The search for a metabolic agent 
with similar efficacy to insulin but without its limitations continues. 
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8.4 Reflections on conducting a clinical trial 
 
The CASPER trial was a phase III clinical trial intended to demonstrate a therapeutic 
benefit, confirm the safety of perhexiline in patients undergoing cardiac surgery and 
provide another ‘new trick for an old drug’ (Frenneaux, 2002). The trial design, 
endpoints and power were derived from previous local trials of GIK, an agent with a 
long history of use in myocardial protection that had been successful, positive and 
published. In retrospect, it would have been prudent to have first conducted proof-of-
concept studies with non-clinical endpoints; these could have included an animal 
model of ischaemia-reperfusion building upon the initial work of Kennedy et al. 
(2000). If these preliminary studies had demonstrated biologically plausible benefits, 
they should have been followed by a phase II study to improve dosing of patients to 
achieve therapeutic serum levels, explore its use in patient sub-groups such as those 
with diabetes and provide endpoint data to enable a validated power calculation 
based on the same drug in the same circumstances. It is likely that these studies 
would have led to the same conclusion as the multi-centre trial but perhaps at greater 
efficiency of time, money, effort and patient participation. 
 
8.4.1 Recruitment 
The conduct of a clinical trial is a complex process and unanticipated difficulties are 
likely to arise in every trial. Recruitment is a common problem; most publically funded 
trials fail to meet their original recruitment target (Campbell et al., 2007), requiring 
either an extended recruitment period or reconsideration of variables in the power 
calculation (Carter, 2004). Projected recruitment may have been unconsciously 
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overambitious in order to secure funding whilst procedural delays may be protracted 
and beyond the researchers’ control. Poor recruitment may increase the probability of 
a type II error, increase costs due to extending the period of the trial, and prolong 
uncertainty over the effectiveness of the treatment (Watson and Torgerson, 2006). 
Recruitment efficiency may be improved by the establishment of a research network 
with experienced clinical and management personnel, familiarity with trial processes, 
a programme of education for trialists and an awareness of the existence and 
limitations of the pool of potential trial participants (Barnard et al., 2010). 
 
The CASPER trial is the largest randomised controlled trial in cardiac surgery to have 
been conducted at our institution and the first to involve another centre. However, 
recruitment of patients represented a major challenge and was constrained by the 
throughput of suitable cases. The MESSAGE trial took 32 months to recruit 280 
patients undergoing CABG with six Consultant Surgeons from 2000 to 2002 (Quinn 
et al., 2006). However, the number of patients undergoing CABG in the department 
has been gradually declining over the subsequent decade from 569 in 2000, to 468 in 
2006 and now to 318 in 2010; amongst these, the proportion of patients with diabetes 
increased from 19.6% in 2000 to 25.4% in 2010 (Barnett, 2011). Initially only four of 
the six Surgical Consultants agreed to contribute patients due to simultaneous trials 
recruiting patients undergoing CABG within the department (Rahman et al., 2010); 
later two more Consultants, one newly appointed, agreed to collaborate. 
 
Of the 564 patients who fulfilled the inclusion/exclusion criteria, only 286 (50.7%) 
progressed through to be included in the final analysis. The major reason was that 
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148 (26.2%) suitable patients undergoing heart surgery declined to participate in a 
trial that aimed to make their surgery safer. There are many reasons why patients 
refuse to participate in trials including inconvenience, financial and protocol issues 
(Brintnall-Karabelas et al., 2011). However in the year prior to commencing the 
CASPER trial, a catastrophic incident related to a drug trial in the UK was widely 
reported. During a phase I safety trial at Northwick Park Hospital in London, all six 
healthy volunteers administered TGN1412, a monoclonal antibody, rapidly developed 
multi-organ failure and required admission to Intensive Care (Boseley, 2006). The 
negative publicity surrounding drug trials per se at this time is likely to have made 
patient recruitment more difficult. Indeed, perhexiline itself has a chequered history 
and was once withdrawn on safety grounds (Shah, 2006). On searching Google with 
the term perhexiline, the highest ranked webpage is a Wikipedia (2011) article in 
which the first paragraph states: 
‘It was outlawed in many countries due to its adverse effects...’ 
 
Despite being the fifth randomised controlled trial on myocardial protection to be 
undertaken at QEH, Birmingham, this trial was the first to require intervention prior to 
arrival in the anaesthetic room; previous trials had used either an infusion of GIK 
(MESSAGE, MESSAGE-2, HINGE) or inflation of a blood pressure cuff (REMOTE) to 
induce metabolic or ischaemic preconditioning, respectively. A lower recruitment rate 
in the CASPER trial may have been expected as it required the active participation of 
patients to take the IMP at home prior to surgery rather than the passive engagement 
of an additional infusion whilst under anaesthesia. It soon became clear that this trial 
would take longer than the 3 years of secured funding to complete at a single site. 
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There are several centres in the West Midlands who could have been approached to 
form a local research network. However, from May 2008, discussions took place to 
expand the trial to a second site at RSCH, Brighton; whilst geographically distant, two 
of the Consultants in Brighton had trained in Birmingham and were familiar with the 
MESSAGE trials. Following a visit in late 2008, I submitted a substantial amendment 
to obtain ethical, MHRA, sponsor and local NHS Trust approval to expand the trial. 
Recruitment began at the new site in March 2009 and the first patient underwent 
surgery the following month. I made numerous visits to Brighton during the trial, 
attending preliminary meetings and collecting data on the first two patients. Over the 
next 12 months, local recruitment was coordinated by two research nurses; however, 
only 15 patients were successfully recruited and proceeded through to analysis. 
Figure 40 illustrates the number of patients recruited from the two centres during 
each month of the trial and table 16 documents the contribution of each Consultant. 
 
 
 
 
 
 
 
 
 
 
Figure 40. Number of patients in the trial undergoing surgery each month. 
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Centre Consultant Cases Months Cases/month 
QEH Pagano, D 78 36 2.17 
 Rooney, SJ 68 38 1.79 
 Graham, TR 54 38 1.42 
 Wilson, IC 38 38 1.00 
 Mascaro, CJG 28 16 1.75 
 Dandekar, U 5 6 0.83 
RSCH Lewis, ME 10 12 0.83 
 Hyde, JAJ 4 6 0.66 
 Cohen, AS 1 3 0.33 
Both sites All Consultants 286 38 7.53 
QEH, Queen Elizabeth Hospital, Birmingham; RSCH, Royal Sussex County Hospital, Brighton. 
 
Table 16. Patients completing the trial contributed by each Consultant Surgeon. 
 
8.4.2 Investigational Medicinal Product 
In Birmingham, several issues slowed the progress of the trial. There were delays in 
obtaining perhexiline from Australia; a large batch of matching placebo tablets were 
already available in the UK but it took more than three months for the IMP tablets to 
be imported, undergo testing and QP release, be bottled and labelled according to 
the randomisation code and be available for allocation, delaying the start of the trial. 
As perhexiline has a shelf-life of 24 months (Sigma Pharmaceuticals, 2009), two 
further batches of tablets had to be ordered during the trial; whilst hold-ups in this 
process never halted recruitment once underway, it was outside of our control. 
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8.4.3 Clinical scheduling of cases 
The scheduling and rescheduling of patients for surgery presented many difficulties. 
The allocation of patients to forthcoming operating lists often changed for clinical, 
logistic, bureaucratic, social or other unknown reasons. Naturally, some patients had 
their surgery expedited due to a change in their clinical condition. However, patients 
were often scheduled at short notice to cover gaps on operating lists; this led to the 
loss of several randomised patients from the trial and many others who may have 
considering participating (48, 8.5% of suitable patients). It also meant that I had to 
contact some patients regarding a decision on participation and deliver the IMP to 
their homes so that they could start the tablets that day to enable inclusion with at 
least five days of therapy prior to surgery. On the other hand, last minute 
cancellations led to the frequent issuing of a second bottle of tablets to provide a 17-
day extension to the window of IMP therapy. Alas, five patients had their surgery 
delayed beyond (or indeed well beyond) this period, meaning that they were no 
longer taking the IMP at the time of surgery but had to be included on an intention-to-
treat basis; three of these patients were in the perhexiline arm. This situation arose 
due to the limited period of therapy defined in the protocol, driven by a lack of locally 
available therapeutic monitoring, combined with recurrent scheduling difficulties. 
 
In addition, the NHS Trust introduced a four-month waiting list initiative, as part of a 
government drive to reduce waiting times in 2007. As these cases were performed at 
a private hospital which fell beyond the ethical, regulatory and sponsor approval for 
conducting the trial, any patients conscripted to this initiative were lost; unfortunately, 
this removed 25 suitable patients, five of whom had already been randomised. 
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These hindrances reflect the administrative constraints of the NHS but overall their 
impact lessened during the trial as I became more familiar with the practices of those 
involved and took steps to predict future scheduling. The conduct of the trial would 
have benefitted from the involvement a Clinical Trials Unit, with knowledgeable staff 
and well-oiled infrastructure, rather than a single-handed approach. However, given 
the absence of trial managerial or administrative support, my lack of previous trial 
experience and the constraints outlined, I am proud that the trial was completed. 
Personally, my understanding of the design, conduct and analysis of clinical trials has 
vastly improved during this process and I aim to build upon this experience. 
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8.5 Limitations of the work presented 
 
8.5.1 Chapter 3: Methods 
In the analysis, although the groups were randomised and seemingly well-matched at 
baseline, the finding of a lower mean pre-ischaemia cardiac index in the perhexiline 
group remains unexplained with neither probability nor biological explanations being 
satisfactory. This conundrum could have been avoided by including a quantitative 
measure of ventricular function, such as transthoracic echocardiography, prior to trial 
therapy in the protocol to differentiate unbalanced groups from treatment effect. 
 
Cardiac index is a load sensitive measure of contractility. In the protocol, this was 
taken into consideration by targets for CVP and PAWP to maintain consistency of 
ventricular loading conditions. During the trial, my presence in theatre, at the bedside 
during the first six hours and active involvement in the perioperative care of patients 
attempted to ensure optimisation of haemodynamic variables. Whilst this seems to 
have been accomplished with only a minor difference in PAWP between groups at six 
hours (table 13), it is not certain that this was achieved for every individual patient. 
 
Measurement of serum troponin-T occurred up to 24 hours after aortic cross-clamp 
release. No significant difference in area under the concentration-time curve was 
found (p 0.10) but there was a trend towards lower troponin release in the perhexiline 
group and both groups were well above baseline values. It is unknown whether a 
difference in AUC may have been found if collection had continued to 72 hours, 
although it is unlikely as the mean 24 hour values were almost identical. However, a 
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recent reanalysis of troponometrics from the MESSAGE trials suggests that 72 hour 
AUC is the best predictor of long-term outcomes (Ranasinghe et al., 2011). 
 
8.5.2 Chapter 4: Results – Serum perhexiline concentration 
The aim of the clinical trial was to evaluate whether preoperative metabolic therapy 
with perhexiline as an adjunct to cardioplegia and hypothermia improves myocardial 
protection during cardiac surgery. However, as discussed, 27.4% of patients in the 
treatment group were below the established therapeutic range for serum perhexiline. 
This reflects the inherent weakness of using a one-size-fits-all dosing regimen for a 
drug with a narrow therapeutic index and high inter-individual pharmacokinetic 
variability. The proportion of sub-therapeutic patients would have been reduced by 
therapeutic drug monitoring and dose adjustment during the preoperative period, as 
intended in the original study design; however, logistical issues relating to the 
location and frequency of the assay were prohibitive. Plasma monitoring may have 
enabled therapy to have been continued beyond 31 days such that the three patients 
for whom surgery was significantly delayed may have been able to continue safely. A 
significant number of sub-therapeutic patients could have led the trial to become 
underpowered for the primary endpoint; reassuringly, the propensity score-matched 
analysis excluding such patients confirmed the lack of therapeutic benefit. 
 
8.5.3 Chapter 5: Perhexiline pharmacokinetics in the myocardium 
The analysis of human myocardial biopsies obtained during surgery is limited by the 
clinical and ethical restrictions of primum non nocere. The ventricular biopsies were 
very small with a mean mass of only 3.6mg (range 1.6-15mg) due to operator 
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difficulties with the technique and clinical unease over the removal of left ventricular 
myocardium. Despite preparation in just 200µL of phosphate buffer, the measured 
perhexiline concentration was near the limit of detection with the standard curve 
using HPLC. The small size of the biopsies may also have increased the influence of 
tissue contamination from any areas of fibrosis within the specimen. Only 28 biopsies 
were used in this analysis as they were also required for other planned experiments. 
 
The degree of perioperative ischaemia at the site of each biopsy was unknown. All 
patients had flow-limiting atherosclerotic disease affecting the proximal left anterior 
descending artery. As biopsies were taken from this territory, it is possible that some 
were of hibernating myocardium. Chronic ischaemia is known to reduce drug uptake 
such that a poorly perfused segment may be regarded as a peripheral compartment 
and may not be representative of the true second compartment (Horowitz and 
Powell, 1986); this may partly explain the inter-patient variability in ventricular to 
serum ratio. In addition, as only one pre-ischaemia biopsy was taken per patient, 
there may be regional differences in myocardial drug content that were undetected. 
 
The total myocardial drug content measured in homogenate may not reflect the true 
concentration of free drug at the site of action due to tissue binding and retention in 
lipid membranes. The tentative comparison with the IC50 of CPT-1 with perhexiline in 
the rat model makes many assumptions including interspecies conservation of CPT-1 
affinity for perhexiline and response to inhibition. Indeed, the concentrations are not 
directly comparable due to different preparation techniques. As discussed in chapter 
5, these extrapolations are only intended to be hypothesis-generating. 
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8.5.4 Chapter 6: Metabolic preconditioning with perhexiline 
During reperfusion, the serum lipid profile was only evaluated at six hours after aortic 
cross-clamp removal; therefore the expected rise in FFA was witnessed only by the 
subsequent rise in TAG re-exported from the liver. Measurement of FFA and TAG at 
more regular time intervals would have provided a greater insight into lipid 
metabolism during the early stages of reperfusion: at release of aortic cross-clamp, 
ten minutes, 30 minutes, one hour, two hours, six hours and 12 hours. 
 
There was significant inter-individual variation in some myocardial metabolites and a 
relatively small number of samples were processed. Surprisingly, there was a trend 
towards lower atrial TAG in the perhexiline group on both the assay (p 0.21) and 
histology (p 0.20); a larger cohort of samples may have reached significance. It would 
also have been informative to measure CPT-1 activity in the myocardial biopsies but 
the resources to process ‘hot’ samples were not available locally during the trial. 
 
In the MS metabolomic analysis, it is important to note that we did not measure the 
entire metabolome of the human myocardium; only the negative ion mode of the 
polar fraction was evaluated in order to focus on the intermediates of carbohydrate 
metabolism. Positive ion mode and lipidomic analyses were not performed and hence 
any perturbations in peptide or lipid intermediates with perhexiline were not assessed 
(Griffin et al., 2011). The ventricular biopsies used in this analysis were also limited 
by the same factors as noted previously: small mass, extent of chronic ischaemia, 
unknown degree of representation and the suggestion that despite therapeutic serum 
levels, the concentration of perhexiline may not have reached steady-state. 
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8.6 Future research 
 
Over the last five years, I have gained valuable research skills and an improved 
understanding of clinical and translational research, including extensive experience in 
the design and conduct of a clinical trial. Building on the foundation of this thesis, I 
am pursuing a number of avenues of research into areas either directly related to this 
work or using the same concepts and techniques to address diverse yet important 
and novel research questions. 
 
8.6.1 Myocardial protection 
The HYPER trial is a prospective, multi-centre, double-blind, randomised, placebo-
controlled trial of preoperative oral perhexiline in patients with left ventricular 
hypertrophy undergoing aortic valve replacement for aortic stenosis, with or without 
concomitant CABG, on cardiopulmonary bypass with cold blood cardioplegic arrest 
(NCT: 00989508). As hypertrophy is associated with cardiac energetic impairment 
and metabolic downregulation (Neubauer, 2007), the myocardium is more vulnerable 
to ischaemia-reperfusion and may derive greater benefit from improved metabolism. I 
am a co-investigator on this trial which began recruitment in October 2009, examining 
the same clinical endpoints for myocardial protection as our previous trials. A sub-
study is also underway using 31P magnetic resonance spectroscopy to assess 
metabolic changes with perhexiline in these patients prior to surgery. In light of the 
clinical and metabolic findings of the CASPER trial, the futility of continuing with the 
HYPER trial is currently being discussed by the independent DSMB. 
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As an alternative, we are investigating the potential application of oral fumarate to 
myocardial protection. In a murine model, both inactivation of the fumarate hydratase 
(Fh11) gene and oral supplementation with dimethylfumarate resulted in significant 
attenuation of myocardial injury following a period of ischaemia-reperfusion with 
improved haemodynamics and reduced troponin release (Ashrafian et al., 2012). 
Fumarate is both a strategic intermediate in the citric acid cycle and a potent activator 
of the Nrf2-antioxidant response element signalling pathway, a key mechanism in the 
regulation of cellular oxidative stress (Linker et al., 2011). We are currently applying 
for funding for a clinical trial of determine whether oral dimethylfumarate prior to 
cardiac surgery improves clinical markers of myocardial protection, using the same 
outcome measures as the CASPER trial but with a more heterogeneous patient 
population. We will also analyse left ventricular biopsies to determine changes in the 
expression of the Nrf2 signalling pathway and the MS-visible polar metabolome. 
 
8.6.2 Mechanism of action of perhexiline 
Unger and colleagues (2005) demonstrated that the increased efficiency derived from 
perhexiline is in part independent of CPT inhibition and it has been suggested that 
this may be due to modulation of cellular oxidative stress; trimetazidine has been 
shown to decrease global markers of oxidative stress following ischaemia-reperfusion 
associated with cardiac surgery (Iskesen et al., 2006). The thioredoxin (TRX) system 
is a ubiquitous thiol oxidoreductase system that regulates cellular reduction-oxidation 
status (World et al., 2006). It plays an essential role by limiting oxidative stress, 
directly via antioxidant effects and indirectly by influencing key signalling molecules 
such as thioredoxin-interacting protein (TXNIP). There is accumulating evidence that 
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TXNIP plays a pivotal role in cardiovascular disorders, functioning as a sensor for 
biochemical and oxidative stress. It has been shown in a working rat heart model that 
ischaemia-reperfusion down-regulates TRX expression and that hearts over-
expressing TRX had improved post-ischaemic recovery (Turoczi et al., 2003). These 
studies implicate a protective role for endogenous TRX. On the other hand, TXNIP 
inhibits TRX by binding to its catalytic site and thereby preventing reduction of 
oxidised cellular proteins; in practice, levels of TXNIP expression generally control 
net TRX activity (Junn et al., 2000). In collaboration with Dr Doan T. Ngo and 
Professor John D. Horowitz at the University of Adelaide, I am studying the effect of 
perhexiline on the thioredoxin and AMPK/PGC-1α systems in serial left ventricular 
biopsies obtained during the CASPER trial. Using Western blot analysis of protein 
expression, we have found a significant reduction in TXNIP and increases in AMPK 
and PGC-1α expression with perhexiline, suggesting that the effects may contribute 
to the beneficial impact of perhexiline on redox stress and energetic impairment. This 
preliminary work was presented at the annual meeting of the American Heart 
Association in Orlando, FL in November 2011 (Ngo et al., 2011). 
 
In further proposed work, the collection of ‘hot’ biopsies from patients undergoing 
cardiac surgery with perhexiline could be used to replicate the rat heart experiments 
of Kennedy et al. (1996). The inhibition of CPT-1 in human myocardial homogenate 
and isolated mitochondria may be correlated with the ex vivo myocardial perhexiline 
concentration to clarify whether there is indeed inter-species preservation of CPT-1. 
Preliminary work suggests that this may soon become feasible locally. 
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8.6.3 Pharmacokinetics 
The study of myocardial pharmacokinetics described in this thesis is being extended 
to measure the relative concentrations of perhexiline enantiomers and determine 
whether myocardial uptake is enantiomer selective; it has previously been suggested 
that the (+) and (–) enantiomers have different pharmacokinetic profiles (Davies et 
al., 2008). We also intend to use population modelling techniques to further evaluate 
factors that influence the pharmacokinetics of perhexiline. 
 
The measurement of drug levels in a target tissue and correlation with cellular effects 
is widely applicable to understanding the pharmacokinetics of other drugs. I have 
designed a novel study applying these principles to the use of immunosuppressant 
therapy following heart transplantation (NCT: 01423552). In collaboration with 
Professor Robert S. Bonser in Birmingham and Associate Professor Benedetta C. 
Sallustio and colleagues at the University of Adelaide, we will measure the relative 
concentrations of ciclosporin and mycophenolate in whole blood, isolated T-
lymphocytes and transvenous endomyocardial biopsies to correlate relative drug 
levels, pharmacogenomics and pharmacodynamics with clinical and pathological 
evidence of rejection in patients following heart transplantation in Birmingham. This 
study aims to improve our understanding of interindividual variations in the clinical 
pharmacology of these drugs using pharmacokinetic and pharmacodynamic 
endpoints to optimise the dosing of immunosuppressive therapy and outcomes in 
these vulnerable patients. 
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8.6.4 Metabolomics 
At the University of Birmingham, we are fortunate to have one of the most advanced 
metabolomic platforms in the world under the directorship of Professor Mark R. Viant 
in the School of Biosciences. An ultra-high resolution, high accuracy tool for the 
detection of biological molecules, FT-ICR mass spectrometry is a valuable addition to 
the armamentarium of cardiac surgery research. I intend to harness this new 
technology to improve our understanding of myocardial metabolism in normal, 
ischaemic, reperfused, hypertrophied and cyanotic hearts in order to generate new 
hypotheses on how they may be better protected. 
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9. APPENDICES 
 
9.1 Letter from Mr James R. Edwards, RAH Adelaide, 9th December 2005 
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 9.2 Patient Information Sheet, version 3a, 17th September 2008 
The CASPER trial Version 3a: 17/09/2008 
 
 
 
 
PATIENT INFORMATION 
 
Support of the heart during Coronary Artery Surgery with Perhexiline 
Principal Investigator: Mr D Pagano, Consultant Cardiothoracic Surgeon 
 
AN INVITATION TO PARTICIPATE IN RESEARCH 
 
The heart surgery team at the Queen Elizabeth Hospital, Birmingham is inviting patients to 
participate in research aimed at making coronary artery surgery safer. We would like to 
recruit patients undergoing this kind of surgery into a clinical trial where potentially 
advantageous methods of altering the way we treat patients are used to see what differences 
they actually make to patients’ progress. We include a simple and non-technical summary of 
the reasons for the study and what it will involve for you over and above your routine 
treatment if you take part. 
 
If you are being approached in the outpatient clinic, we would like you to take this patient 
information sheet home with you to read and consider participating in this study. At the Pre-
admission clinic, the doctor will ask you whether you wish to participate and to sign a consent 
form. You can only be included in this clinical trial if you give your express permission in the 
form of signed consent. On admission for your operation, a heart surgical research doctor will 
be available to discuss the study further and answer any questions.  
 
If you are already an inpatient on the ward, a member of the heart surgical team will be 
happy to discuss the study with you once you have had at least 24 hours to read through this 
information sheet. 
 
Questions? Please contact Mr Nigel Drury, Clinical Research Fellow in Cardiac Surgery via 
the Queen Elizabeth Hospital, Birmingham switchboard on 0121 472 1311. 
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WHAT IS THE STUDY ABOUT? 
This study is about trying to improve the treatment of patients undergoing coronary artery 
surgery. To perform this heart operation requires the help of a heart-lung machine, which 
supports your body’s circulation whilst the surgeon bypasses the diseased blood vessels. 
During your surgery, the heart has to be protected so that it is not injured by the strain of the 
operation. Despite using standard techniques to protect the heart, some temporary injury still 
occurs from which the heart gradually recovers during the first few hours and days following 
the operation. We are seeking ways to improve on these established ‘protective techniques’ 
by preparing the heart before surgery with a drug that switches the fuel of the heart from less 
efficient fatty acids to more efficient sugars. 
 
In summary, taking the drug perhexiline before your operation has the potential to benefit the 
way your heart works during periods of strain during and immediately after your surgery. 
 
HOW HAS THIS CLINICAL TRIAL BEEN DESIGNED? 
This study is a multi-centre double-blind randomised placebo-controlled trial. This means that 
if you agree to take part, you would be allocated by chance to receive either the drug 
perhexiline or a placebo – a tablet that looks the same but has no medicinal properties. The 
tablets are coded so that neither you nor the heart surgical team will know which one you are 
receiving. The code is revealed once all the patients in the trial have been completed. By 
giving the tablets in this way, we can determine the benefits of using them in patients 
undergoing coronary artery surgery. 
 
HOW WILL WE MEASURE THE EFFECTS OF THIS TABLET? 
To detect changes in heart function, we need to take measurements of performance before, 
during and after surgery to show whether the treatment has made a difference. To do this we 
will make use of small monitoring catheters (plastic tubes) inserted into blood vessels. These 
tubes are routinely used in two out of three patients who are not in the trial. These catheters 
are placed in position in blood vessels whilst you are under anaesthetic (asleep) and are 
usually removed on the first or second day following surgery. We will record measurements 
from these catheters during this period at specific time points. We will insert an additional 
sampling catheter into your heart during your operation to monitor blood in the veins of your 
heart. This catheter is normally used as an additional way to deliver protection to the heart in 
patients at high-risk for surgery; in your case, it will be used only to withdraw a sample of 
blood from your heart veins. It will be removed at the end of the use of the heart-lung 
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machine. We will also use a special camera to look at how the heart is working. This will be 
placed in the gullet whilst you are asleep and used to measure the function of the heart 
before the operation. We will also look at how the heart is working later on the intensive care 
unit. This camera will be removed from the gullet before you wake up. It is now used 
routinely in the majority of patients requiring heart valve surgery and in those who require 
more heart support in the intensive care unit in our hospital. 
 
MEASURING THE POSSIBLE BENEFICIAL EFFECTS OF THE TABLET ON THE HEART’S METABOLISM  
The sampling of additional blood tests: The blood tests performed on these samples can tell 
us how well the heart is tolerating the surgery. These blood samples are removed through 
the same monitoring lines already mentioned. The total amount of additional blood taken for 
this study is about a cupful (approximately 60ml or 2fl oz). 
 
Imaging the heart using a transthoracic echocardiogram: An Echocardiogram is a scan that 
uses ultrasound (sound waves) to produce pictures of the heart. The test is painless and 
without side effects. An ultrasound probe and a small amount of gel are gently placed on 
your chest and moved to different positions. The scan will take approximately 20-40 minutes 
to complete and will be performed once before surgery and once after. 
 
Imaging the heart using a transoesophageal echocardiogram: This is a similar test to the one 
above (transthoracic echocardiography) but instead the ultrasound probe is placed in the 
gullet. It allows the doctors to look at the heart during the operation as the previous test 
cannot be used at this stage. This is performed in most patients undergoing heart surgery but 
extra pictures will be taken to analyse the heart function in more detail. This will be placed 
whilst you are asleep and removed before you are woken up. 
 
The removal of tiny samples of the heart muscle known as biopsies: This will help tell us how 
the perhexiline tablet improves the way the heart works. We would aim to obtain 3 heart 
muscle biopsies, all whilst you are asleep under the anaesthetic, one each at the beginning, 
middle and end of being on the heart-lung machine. They will be performed by the operating 
surgeon and are very small, about so long and thin (▬▬). A suture is placed in the tiny 
defect left behind and their removal incurs no increased risk during the surgery nor has any 
effect on the strength of the heartbeat. Although there is a hypothetical risk of bleeding in 
taking this biopsy, we have performed more than 1500 biopsies in patients at the time of 
writing this information leaflet with no complications. 
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WHAT WILL I HAVE TO DO? 
If you decide to participate, there are a number of stages to the study. You will be guided 
through these stages by us (the research doctors looking after you). You have been given 
this written information sheet and asked to read it at your leisure at home or on the ward, if 
you are already an inpatient. Before your surgery, in either the pre-operative assessment 
clinic or on the ward, a member of the research team will visit so you can ask any questions. 
If you give signed consent, we will then randomise you to receive either the tablet or the 
placebo and we will give you the medication with a date to start taking it. Before the 
operation you may be asked to have one of the scans listed above.  
 
In the anaesthetic room of the operating theatre, the Anaesthetist will give you a general 
anaesthetic. Once you are asleep, the Anaesthetist will insert the pressure-measuring 
catheters normally inserted at this stage. The operation will be conducted in a normal way 
under the care of the Consultant Cardiac Surgeon who is in charge of your case. The blood 
samples and biopsies will be performed while you are asleep and you will be unaware of 
them. The sampling of blood from the veins of the heart will also be performed whilst you are 
asleep during the use of the heart-lung machine only. 
 
When you awake, you will be on the intensive care unit as routine. Only some further blood 
samples and monitoring tests will remain. The last blood test will be performed at 24 hours 
after the operation. 
 
In summary, we will be taking measurements from pressure-measuring catheters that are 
routinely used in heart surgery. The entire sampling of blood for the research will total 60 ml 
and will not affect your recovery and, because we can use intravenous pressure-measuring 
lines, there will be no additional need for needles. The biopsies that we take are removed 
painlessly during the operation and have no effect on the heartbeat. 
 
WHAT ARE THE BENEFITS? 
We do not know whether giving patients the tablet perhexiline will benefit them as an 
individual – this study is investigating that question. It is hoped that this study will provide 
information that will benefit future patients undergoing cardiac surgery. In particular it will 
help us design more suitable treatments for patients who have a very weak heartbeat before 
surgery and are at high risk of complications after surgery. In the future and after more 
research, the use of this tablet could significantly improve their recovery from heart surgery. 
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WHAT ARE THE RISKS? 
Previous studies with perhexiline have shown that it is safe. Some patients may feel a bit sick 
after the first tablet but that usually passes very soon. If these tablets continue to make you 
feel sick, you can simply stop taking them without harm and your surgery will proceed as 
planned. If you stop taking these tablets, we would be grateful if you could contact the 
hospital to the Heart Surgery Research team know – telephone number on page 7. 
 
In some patients who had taken the tablet for long periods of time (many months or years), a 
very small number developed some numbness or muscle weakness and/or mild liver 
changes including going yellow (jaundice) and loss of appetite. It has since been shown that 
this can be avoided by monitoring the level of the drug in the blood. These side effects do not 
occur when people take the tablet for just a few weeks and so will not affect you.  However, if 
you have any concerns, we would ask you to contact one of the Heart Surgery Research 
team at the Queen Elizabeth Hospital, Birmingham on the contact number on page 7. You 
can also contact your GP, who will be given more information about the tablet and the trial if 
you agree to participate. 
 
All heart operations carry some risk and these will have already been discussed with you. 
For this study we insert routinely-used monitoring lines to measure heart function. The risks 
of this are minimal and the possibility of a severe complication is in the region of 1 in 15,000. 
The only additional invasive procedure performed on you is the biopsy of the heart muscle. 
There is a very small risk of bleeding following this procedure. However, we have performed 
approximately 1,500 biopsies so far and this complication has never happened. 
 
WHAT ARE THE ALTERNATIVES? 
If you do not wish to take part in the study, your surgery will be undertaken in the standard 
manner without any additional measurements, treatments or tests. Your surgeon and 
anaesthetist may still use the monitoring lines that we have described if they feel that their 
use is in your best interest. 
 
WHAT HAPPENS TO THE INFORMATION? 
All the study data will be collected by the Heart Surgery Research team. It will be stored as 
paper files and on a hospital computer which are kept in a locked office. The information from 
the study will be analysed. The information will be presented at scientific meetings and 
published in scientific journals to inform other doctors and health professionals of the 
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research findings. All data is coded and confidential, ensuring that your identity will not be 
revealed at any time. All necessary measures will be taken to keep your data safe and 
confidential and to comply with the Data Protection Act. Only the Heart Surgery Research 
team and the Research & Development office will have access to this data. Following 
completion of this trial, the data will be kept for 15 years and then destroyed. 
 
WHAT HAPPENS TO THE SAMPLES? 
All of the biopsies will be stored in a coded form in a locked laboratory and only the Heart 
Surgery Research team will have access to these samples. The samples will be analysed to 
look at how much perhexiline is taken up by the heart. We will also look at what effect this 
has on the heart in terms of how it works and how much energy it can store. The biopsies are 
very small and the simple act of analysing them will destroy the sample. 
 
WHO ELSE IS TAKING PART? 
We will recruit 300 patients to this study.  
 
WHAT IF SOMETHING GOES WRONG? 
The standard care of patients undergoing heart surgery involves intensive monitoring. This 
monitoring allows us to detect any problems early in their development. We do not expect the 
study itself to cause any problems, however as for all heart surgery, we are in an ideal 
position to deal with any untoward events during your operation and these will be treated in 
the normal manner, regardless of the research study. At the time of the measurements, you 
will be in either the theatre or the ICU where trained staff are at hand at all times. Your safety 
during and after surgery is paramount, and takes precedence over any research. 
 
In the event that something does go wrong and you are harmed during the research study, 
there are no special compensation arrangements. If you are harmed due to someone’s 
negligence, you may have grounds for a legal action for compensation against University 
Hospital Birmingham NHS Foundation Trust but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will be available to you. Further 
information can be obtained from the Patient Advice & Liaison Service (PALS) which is 
available Monday to Friday 9am to 5pm on 0121 627 8820. 
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WHAT HAPPENS AT THE END OF THE STUDY? 
At the end of the study, your treatment will continue as would that of a patient who had not 
been involved with the study. 
 
WHAT IF I HAVE MORE QUESTIONS OR DO NOT UNDERSTAND SOMETHING? 
Please ask one of the investigators about any questions or worries that you may have so that 
any points can be clarified. You should feel free to ask questions at any time. Contact QE 
Hospital switchboard on 0121 472 1311 and ask them to telephone Mr Nigel Drury, Clinical 
Research Fellow. If you are on the ward, ask one of the nurses to contact Mr Drury. If he is 
unavailable, ask for either Mr Howell (Clinical Lecturer) or Mr Pagano (Consultant Surgeon). 
 
WHAT HAPPENS NOW IF I DECIDE TO TAKE PART? 
We will take some details and ask you to sign a consent form that documents your 
willingness to participate. We will give you the tablets, which will be either perhexiline or the 
placebo, and instructions on when to take them. You will need to take one or more tablets 
twice per day prior to your operation – in the morning and in the evening. We will also write to 
your GP to let them know that you have agreed to join this study and giving them more 
details. You will be listed for surgery as normal. You are free to withdraw from the study after 
initially consenting without giving reason and without prejudice to your continuing care or the 
standard care of any future treatment. 
 
WHO IS ORGANISING AND FUNDING THIS RESEARCH? 
This research has been organised and developed by the Heart Surgery Research teams at 
the Queen Elizabeth Hospital, Birmingham and the Royal Sussex County Hospital, Brighton. 
It is being funded by the British Heart Foundation. 
 
WHO HAS REVIEWED THIS STUDY? 
This study was given a favourable ethical opinion for conduct in the NHS by the 
Cambridgeshire 1 Research Ethics Committee in Cambridge, UK. 
 
THANK YOU 
Finally the Heart Surgery Research team would like to thank you for taking the time to 
consider this research proposal. 
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PROPOSED STUDY INVOLVEMENT 
This summary flow chart demonstrates what will happen if you consent to join this study: 
 
When you were seen by your Surgeon for the first time to discuss your operation, you will 
have been invited to join this trial and given this information leaflet. 
 
In your free time, we would like you to read this leaflet and consider joining the study. 
 
In a few weeks, in the pre-operative assessment clinic (or on the ward if you are already an 
inpatient), you will be seen by a member of the Research team.   
 
If you are happy to join this trial, we will ask you to give written consent to join the trial. 
You will then be randomised to receive either the perhexiline tablets or the placebo (the 
dummy tablets). Neither you nor the research team will know which one you are given. 
You will then be given a date for your operation and a date to start taking the tablets. 
An information leaflet and instructions will be included with your tablets. 
 
On your admission to the hospital for your surgery, you will be seen by a member of the 
Research team. You may then be invited to have an extra scan of the heart, as detailed in 
this leaflet, depending upon what scans you have already had. 
 
You will then be taken to theatre for your operation as normal. 
After you have been put to sleep by the anaesthetist, we will do some blood tests and 
measure how well your heart is working. 
 
After your operation you will be taken to the Intensive Care Unit as normal. 
We will then make further tests of how well your heart is working. 
 
After the operation, you will be have a several extra blood tests, not using a needle but from 
the special monitoring lines that will be in place. Before you are discharged home, we will 
take an extra heart tracing and you may be asked to have another scan. 
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9.3 Consent form, version 3a, 17th September 2008 
The CASPER trial Version 3a: 17/09/2008 
 
 
 
 
CONSENT FORM 
 
Support of the heart during Coronary Artery Surgery with Perhexiline  
Principal Investigator: Mr D Pagano, Consultant Cardiothoracic Surgeon 
 
Please initial boxes 
 
I confirm that I have read and understand the information sheet (Version 3a, 
dated 17/09/2008) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
 
I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
 
I understand that relevant sections of any of my medical notes and data collected during the 
study, may be looked at by responsible individuals from the NHS Trust, where it is relevant 
to my taking part in this research. I give permission for these individuals to have access to 
my records. 
 
I understand that blood and tissue samples will be kept for the purpose of research and I 
give permission for these samples to be taken and stored. 
 
 
 
I agree to my GP being informed of my participation in the study. 
 
 
 
 
I agree to take part in the above study. 
 
 
 
 
      
Name of Patient  Signature  Date 
 
 
 
      
Researcher  Signature  Date 
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9.4 Letter from Prof John D. Horowitz, TQEH Adelaide, 2nd March 2007 
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9.5 Statistical Analysis Plan, version 2, 5th July 2010 
The CASPER trial Version 2: 05/07/2010 
 
 
STATISTICAL ANALYSIS PLAN 
 
Efficacy 
 
Primary Outcome 
Incidence of Low Cardiac Output Episode (LCOE) 
 
Secondary Outcomes 
Cardiac index 
Inotrope usage 
Peak cardiac troponin-T 
ECG evidence of new myocardial injury 
Composite endpoint of either peak troponin-T or ECG evidence of new myocardial injury  
Length of stay in the Intensive Care Unit and Hospital 
 
 
Safety Outcome Measures 
 
Postoperative death 
Stroke with residual deficit 
Requirement for renal replacement therapy 
Reoperation 
Chest drainage at 12 hours 
Treated infection episodes 
Respiratory index (PaO2/FiO2) on arrival in Intensive Care and 12 hours postoperatively 
 
 
STATISTICAL METHODS AND DATA CONSIDERATIONS 
 
Analysis will be carried out using SAS version 9.2 All statistical tests will be two-sided, and 
deemed to be statistically significant if p<0.05. No adjustments for multiplicity will be made. 
All analyses will be undertaken stratified for LV function at baseline and elective/urgent 
surgery. Consultant surgeon will be accounted for as a random effect. The only data which 
will be formally analyzed are those which could potentially be affected by which treatment 
group they are assigned to. Demographic and other baseline data will not be formally 
analyzed, other than descriptively. 
 
The two treatment groups of patients in this study will be identified in tables and listings as: 
Perhexiline 
Control 
 
 
Handling of missing and incomplete data 
 
Primary efficacy variable 
In the event of death before assessment of primary endpoint, LCOE will be assigned. 
 
Secondary efficacy variables 
Missing secondary endpoints will be excluded from the analysis. 
 225 
 
PRIMARY OUTCOME MEASURE AND ESTIMATION OF SAMPLE SIZE 
 
LCOE after cardiac surgery is an indicator of inadequate myocardial protection and 
contributes to postoperative morbidity and mortality. For the purpose of this study LCOE is 
defined as: 
 
Hypotension (mean arterial pressure < 65mmHg) with cardiac index  2.2L/min/m2 in the 
presence of adequate filling pressures (CVP 8-12mmHg, PCWP 12-16mmHg) and heart rate 
(> 75bpm) where systolic blood pressure < 90mmHg and/or inotropic support  intra-aortic 
balloon pump for > 60 minutes is required to maintain such a clinical picture within the first 
six hours after removal of the aortic X-clamp. 
 
We hypothesise that the use of perhexiline will reduce the incidence of LCOE compared to 
control and the sample size has been estimated by extrapolating data from our recently 
completed MESSAGE trials, in which a reduction of 50% in incidence in LCOE was detected 
in the GIK group compared with control [difference between incidence in groups 0.19 
versus 0.37 to achieve similar difference with an α 0.05% and 1-β 0.9]. 
 
This requires a total of 280 patients, randomised 1:1 between treatment and placebo which 
will also provide sufficient statistical power to examine the range of important secondary 
endpoints outlined below. 
 
 
ANALYSIS 
 
Primary efficacy variable 
 
The primary objective is to evaluate the effects of perhexiline on the incidence of LCOE. The 
primary analysis will be a non-linear mixed model accounting for baseline LV function and 
elective/urgent surgery with surgeon as a random effect. Odds ratio 95% CI and p value will 
be presented. 
 
The presence of LCOE is adjudicated by the blinded CASPER Endpoints Committee. 
 
Exploratory analysis. The predictive value of the following baseline characteristics (where 
feasible) will be examined: age, ventricular function, urgent surgery and logistic EuroSCORE. 
A parsimonious statistical model describing the predictive value of the listed parameters will 
be estimated, using a stepwise model building procedure.  The linearity in response of 
continuous variables will be examined and model fit assessed using the AIC. 
 
Efficacy evaluable population. This will consist of the all-patients-randomised population 
who received therapy (perhexiline or placebo) and underwent surgery on CPB. 
 
Exploratory analysis of the primary outcome for those that reached the lower limit of 
the therapeutic serum perhexiline. Based on a model which identifies predictors of LCOE, 
a propensity score will be generated. Patients with a sub-therapeutic plasma perhexiline level 
and matched controls (based on propensity score) will be removed and an exploratory 
analysis of treatment effect in those reaching the lower end of the therapeutic range for 
plasma perhexiline at the time of surgery (0.15 mg/L or above) undertaken.   
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Secondary outcome measures 
 
Cardiac index: to detected an increase of 0.3 L/min/m2 in cardiac index in the first 6 hours 
from release of aortic cross clamp in the treatment group. 
 
1. Cardiac index at six hours will be analysed using generalised linear modelling with 
baseline cardiac index, elective/urgent surgery, baseline LV function and treatment 
(perhexiline/control) as covariates and surgeon as a random effect. 
 
2. Cardiac index up to 12 hours will be analysed using generalised linear modelling with 
cardiac index (baseline, pre, post, 2, 4, 6, 9 & 12 hours) as repeated measures, adjusted to 
baseline, and accounting for elective/urgent surgery, LV function and perhexiline as 
covariates and surgeon as a random effect. 
 
3. Exploratory repeated measures analysis accounting for time-dependent inotrope use. 
 
Inotrope usage: assessed by incidence of use based on predetermined protocols and total 
dosage/kg in the first 6 and 12 hours postoperatively. Incidence and dose will be assessed: 
 
1. In the first six hours after removal of aortic X-clamp (also includes on CPB). 
 
2. In the first 12 hours after removal of aortic X-clamp. 
 
The incidence of inotrope use in each time period will be assessed using a non-linear mixed 
model accounting for urgency of surgery and LV function with surgeon as a random effect. 
 
Peak cardiac troponin-T: in the first 24 hours following release of the aortic cross clamp  
 
1. Linear model with baseline troponin-T as a covariate accounting for LV function, urgency 
of surgery and with surgeon as a random effect (using peak troponin-T at any time point). 
 
2. Repeated measures analysis – baseline, 6 hours, 12 hours, 24 hours. 
 
ECG evidence of new myocardial injury: assessed by a blinded Cardiologist according to 
standard criteria using the presence of new Q waves, new bundle branch block or loss of R 
wave progression. The presence of ECG evidence of new myocardial injury will be assessed 
using a non-linear mixed model (logistic) accounting for baseline LV function and 
elective/urgent surgery with surgeon as a random effect. 
 
Length of stay: this will include both intensive care and hospital stay within the Department 
of Cardiothoracic Surgery. The effect of perhexiline on mean length of stay (days) will be 
assessed using a non-linear mixed model (Poisson distribution) accounting for baseline LV 
function and elective/urgent surgery with surgeon as a random effect.  
 
Safety outcome measures: will be monitored by the DSMB and include postoperative 
death, stroke with residual deficit, requirement for renal replacement therapy, reoperation, 
chest drainage at 12 hours, treated infection episodes, respiratory index (PaO2)/FiO2 on 
arrival in Intensive Care and 12 hours postoperatively. 
 
Should any patient report the same event more than once, this event will only be counted 
once and summarised at the highest observed severity in relationship to study drug. Adverse 
events that occur in at least 5% of patients will be formally tested using Fisher’s exact test. 
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9.6 Statistical tests used in this thesis 
 
Analysis of variance (ANOVA) is a linear model used to test whether there is a 
difference between two or more means. For example, the mean cardiac index at six 
hours was significantly lower in the treatment group (2.51L/min/m2, SD 0.43) than in 
the control group (2.70L/min/m2, SD 0.54) (DiM 0.17, 95% CI 0.05 to 0.29, p 0.005). 
 
Area under the concentration-time curve (AUC) is a technique to describe the 
summative concentration of a molecule over a period of time and is often used in 
pharmacokinetics to estimate drug exposure. It may also represent the release of a 
biomarker in response to a stimulus; for example, there was no significant difference 
in AUC for troponin-T between the treatment group 3.98ng.hr/ml (SD 3.79) and the 
control group 4.71ng.hr/ml (SD 5.32) (p 0.12) in the 24 hours following reperfusion. 
 
False discovery rate (FDR) control is a method used in multiple hypothesis testing to 
correct for multiple comparisons and reduce the expected proportion of falsely 
rejected null hypotheses. For example, all 4039 peaks in the final metabolomic 
intensity matrix were examined using univariate statistics and a FDR of 5% applied. 
 
Fisher’s exact test is used to detect the significance of any deviation from a null 
hypothesis with small samples of categorical data, usually in the form of a 2 x 2 
contingency table. For example, there was no difference between the incidence of 
postoperative atrial fibrillation between the treatment group (55/139, 39.6%) and the 
control group (66/147, 44.9%) (p 0.40). 
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Kolmogorov-Smirnov test determines whether a sample is significantly different from 
a normally distributed population.  A significant value indicates deviation from 
normality; for example, the concentration of serum perhexiline in the treatment group 
was not normally distributed (D=0.18, p<0.001). 
 
Partial least squares discriminant analysis (PLS-DA) is a multiple linear regression 
tool that enables discrimination between groups by the levels of continuous predictor 
variables and can therefore be used to maximise separation of groups. For example, 
metabolomic profiles of the control and treatment samples were minimally separated 
and the associated mean classification error rates for predicting group membership 
were 43% and 47%, respectively, suggesting no difference between groups. 
 
Power is the probability that a test will correctly reject the null hypothesis and is used 
to estimate the minimum sample size required for the test to detect an effect of a 
particular size. It is a trade-off between the probability of a false negative (β, type II 
error) and the probability of a false positive (α, type I error). For example, by 
extrapolating the 50% reduction in incidence of the primary endpoint, a low cardiac 
output episode, from previous trials, it was determined that to achieve a similar 
difference between groups, with α 0.05 and 1-β 0.9, the CASPER trial required at 
least 280 patients randomised in a 1:1 ratio. 
 
Principal component analysis (PCA) is a multivariate technique to identify the linear 
components of a set of variables and reduce its dimensionality. For example, PCA 
was used to visualise the metabolomic similarities and differences between groups. 
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Regression is a technique for modelling the relationship between a dependent 
variable and one or more independent variables and in some circumstances, unlike 
correlation, it can infer causation. For example, linear regression was used to assess 
the impact of serum perhexiline on the concentration in the ventricular myocardium 
with an R value of 0.85, R2 of 0.73 and F-ratio of 69.1 (p<0.001). 
 
Repeated measures ANOVA is an analysis of variance in which a variable has been 
measured several time on the same participants. For example, with pre-ischaemia 
cardiac index as a covariate, cardiac index during reperfusion was not significantly 
affected by perhexiline therapy, F (3.57, 896.9) = 1.02, p 0.40. 
 
Spearman’s rank correlation (rs) is a standardised non-parametric measure of the 
strength of the relationship between two variables. For example, the correlation 
between serum perhexiline and length of therapy was rs 0.13 (p 0.14), suggesting 
that length of therapy did not significantly affect serum perhexiline concentration. 
 
Student’s t-test establishes whether the difference between two means is significantly 
different from zero in a normal distribution. An independent test is used when the 
means are collected from unrelated samples of continuous data; for example, FFA 
were significantly higher in the perhexiline group 0.75mmol/L (SD 0.08) than in the 
control group 0.50mmol/L (SD 0.13) (p<0.001). In regression, it is used to test 
whether the standardised regression coefficient β is significantly different from zero; 
there was no significant relationship between serum perhexiline concentration and 
pre-ischaemia cardiac index (β -0.05, 95% CI -0.30 to 0.20, p 0.69).  
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9.7 Putative metabolite identification of peaks detected in mass spectra 
 
Only peaks that were putatively annotated to at least one named metabolite using the 
transformation mapping approach are listed (Weber and Viant, 2010). None of the 
metabolite assignments reported can be regarded as definitive as they do not fulfil 
the Metabolomics Standards Initiative for identification (Sumner et al., 2007). 
 
Observed Putative Identification 
m/z 
Average 
intensity 
1
 
Empirical 
formula 
Ion form 
2
 
Theoretical 
mass (Da) 
Error 
(ppm) 
3
 
Putative metabolite name(s) 
4
 
102.05601 5462.3 C4H9NO2 [M-H]- 102.05605 -0.42 
4-Aminobutanoate 
N,N-Dimethylglycine 
103.04003 4956.8 C4H8O3 [M-H]- 103.04007 -0.37 (R)-3-Hydroxybutanoate 
104.03527 1718.6 C3H7NO3 [M-H]- 104.03532 -0.46 D-Serine', 'L-Serine 
105.01929 95319.1 C3H6O4 [M-H]- 105.01933 -0.42 D-Glycerate 
109.04069 7535.2 C5H6N2O [M-H]- 109.04074 -0.43 Imidazole-4-acetaldehyde 
113.02197 1491.3 C3H8O3 [M+Na-2H]- 113.02201 -0.39 Glycerol 
114.05602 2688.4 C5H9NO2 [M-H]- 114.05605 -0.29 D-Proline, L-Proline 
115.00366 4805.8 C4H4O4 [M-H]- 115.00368 -0.21 Fumarate, Maleic acid 
116.07168 8315.2 C5H11NO2 [M-H]- 116.07170 -0.19 
4-Methylaminobutyrate 
5-Aminopentanoate, Betaine 
117.01931 14311.3 C4H6O4 [M-H]- 117.01933 -0.2 Succinate 
125.00107 9964.8 C3H6O3 [M+Cl]- 125.00110 -0.21 
(R)-Lactate, (S)-Lactate, 
D-Glyceraldehyde, Glycerone 
125.00107 9964.8 C4H8O2 [M+K-2H]- 125.00104 0.27 (R)-Acetoin, Butanoic acid 
125.03562 5027.5 C5H6N2O2 [M-H]- 125.03565 -0.25 Imidazole-4-acetate, 'Thymine 
127.01672 2744.7 C3H8O3 [M+Cl]- 127.01675 -0.21 Glycerol 
127.01672 2744.7 C4H10O2 [M+K-2H]- 127.01669 0.26 (R,R)-Butane-2,3-diol 
127.05127 372519.9 C5H8N2O2 [M-H]- 127.05130 -0.25 
5,6-Dihydrothymine, gamma-
Amino-gamma-cyanobutanoate 
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128.03528 655414.2 C5H7NO3 [M-H]- 128.03532 -0.29 
1-Pyrroline-4-hydroxy-2-
carboxylate, 4-Oxoproline, 
5-Oxo-D-proline, 5-Oxoproline, 
L-1-Pyrroline-3-hydroxy-5-
carboxylate 
129.01931 8144.9 C5H6O4 [M-H]- 129.01933 -0.18 
2,5-Dioxopentanoate, 
2-Methylmaleate, 
4,5-Dioxopentanoate 
Mesaconate 
130.05094 5129 C5H9NO3 [M-H]- 130.05097 -0.21 
(S)-4-Amino-5-oxopentanoate, 
2-Amino-4-oxopentanoic acid, 
5-Amino-2-oxopentanoic acid, 
5-Aminolevulinate, 
L-Glutamate 5-semialdehyde, 
cis-4-Hydroxy-D-proline, 
trans-4-Hydroxy-L-proline 
130.06217 241162.8 C4H9N3O2 [M-H]- 130.06220 -0.24 Creatine 
130.08732 59580.2 C6H13NO2 [M-H]- 130.08735 -0.25 
(3R)-beta-Leucine, 
6-Aminohexanoate, 
L-Isoleucine, L-Leucine 
131.04619 16585.6 C4H8N2O3 [M-H]- 131.04622 -0.2 L-Asparagine 
131.08257 4120.4 C5H12N2O2 [M-H]- 131.08260 -0.24 
(2R,4S)-2,4-Diaminopentanoate, 
D-Ornithine, L-Ornithine 
132.0302 94521.3 C4H7NO4 [M-H]- 132.03023 -0.25 D-Aspartate, L-Aspartate 
133.01422 48717.7 C4H6O5 [M-H]- 133.01425 -0.22 
(R)-Malate, (S)-Malate, 
3-Dehydro-L-threonate 
134.04719 8941.2 C5H5N5 [M-H]- 134.04722 -0.21 Adenine 
135.02987 10600.7 C4H8O5 [M-H]- 135.02990 -0.21 Threonate 
135.0312 2324.2 C5H4N4O [M-H]- 135.03123 -0.26 Hypoxanthine 
136.0516 2490.4 C6H7N3O [M-H]- 136.05164 -0.26 Isoniazid 
145.09822 5757.4 C6H14N2O2 [M-H]- 145.09825 -0.22 
(3S)-3,6-Diaminohexanoate, 
(3S,5S)-3,5-Diaminohexanoate, 
2,5-Diaminohexanoate, 
D-Lysine, L-Lysine 
156.02779 658.2 C4H9NO4 [M+Na-2H]- 156.02783 -0.24 4-Hydroxy-L-threonine 
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157.0273 1097.1 C8H8O2 [M+Na-2H]- 157.02710 1.28 4-Hydroxyphenylacetaldehyde 
161.04552 15205 C6H10O5 [M-H]- 161.04555 -0.18 
(2R,3S)-2,3-Dimethylmalate, 
(S)-2-(Hydroxymethyl)glutarate, 
2-Dehydro-3-deoxy-D-fuconate, 
2-Dehydro-3-deoxy-L-
rhamnonate, 
2-Deoxy-scyllo-inosose, 
L-Rhamnono-1,4-lactone 
163.06114 89290.6 C6H12O5 [M-H]- 163.06120 -0.36 
6-Deoxy-L-galactose, 
L-Fuculose, L-Rhamnofuranose, 
L-Rhamnose, L-Rhamnulose 
164.07168 5482.5 C9H11NO2 [M-H]- 164.07170 -0.14 
D-Phenylalanine, 
L-Phenylalanine 
165.04029 625 C5H10O6 [M-H]- 165.04046 -1.05 D-Xylonate, L-Arabinonate 
166.03886 10141.5 C4H9N3O2 [M+Cl]- 166.03888 -0.11 Creatine 
166.03886 10141.5 C5H11N3O [M+K-2H]- 166.03882 0.25 4-Guanidinobutanal 
166.97508 4082.3 C3H5O6P [M-H]- 166.97510 -0.13 
3-Phosphonopyruvate, 
Phosphoenolpyruvate 
166.97508 4082.3 C4H4O5 [M+Cl]- 166.97528 -1.18 
Oxaloacetate, 
trans-2,3-Epoxysuccinate 
166.97508 4082.3 C5H6O4 [M+K-2H]- 166.97522 -0.82 
2,5-Dioxopentanoate, 
2-Methylmaleate, 
4,5-Dioxopentanoate, 
Mesaconate 
167.01165 720.5 C4H9O5P [M-H]- 167.01149 0.98 Butanoylphosphate 
167.01165 720.5 C5H8O4 [M+Cl]- 167.01166 -0.07 
(S)-2-Acetolactate, 
2-Acetolactate, 3-Hydroxy-3-
methyl-2-oxobutanoic acid 
167.01165 720.5 C6H10O3 [M+K-2H]- 167.01160 0.29 
(S)-3-Methyl-2-oxopentanoic 
acid, 4-Methyl-2-oxopentanoate, 
Adipate semialdehyde, 
beta-Ketoisocaproate 
167.02104 7583.2 C5H4N4O3 [M-H]- 167.02106 -0.15 Urate 
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168.02779 43985.4 C5H9NO4 [M+Na-2H]- 168.02783 -0.22 
2-Oxo-4-hydroxy-5-
aminovalerate, D-Glutamate, 
DL-Glutamate, 
L-4-Hydroxyglutamate 
semialdehyde, L-Glutamate, 
L-threo-3-Methylaspartate, 
O-Acetyl-L-serine 
168.04311 4676.8 C6H13NO2 [M+K-2H]- 168.04324 -0.75 
(3R)-beta-Leucine, 
6-Aminohexanoate, 
L-Isoleucine, L-Leucine 
168.99074 2437.2 C3H7O6P [M-H]- 168.99075 -0.07 
D-Glyceraldehyde 3-phosphate, 
Glycerone phosphate 
168.99074 2437.2 C4H6O5 [M+Cl]- 168.99093 -1.1 
(R)-Malate, (S)-Malate, 
3-Dehydro-L-threonate 
168.99074 2437.2 C5H8O4 [M+K-2H]- 168.99087 -0.75 
(S)-2-Acetolactate, 
2-Acetolactate, 3-Hydroxy-3-
methyl-2-oxobutanoic acid 
169.02726 551.5 C5H10O4 [M+Cl]- 169.02731 -0.31 
(R)-2,3-Dihydroxy-3-
methylbutanoate, 2,3-Dihydroxy-
3-methylbutanoate 
169.02726 551.5 C9H8O2 [M+Na-2H]- 169.02710 0.95 
4-Hydroxycinnamyl aldehyde, 
trans-Cinnamate 
170.02387 2023.4 C5H5N5 [M+Cl]- 170.02390 -0.16 Adenine 
171.00639 21316.7 C3H9O6P [M-H]- 171.00640 -0.07 sn-Glycerol 3-phosphate 
171.00639 21316.7 C4H8O5 [M+Cl]- 171.00658 -1.09 Threonate 
171.00639 21316.7 C5H10O4 [M+K-2H]- 171.00652 -0.74 
(R)-2,3-Dihydroxy-3-
methylbutanoate, 2,3-Dihydroxy-
3-methylbutanoate 
171.02748 9568.7 C5H10O5 [M+Na-2H]- 171.02749 -0.08 
D-Lyxose, D-Ribose,D-Ribulose, 
D-Xylose, D-Xylulose, 
L-Arabinose, L-Lyxose, 
L-Ribulose, L-Xylulose 
171.0427 636237.6 C9H10O2 [M+Na-2H]- 171.04275 -0.28 
4-Coumaryl alcohol, 
Phenylpropanoate 
172.00175 1069.5 C4H9NO4 [M+K-2H]- 172.00177 -0.09 4-Hydroxy-L-threonine 
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173.00916 3776.7 C6H6O6 [M-H]- 173.00916 -0.02 Dehydroascorbate, cis-Aconitate 
173.09312 567.9 C7H14N2O3 [M-H]- 173.09317 -0.27 N-Acetylornithine 
173.10438 5872.4 C6H14N4O2 [M-H]- 173.10440 -0.11 D-Arginine, L-Arginine 
174.0884 1065 C6H13N3O3 [M-H]- 174.08842 -0.09 L-Citrulline 
175.0248 1250.6 C6H8O6 [M-H]- 175.02481 -0.08 
(4S)-4,6-Dihydroxy-2,5-
dioxohexanoate, 5-Dehydro-4-
deoxy-D-glucuronate, 
Ascorbate, D-Glucuronolactone, 
L-xylo-Hexulonolactone 
177.04043 549 C6H10O6 [M-H]- 177.04046 -0.19 
2,4,6/3,5-
Pentahydroxycyclohexanone 
2-Dehydro-3-deoxy-D-gluconate, 
2-Deoxy-5-keto-D-gluconic acid, 
5-Deoxy glucuronic acid, 
D-Galactono-1,4-lactone, 
D-Glucono-1,5-lactone, 
L-Galactono-1,4-lactone, 
L-Gulono-1,4-lactone 
179.0115 3779.7 C6H8O4 [M+Cl]- 179.01166 -0.9 
2,3-Dimethylmaleate, 
2-Methyleneglutarate 
Methylitaconate 
179.0561 16787.6 C6H12O6 [M-H]- 179.05611 -0.08 
D-Fructose, D-Fuconate, 
D-Galactose, D-Glucose, 
D-Mannose, D-Tagatose, 
L-Galactose, L-Rhamnonate, 
L-Sorbose, alpha-D-Glucose, 
beta-D-Fructose, 
beta-D-Glucose, myo-Inositol 
179.05735 1052.4 C7H8N4O2 [M-H]- 179.05745 -0.56 
1,7-Dimethylxanthine, 
Theobromine 
180.06661 7890.5 C9H11NO3 [M-H]- 180.06662 -0.04 
3-Amino-3-(4-
hydroxyphenyl)propanoate, 
L-Tyrosine 
181.07151 685826.3 C6H14O6 [M-H]- 181.07176 -1.4 D-Sorbitol, Galactitol, Mannitol 
184.00177 6718.1 C3H8NO6P [M-H]- 184.00165 0.65 O-Phospho-L-serine 
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184.00177 6718.1 C5H9NO4 [M+K-2H]- 184.00177 0.02 
2-Oxo-4-hydroxy-5-
aminovalerate, D-Glutamate, 
DL-Glutamate, 
L-4-Hydroxyglutamate 
semialdehyde, L-Glutamate, 
L-threo-3-Methylaspartate, 
O-Acetyl-L-serine 
184.98564 5791.1 C3H7O7P [M-H]- 184.98567 -0.14 
2-Phospho-D-glycerate, 
3-Phospho-D-glycerate 
184.98564 5791.1 C4H6O6 [M+Cl]- 184.98584 -1.09 
(R,R)-Tartaric acid, 
meso-Tartaric acid 
184.98564 5791.1 C5H8O5 [M+K-2H]- 184.98578 -0.77 
(R)-2-Methylmalate, 
(S)-2-Methylmalate, 
2-Dehydro-3-deoxy-D-xylonate, 
2-Dehydro-3-deoxy-L-
arabinonate, D-Xylonolactone, 
D-erythro-3-Methylmalate, 
L-Arabinono-1,4-lactone 
186.11354 44783.5 C9H17NO3 [M-H]- 186.11357 -0.15 N2-Acetyl-L-lysine 
187.00142 7015.3 C5H10O5 [M+K-2H]- 187.00143 -0.06 
D-Lyxose, D-Ribose,D-Ribulose, 
'D-Xylose, D-Xylulose, 
L-Arabinose, L-Lyxose, 
L-Ribulose, L-Xylulose 
187.00593 698.7 C6H6N4S [M+Na-2H]- 187.00599 -0.3 6-Methylmercaptopurine 
187.03787 2754.2 C5H12O5 [M+Cl]- 187.03788 -0.04 L-Arabitol, Ribitol, Xylitol 
187.03787 2754.2 C9H10O3 [M+Na-2H]- 187.03766 1.1 
3-(2-Hydroxyphenyl)propanoate, 
3-(3-Hydroxy-phenyl)-propanoic 
acid, 3-Methoxy-4-
hydroxyphenylacetaldehyde 
188.05641 708.6 C7H11NO5 [M-H]- 188.05645 -0.2 
L-2-Amino-6-oxoheptanedioate, 
N-Acetyl-L-glutamate 
188.957 720.9 C3H5O6P [M+Na-2H]- 188.95705 -0.25 
3-Phosphonopyruvate, 
Phosphoenolpyruvate 
189.04047 3389 C7H10O6 [M-H]- 189.04046 0.03 
2,4-Dihydroxyhept-2-enedioate, 
3-Dehydroquinate 
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189.0517 2695.2 C6H10N2O5 [M-H]- 189.05170 0.02 N-Carbamyl-L-glutamate 
189.07685 9257.5 C8H14O5 [M-H]- 189.07685 0.01 
(R)-3-((R)-3-
Hydroxybutanoyloxy)butanoate 
189.08807 959.2 C7H14N2O4 [M-H]- 189.08808 -0.06 
LL-2,6-Diaminoheptanedioate, 
meso-2,6-Diaminoheptanedioate 
189.98882 2741.4 C3H8NO5P [M+Na-2H]- 189.98868 0.73 
2-Amino-3-
phosphonopropanoate 
190.07209 1667.2 C7H13NO5 [M-H]- 190.07210 -0.04 
2-Amino-3,7-dideoxy-D-threo-
hept-6-ulosonic acid 
191.01972 42163.2 C6H8O7 [M-H]- 191.01973 -0.05 
(4R,5S)-4,5,6-Trihydroxy-2,3-
dioxohexanoate, 
5-Dehydro-4-deoxy-D-glucarate, 
Citrate, Isocitrate 
191.05612 12923 C7H12O6 [M-H]- 191.05611 0.03 Quinate 
192.98839 2227.1 C3H9O6P [M+Na-2H]- 192.98835 0.22 sn-Glycerol 3-phosphate 
193.03539 1757.2 C6H10O7 [M-H]- 193.03538 0.06 
2-Keto-D-gluconic acid, 
3-Dehydro-L-gulonate, 
D-Fructuronate, 
D-Galacturonate, 
D-Glucuronate, D-Tagaturonate 
193.07176 7304.9 C7H14O6 [M-H]- 193.07176 -0.02 
1-O-Methyl-myo-inositol, 
3-O-Methyl-myo-inositol 
194.05469 926.2 C6H11N3O3 [M+Na-2H]- 194.05471 -0.11 5-Guanidino-2-oxopentanoate 
194.06703 1752.4 C6H13NO6 [M-H]- 194.06701 0.09 2-Amino-2-deoxy-D-gluconate 
195.043 1060.9 C8H14O3 [M+K-2H]- 195.04290 0.5 
2-n-Propyl-4-oxopentanoic acid, 
3-Oxovalproic acid 
195.05104 3437.7 C6H12O7 [M-H]- 195.05103 0.06 
D-Altronate, D-Gluconic acid, 
D-Mannonate 
195.05237 1247.2 C7H8N4O3 [M-H]- 195.05236 0.03 
1,7-Dimethyluric acid, 
3,7-Dimethyluric acid 
196.98578 630.8 C5H6O6 [M+Cl]- 196.98584 -0.31 D-4-Hydroxy-2-oxoglutarate 
196.98578 630.8 C6H8O5 [M+K-2H]- 196.98578 -0.01 
2-Formylglutarate, 
2-Oxoadipate, 3D-(3,5/4)-Tri-
hydroxycyclohexane-1,2-dione 
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197.00679 3507.5 C6H8O6 [M+Na-2H]- 197.00676 0.16 
(4S)-4,6-Dihydroxy-2,5-
dioxohexanoate, 5-Dehydro-4-
deoxy-D-glucuronate,Ascorbate, 
D-Glucuronolactone, 
L-xylo-Hexulonolactone 
197.05862 1211.3 C8H16O3 [M+K-2H]- 197.05855 0.35 
3-Hydroxyvalproic acid, 
4-Hydroxyvalproic acid, 
5-Hydroxyvalproic acid 
199.00137 1302.8 C4H9O7P [M-H]- 199.00132 0.27 D-Erythrose 4-phosphate 
199.00137 1302.8 C6H10O5 [M+K-2H]- 199.00143 -0.31 
(2R,3S)-2,3-Dimethylmalate, 
(S)-2-(Hydroxymethyl)glutarate, 
2-Dehydro-3-deoxy-D-fuconate, 
2-Dehydro-3-deoxy-L-
rhamnonate, 
2-Deoxy-scyllo-inosose, 
L-Rhamnono-1,4-lactone 
199.02248 2872.5 C6H10O6 [M+Na-2H]- 199.02241 0.36 
2,4,6/3,5-
Pentahydroxycyclohexanone, 
2-Dehydro-3-deoxy-D-gluconate, 
2-Deoxy-5-keto-D-gluconic acid, 
5-Deoxy glucuronic acid, 
D-Galactono-1,4-lactone, 
D-Glucono-1,5-lactone, 
L-Galactono-1,4-lactone, 
L-Gulono-1,4-lactone 
199.03779 116504.7 C10H10O3 [M+Na-2H]- 199.03766 0.64 Coniferyl aldehyde 
199.03779 116504.7 C6H12O5 [M+Cl]- 199.03788 -0.44 
6-Deoxy-L-galactose, 
L-Fuculose, L-Rhamnofuranose, 
L-Rhamnose, L-Rhamnulose 
199.99664 1270.7 C5H9NO5 [M+K-2H]- 199.99668 -0.2 L-erythro-4-Hydroxyglutamate 
200.03301 2277.1 C6H13NO4 [M+K-2H]- 200.03307 -0.28 2-Deoxy-scyllo-inosamine 
200.04837 962.3 C9H11NO2 [M+Cl]- 200.04838 -0.05 
D-Phenylalanine, 
L-Phenylalanine 
200.05408 9870.2 C6H13NO5 [M+Na-2H]- 200.05404 0.19 D-Glucosamine 
201.01696 1158.4 C5H10O6 [M+Cl]- 201.01714 -0.9 D-Xylonate, L-Arabinonate 
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201.01696 1158.4 C6H12O5 [M+K-2H]- 201.01708 -0.6 
6-Deoxy-L-galactose, 
L-Fuculose, L-Rhamnofuranose, 
L-Rhamnose, L-Rhamnulose 
201.01696 1158.4 C9H8O4 [M+Na-2H]- 201.01693 0.16 
2-Hydroxy-3-(4-
hydroxyphenyl)propenoate, 
3-(4-Hydroxyphenyl)pyruvate, 
Caffeate, 
trans-2,3-Dihydroxycinnamate 
201.03229 2192.3 C13H8O [M+Na-2H]- 201.03218 0.53 Fluoren-9-one 
201.03229 2192.3 C9H10O3 [M+Cl]- 201.03240 -0.53 
3-(2-Hydroxyphenyl)propanoate, 
3-(3-Hydroxy-phenyl)-propanoic 
acid, 3-Methoxy-4-
hydroxyphenylacetaldehyde 
201.03808 16997.8 C6H12O6 [M+Na-2H]- 201.03806 0.11 
D-Fructose, D-Fuconate, 
D-Galactose, D-Glucose, 
D-Mannose, D-Tagatose, 
L-Galactose, L-Rhamnonate, 
L-Sorbose, alpha-D-Glucose, 
beta-D-Fructose, 
beta-D-Glucose, myo-Inositol 
201.05355 4583.3 C10H12O3 [M+Na-2H]- 201.05331 1.18 Coniferyl alcohol 
203.08264 14621.7 C11H12N2O2 [M-H]- 203.08260 0.19 L-Tryptophan 
204.01994 934.7 C4H12NO4P [M+Cl]- 204.01980 0.69 Phosphodimethylethanolamine 
204.04331 3352.3 C8H11NO3 [M+Cl]- 204.04330 0.07 Pyridoxine 
204.04331 3352.3 C9H13NO2 [M+K-2H]- 204.04324 0.36 3-Methoxytyramine 
204.93102 1138.4 C3H5O6P [M+K-2H]- 204.93098 0.17 
3-Phosphonopyruvate, 
Phosphoenolpyruvate 
204.99815 1103.8 C5H4N4O4 [M+Na-2H]- 204.99792 1.1 5-Hydroxyisourate 
205.03543 15956.3 C7H10O7 [M-H]- 205.03538 0.25 
(2S,3R)-3-Hydroxybutane-1,2,3-
tricarboxylate, Homoisocitrate 
205.96285 2556.5 C3H8NO5P [M+K-2H]- 205.96262 1.12 
2-Amino-3-
phosphonopropanoate 
206.96766 35241.3 C3H7O7P [M+Na-2H]- 206.96761 0.23 
2-Phospho-D-glycerate, 
3-Phospho-D-glycerate 
206.98315 746.2 C3H9O6P [M+Cl]- 206.98308 0.34 sn-Glycerol 3-phosphate' 
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208.96238 1936.4 C3H9O6P [M+K-2H]- 208.96228 0.46 sn-Glycerol 3-phosphate 
208.98591 39463.6 C6H6O6 [M+Cl]- 208.98584 0.33 Dehydroascorbate, cis-Aconitate 
208.98591 39463.6 C7H8O5 [M+K-2H]- 208.98578 0.61 
2-Hydroxy-5-methyl-cis,cis-
muconate, 2-Hydroxyhepta-2,4-
dienedioate, 2-Oxo-5-methyl-cis-
muconate, 2-Oxohept-3-
enedioate, 3-Dehydroshikimate 
209.02213 12081.9 C7H10O5 [M+Cl]- 209.02223 -0.46 
(2S)-2-Isopropyl-3-oxosuccinate, 
Shikimate 
209.05867 875.4 C8H14O4 [M+Cl]- 209.05861 0.28 2-Propylglutaric acid 
209.06981 600.7 C7H14N2O3 [M+Cl]- 209.06984 -0.17 N-Acetylornithine 
209.08114 2265.9 C6H14N4O2 [M+Cl]- 209.08108 0.3 D-Arginine, L-Arginine 
210.02852 170043.1 C4H10N3O5P [M-H]- 210.02853 -0.06 Phosphocreatine 
210.02852 170043.1 C6H11N3O3 [M+K-2H]- 210.02865 -0.61 5-Guanidino-2-oxopentanoate 
210.03845 3842 C7H11NO5 [M+Na-2H]- 210.03839 0.27 
L-2-Amino-6-oxoheptanedioate, 
N-Acetyl-L-glutamate 
211.00143 2352.8 C6H8O6 [M+Cl]- 211.00149 -0.29 
(4S)-4,6-Dihydroxy-2,5-
dioxohexanoate, 5-Dehydro-4-
deoxy-D-glucuronate, 
Ascorbate, D-Glucuronolactone, 
L-xylo-Hexulonolactone 
211.00143 2352.8 C7H10O5 [M+K-2H]- 211.00143 -0.01 
(2S)-2-Isopropyl-3-oxosuccinate, 
Shikimate 
211.03368 1909.3 C6H10N2O5 [M+Na-2H]- 211.03364 0.18 N-Carbamyl-L-glutamate 
211.04918 15755.7 C7H14N2O3 [M+K-2H]- 211.04905 0.62 N-Acetylornithine 
212.03311 3282.8 C10H9NO3 [M+Na-2H]- 212.03291 0.93 5-Phenyl-1,3oxazinane-2,4dione 
212.05412 1806 C7H13NO5 [M+Na-2H]- 212.05404 0.37 
2-Amino-3,7-dideoxy-D-threo-
hept-6-ulosonic acid 
212.98075 3530.4 C4H7O8P [M-H]- 212.98058 0.79 
2-Oxo-3-hydroxy-4-
phosphobutanoate 
212.98075 3530.4 C6H8O6 [M+K-2H]- 212.98070 0.25 
(4S)-4,6-Dihydroxy-2,5-
dioxohexanoate, 5-Dehydro-4-
deoxy-D-glucuronate, 
Ascorbate, D-Glucuronolactone, 
L-xylo-Hexulonolactone 
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213.00173 2033.9 C6H8O7 [M+Na-2H]- 213.00167 0.26 
(4R,5S)-4,5,6-Trihydroxy-2,3-
dioxohexanoate, 5-Dehydro-4-
deoxy-D-glucarate, 
Citrate, Isocitrate 
213.03811 1266.7 C7H12O6 [M+Na-2H]- 213.03806 0.24 Quinate 
214.04862 116610.9 C10H11NO3 [M+Na-2H]- 214.04856 0.27 
3-Carbamoyl-2-
phenylpropionaldehyde, 
4-Hydroxy-5-phenyltetrahydro-
1,3-oxazin-2-one 
214.04862 116610.9 C5H14NO6P [M-H]- 214.04860 0.09 
sn-glycero-3-
Phosphoethanolamine 
214.04862 116610.9 C6H13NO5 [M+Cl]- 214.04878 -0.73 D-Glucosamine 
214.98975 3280.7 C5H10N2O3S [M+K-2H]- 214.98982 -0.33 Cys-Gly 
214.9961 734.1 C4H9O8P [M-H]- 214.99623 -0.61 4-Phospho-D-erythronate 
214.9961 734.1 C6H10O6 [M+K-2H]- 214.99635 -1.15 
2,4,6/3,5-
Pentahydroxycyclohexanone, 
2-Dehydro-3-deoxy-D-gluconate, 
2-Deoxy-5-keto-D-gluconic acid, 
5-Deoxy glucuronic acid, 
D-Galactono-1,4-lactone, 
D-Glucono-1,5-lactone, 
L-Galactono-1,4-lactone, 
L-Gulono-1,4-lactone 
215.01737 4629.4 C6H10O7 [M+Na-2H]- 215.01732 0.22 
2-Keto-D-gluconic acid, 
3-Dehydro-L-gulonate, 
D-Fructuronate, 
D-Galacturonate, 
D-Glucuronate, D-Tagaturonate 
215.02714 634.1 C13H8O [M+Cl]- 215.02692 1.04 Fluoren-9-one 
215.03278 91480 C10H10O4 [M+Na-2H]- 215.03258 0.94 
5-Hydroxyconiferaldehyde, 
Ferulate 
215.03278 91480 C5H13O7P [M-H]- 215.03262 0.76 
2-C-Methyl-D-erythritol 
4-phosphate 
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215.03278 91480 C6H12O6 [M+Cl]- 215.03279 -0.05 
D-Fructose, D-Fuconate, 
D-Galactose, D-Glucose, 
D-Mannose, D-Tagatose, 
L-Galactose, L-Rhamnonate, 
L-Sorbose, alpha-D-Glucose, 
beta-D-Fructose, 
beta-D-Glucose, myo-Inositol 
215.05363 1349.5 C7H14O6 [M+Na-2H]- 215.05371 -0.37 
1-O-Methyl-myo-inositol, 
3-O-Methyl-myo-inositol 
216.02799 4357.8 C6H13NO5 [M+K-2H]- 216.02798 0.04 D-Glucosamine 
216.02799 4357.8 C9H9NO4 [M+Na-2H]- 216.02783 0.75 
2-Carboxy-2,3-dihydro-5,6-
dihydroxyindole, Dopaquinone 
216.13542 767.4 C9H19N3O3 [M-H]- 216.13537 0.25 gamma-L-Glutamylputrescine 
217.01213 1572.9 C6H12O6 [M+K-2H]- 217.01200 0.61 
D-Fructose, D-Fuconate, 
D-Galactose, D-Glucose, 
D-Mannose, D-Tagatose, 
L-Galactose, L-Rhamnonate, 
L-Sorbose, alpha-D-Glucose, 
beta-D-Fructose, 
beta-D-Glucose, myo-Inositol 
217.04253 791.3 C13H10O [M+Cl]- 217.04257 -0.17 Fluoren-9-ol 
218.10343 8973.3 C9H17NO5 [M-H]- 218.10340 0.15 Pantothenate 
219.00654 1197.1 C9H10O4 [M+K-2H]- 219.00652 0.11 
3-(2,3-
Dihydroxyphenyl)propanoate, 
3-(4-Hydroxyphenyl)lactate, 
Homovanillate, 
cis-3-(3-Carboxyethenyl)-3,5-
cyclohexadiene-1,2-diol 
219.97849 3886 C3H8NO6P [M+Cl]- 219.97833 0.73 O-Phospho-L-serine 
222.94162 6725.9 C3H7O7P [M+K-2H]- 222.94155 0.32 
2-Phospho-D-glycerate, 
3-Phospho-D-glycerate 
245.07017 6032.6 C10H14N2O3 [M+Cl]- 245.06984 1.33 2,6-Dihydroxypseudooxynicotine 
63.96846 15672 C5H10NO7P [M+K-2H]- 263.96810 1.37 L-Glutamyl 5-phosphate 
302.06573 9744.5 C10H13N5O4 [M+Cl]- 302.06616 -1.41 Adenosine, Deoxyguanosine 
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306.0761 478523.4 C10H17N3O6S [M-H]- 306.07653 -1.41 Glutathione 
308.06946 2138.7 C16H17NO3 [M+K-2H]- 308.06945 0.03 (S)-Norcoclaurine 
308.09828 4051.6 C11H19NO9 [M-H]- 308.09871 -1.39 N-Acetylneuraminate 
311.22236 2738.6 C18H32O4 [M-H]- 311.22278 -1.36 (7S,8S)-DiHODE, 8(R)-HPODE 
326.01567 63391.4 C9H12N3O7P [M+Na-2H]- 326.01596 -0.89 2',3-Cyclic CMP 
326.99966 5927.7 C9H11N2O8P [M+Na-2H]- 326.99997 -0.96 2',3-Cyclic UMP 
328.04489 3199.4 C10H12N5O6P [M-H]- 328.04525 -1.09 
2',3-Cyclic AMP, 
3',5-Cyclic AMP 
335.04271 10082.4 C10H20O7P2 [M+Na-2H]- 335.04310 -1.16 
(+)-Bornyl-diphosphate, 
Geranyl diphosphate 
343.12408 5427 C12H24O11 [M-H]- 343.12459 -1.48 Melibiitol 
344.0268 1559.3 C9H14N3O8P [M+Na-2H]- 344.02652 0.8 3-CMP, CMP 
369.0207 5620.6 C9H17O12P [M+Na-2H]- 369.02044 0.71 
2-(alpha-D-Mannosyl)-3-
phosphoglycerate 
373.03914 1314.7 C12H16O12 [M+Na-2H]- 373.03885 0.78 
4-(4-Deoxy-alpha-D-gluc-4-
enuronosyl)-D-galacturonate 
384.9939 1695.7 C9H17O12P [M+K-2H]- 384.99437 -1.23 
2-(alpha-D-Mannosyl)-3-
phosphoglycerate 
386.01629 18092.6 C9H15N3O10P2 [M-H]- 386.01600 0.76 dCDP 
389.00022 6867.6 C10H13N2O11P [M+Na-2H]- 389.00037 -0.38 Orotidine 5-phosphate 
389.01254 4007.2 C12H16O12 [M+K-2H]- 389.01279 -0.63 
4-(4-Deoxy-alpha-D-gluc-4-
enuronosyl)-D-galacturonate 
400.01021 1097.6 C10H14N5O7PS [M+Na-2H]- 400.00983 0.95 
6-Thioguanosine 
monophosphate 
402.99445 48074.1 C9H14N2O12P2 [M-H]- 402.99493 -1.19 UDP 
406.95553 2818.2 C7H16O13P2 [M+K-2H]- 406.95523 0.74 
D-glycero-D-manno-Heptose 
1,7-bisphosphate, 
Sedoheptulose1,7-bisphosphate 
407.99836 4460 C9H15N3O10P2 [M+Na-2H]- 407.99794 1.03 dCDP 
417.31395 842.7 C28H44O [M+Na-2H]- 417.31388 0.16 
3-Keto-4-methylzymosterol, 
5,7,24(28)-Ergostatrienol, 
5-Dehydroepisterol, Ergosterol, 
Vitamin D2 
426.02083 1828916.5 C11H20NO12P [M+K-2H]- 426.02092 -0.22 Acetylneuraminate 9-phosphate 
440.95039 6666.7 C9H14N2O12P2 [M+K-2H]- 440.95081 -0.95 UDP 
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447.9827 9786 C10H15N5O9P2 [M+K-2H]- 447.98311 -0.92 dADP 
455.09698 4283.9 C17H21N4O9P [M-H]- 455.09734 -0.8 FMN 
462.06713 8018.7 C14H18N5O11P [M-H]- 462.06677 0.78 N6-(1,2-Dicarboxyethyl)-AMP 
463.96836 8167.1 C10H14N5O10PS [M+K-2H]- 463.96851 -0.33 Adenylyl sulfate 
484.04894 14280.2 C14H18N5O11P [M+Na-2H]- 484.04872 0.46 N6-(1,2-Dicarboxyethyl)-AMP 
496.09594 7874.9 C16H27N4O8P2S [M-H]- 496.09521 1.47 2-Methyl-1-hydroxypropyl-ThPP 
500.02272 5669.7 C14H18N5O11P [M+K-2H]- 500.02265 0.13 N6-(1,2-Dicarboxyethyl)-AMP 
504.94246 1827.6 C9H15N2O15P3 [M+Na-2H]- 504.94321 -1.48 UTP 
505.98839 5903.7 C10H16N5O13P3 [M-H]- 505.98848 -0.17 ATP, dGTP 
527.95021 11173.6 C10H16N5O12P3 [M+K-2H]- 527.94945 1.45 dATP 
543.94407 23546.1 C10H16N5O13P3 [M+K-2H]- 543.94436 -0.53 ATP, dGTP 
558.06425 4178.7 C15H23N5O14P2 [M-H]- 558.06440 -0.28 ADP-ribose 
565.04748 11914.7 C15H24N2O17P2 [M-H]- 565.04775 -0.48 UDP-D-galactose, UDP-glucose 
580.04626 5302.8 C15H23N5O14P2 [M+Na-2H]- 580.04635 -0.15 ADP-ribose 
587.02954 26051 C15H24N2O17P2 [M+Na-2H]- 587.02970 -0.27 UDP-D-galactose, UDP-glucose 
588.07499 2797.2 C16H25N5O15P2 [M-H]- 588.07497 0.03 GDP-L-fucose 
596.01996 2716.4 C15H23N5O14P2 [M+K-2H]- 596.02029 -0.55 ADP-ribose 
603.00377 12665.6 C15H24N2O17P2 [M+K-2H]- 603.00364 0.22 UDP-D-galactose, UDP-glucose 
604.06991 853.3 C16H25N5O16P2 [M-H]- 604.06988 0.04 
GDP-L-galactose, 
GDP-L-glucose, GDP-mannose 
606.07387 10431.6 C17H27N3O17P2 [M-H]- 606.07430 -0.71 
UDP-N-acetyl-D-galactosamine, 
UDP-N-acetyl-D-glucosamine, 
UDP-N-acetyl-D-mannosamine 
611.14414 73610.7 C20H32N6O12S2 [M-H]- 611.14469 -0.9 Glutathione disulfide 
613.14004 7208.6 C20H31N4O16P [M-H]- 613.14000 0.07 CMP-N-acetylneuraminate 
628.05573 17769.1 C17H27N3O17P2 [M+Na-2H]- 628.05625 -0.82 
UDP-N-acetyl-D-galactosamine, 
UDP-N-acetyl-D-glucosamine, 
UDP-N-acetyl-D-mannosamine 
633.12603 63138.8 C20H32N6O12S2 [M+Na-2H]- 633.12664 -0.96 Glutathione disulfide 
635.12197 7328.8 C20H31N4O16P [M+Na-2H]- 635.12194 0.04 CMP-N-acetylneuraminate 
649.10006 34790.8 C20H32N6O12S2 [M+K-2H]- 649.10057 -0.79 Glutathione disulfide 
1. Average intensity across all samples (n=22 perhexiline, n=21 control). 
2. Ion form in which metabolite occurs in mass spectrum i.e. [M-H]
-
, [M+Cl]
-
, [M+Na-2H]
-
, [M+K-2H]
-
. 
3. Error between observed and theoretical masses, presented as parts per million of theoretical mass. 
4. Derived from the transformation mapping approach for metabolites (Sumner et al., 2007). 
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